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Abstract 
Investigating the Mechanisms of Hepatocyte or Biliary Epithelial Cell-Mediated Liver 
Regeneration  
 
Jacquelyn Olivia Russell, PhD 
 
University of Pittsburgh, 2019 
 
 
The liver performs a wide array of functions such that it is indispensable for survival. 
Uniquely, the liver is the only human internal organ capable of regeneration. Failure of liver 
regeneration is thought to induce progression of chronic liver disease (CLD) to cirrhosis and end-
stage liver disease, which is currently the 12th leading cause of death in the U.S. The only current 
treatment for end-stage liver disease is a liver transplant, for which there is a major dearth of donor 
organs. Therefore, understanding the molecular mechanisms underlying liver regeneration could 
lead to the development of desperately needed new therapies for liver disease. There are two main 
epithelial cell types in the liver: hepatocytes and biliary epithelial cells (BECs). Typically, liver 
regeneration after an acute injury is mediated by proliferation of hepatocytes. This is the case after 
partial hepatectomy (PHx), where 2/3 of the liver is surgically removed. We identified a role for 
bromodomain and extraterminal (BET) proteins in driving hepatocyte proliferation after PHx. BET 
proteins are a family of chromatin readers that interact with the basic transcriptional machinery to 
promote expression of virtually all genes. One pathway that we found to be especially sensitive to 
BET protein inhibition post-PHx was the Wnt/β-catenin signaling pathway, which is an important 
pathway in both liver development and multiple models of liver regeneration. One of these models 
involves liver regeneration when hepatocyte proliferation is impaired, a model in which BECs are 
theorized to differentiate into hepatocytes to mediate liver regeneration. We demonstrated that 
mice which lack liver-specific Wnt/β-catenin signaling (KO mice) exposed to choline-deficient, 
ethionine-supplemented (CDE) diet-induced liver injury have impaired hepatocyte proliferation. 
 v 
Furthermore, we utilized genetic lineage tracing of both hepatocytes and BECs to prove that BECs 
differentiate into hepatocytes in KO mice but not their wild-type counterparts following CDE diet-
induced liver injury and recovery. Overall, our work has elucidated important signaling pathways 
driving liver regeneration in multiple models of liver injury and sets the stage for future work to 
identify clinically-relevant treatments which can enhance hepatic repair. 
 vi 
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1.0 Introduction 
As an organ that performs a multitude of functions critical to homeostasis, liver health is 
pertinent and indispensable to survival. Thus, the cellular and molecular machinery driving the 
hepatic functions is of utmost relevance to human health. Hepatic epithelial cells are composed of 
hepatocytes, which are the functional units of the liver and perform synthetic, metabolic, 
detoxification and secretory functions; and biliary epithelial cells (BECs), which line bile ducts 
and regulate bile composition and secretion. After injury, both hepatocytes and BECs are capable 
of proliferation to mediate liver regeneration. Many signaling pathways are known to regulate 
these proliferative responses, and in this dissertation we will demonstrate a key role for 
bromodomain and extraterminal (BET) proteins as well as Wnt/β-catenin signaling in hepatocyte-
driven liver regeneration. We will also discuss secondary mechanisms of liver regeneration that 
are activated when hepatocyte proliferation fails, namely BEC-to-hepatocyte transdifferentiation. 
Thus, this dissertation identifies mechanisms of diverse forms of liver regeneration, which may 
eventually be utilized to develop therapies for CLD patients. Some of the information in this 
background was published as a review article in Annual Review of Pathology: Mechanisms of 
Disease, PMID 29125798 (1). A second first-author review article was submitted to Annual 
Review of Pathology: Mechanisms of Disease and is currently under review. As first author, the 
publisher Annual Reviews has granted full permission to reuse the manuscripts in this dissertation. 
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1.1 Bromodomain and Extraterminal Protein Signaling 
The bromodomain and extraterminal (BET) protein family is a family of chromatin readers 
which play major roles in regulating gene transcription. The family consists of four members: 
Brd2, Brd3, Brd4, and Brdt.  The hallmark of the BET protein family are the N-terminal 
bromodomains, which recognize acetylated lysine residues on the tails of histones and allow BET 
proteins to interact directly with chromatin (2). BET proteins function to regulate gene 
transcription by interacting with Mediator, the multi-protein complex which facilitates RNA 
polymerase II-mediated gene transcription (3). A well-studied BET protein is Brd4, which is a 
well-known component of the Mediator complex and is thought to act as an interface between 
transcription factors (TFs) and the RNA polymerase II activation (4, 5). Due to its chromatin 
interaction modules, Brd4 recruits Mediator to the promoter of the target gene (3) (Fig. 1A). Brd4 
also directly interacts with P-TEFb, a heterodimer of cyclin-dependent kinase 9 (6). When RNA 
polymerase II is recruited to a transcription start site, after initiation it becomes arrested within 
approximately 60 nucleotides. This is in part due to the inhibitory function of proteins DSIF and 
NELF, which keep RNA polymerase II in a reversible paused state (7). P-TEFb binds to Brd4 and 
then can phosphorylate and deactivate DSIF and NELF, leading to productive transcript elongation 
(6) (Fig. 1B). Thus, BET proteins such as Brd4 are important for both recruitment of the basic 
transcriptional machinery but also rapid transcriptional induction. In fact, Brd4 has been found to 
be associated with nearly all active promoters and a large portion of enhancers in the genomes of 
multiple cell types (3, 8-10). 
  Several inhibitors have been developed to block the interaction of BET proteins with 
chromatin. One of these is JQ1, which has a high affinity for the bromodomains of the BET protein 
family, resulting in displacement of the BET proteins from chromatin and impairing downstream  
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Figure 1: BET protein signaling 
(a) BET protein Brd4 binds to the acetylated lysine resides (Ac) of histone proteins and recruits 
both Mediator and P-TEFb to the promoter. RNA polymerase II is arrested within a short distance 
of the transcription start site (TSS). P-TEFb phosphorylates and deactivates the regulatory proteins 
NELF and DSIF. (b) The inactivation of NELF and DSIF releases RNA Polymerase II, allowing 
rapid transcript elongation. 
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transcription (3). This drug was identified as a potential treatment for cancer, as it was found to 
extend the survival of mice with patient-derived midline carcinoma xenografts as a dose which 
had little toxicity on non-cancerous tissue (11). It was subsequently found that BET inhibitors had 
a therapeutic effect in other cancers including multiple myeloma, lymphoma, and acute myeloid 
leukemia, and this effect was found to be mediated by suppression of proto-oncogenes such as 
MYC and BCL2 (12-14). It was further described that these genes which were particularly sensitive 
to BET inhibition had particularly high Brd4 occupancy in their nearby enhancers (3, 12). These 
enhancers have been termed “super-enhancers”, which can extend for tens of kilobases with high 
Brd4 occupancy throughout (3, 8). In addition to the role of BET proteins in cancer cell survival, 
there have been some reports on the role of BET proteins in liver pathophysiology. Expression of 
a shRNA against BRD4 in a hepatocellular carcinoma cell line resulted in reduced proliferation, 
migration, and invasion (15). Another group found that co-treatment of JQ1 in mice with carbon 
tetrachloride-induced liver fibrosis reduced hepatic stellate cell activation and overall fibrosis 
levels (16). We have previously reported that treatment of JQ1 impairs BEC-driven liver 
regeneration in both zebrafish and mouse models (17). In this dissertation we will further describe 
the role of BET proteins in hepatocyte-driven liver regeneration. 
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1.2 The Wnt/β-catenin Signaling Pathway 
1.2.1  Canonical Wnt/β-catenin Signaling 
 
Figure 2: Canonical Wnt/β-catenin Signaling 
(a) In the absence of Wnt binding to its receptor and co-receptor, β-catenin is phosphorylated by 
its destruction complex and targeted for proteasomal degradation by β-TRCP. The Frizzled 
receptor is targeted for proteasomal degradation via the activity of ZNRF3/RNF43. (b) Upon 
release of biologically-active Wnt from a neighboring cell by cargo receptor Wntless, the Wnt 
protein bind its receptor and co-receptor, which triggers recruitment of the β-catenin destruction 
complex to the plasma membrane through scaffolding protein Dishevelled. This interaction is 
further stabilized by R-spondin binding to an LGR receptor. β-catenin cannot be phosphorylated, 
accumulates in the cytoplasm, and translocates to the nucleus to bind the TCF/LEF family of 
transcription factor to induce target gene transcription. 
 
 
When canonical Wnt/β-catenin signaling is inactive, the levels of the major transducer of 
Wnt signaling, β-catenin, are kept low via its degradation by the destruction complex (Fig. 2A). 
This complex consists of the proteins Axin, adenomatous polyposis coli (APC), glycogen synthase 
kinase 3β (GSK3β), and casein kinase 1α (CK1α) (18, 19). The scaffold protein Axin brings 
together the components of the destruction complex, mediating the phosphorylation of β-catenin 
first by CK1α at serine 45 and subsequently phosphorylation of serines 33 and 37 and threonine 
 6 
41 by GSK3β (20, 21). Phosphorylated β-catenin is recognized by β-transducin repeat-containing 
protein (βTRCP), a component of the E3 ubiquitin ligase complex, which triggers the 
ubiquitination and subsequent proteasomal degradation of β-catenin (22, 23).  
Activation of the Wnt/β-catenin signaling pathway is mediated through Wnt ligands, a 
family of secreted glycoproteins (Fig. 2B). In order to be bioactive, Wnt ligands must be 
glycosylated and palmitoylated by the enzyme porcupine (24). This modification occurs in the 
endoplasmic reticulum, and palmitoylation, the hydrophobic lipid modification, renders Wnts 
relatively insoluble (25). Secretion of hydrophobic Wnts from the cell requires the cargo receptor 
Wntless, a multi-pass transmembrane protein which mediates protein trafficking between the 
Golgi apparatus and cell membrane (26, 27). Once secreted, the Wnt ligand binds to a Frizzled 
receptor and the co-receptor low-density lipoprotein receptor-related protein (LRP) 5 or 6 to 
mediate activation of the Wnt/β-catenin signaling pathway (28-31). Wnt binding to Frizzled and 
LRP5/6 triggers recruitment of the scaffolding protein Dishevelled (Dvl), phosphorylation of 
LRP5/6, and phosphorylated LRP5/6-mediated recruitment of Axin to the plasma membrane (32, 
33). Interestingly, the family of R-spondin secreted proteins enhance Wnt signaling through 
binding to the leucine-rich repeat-containing G-protein coupled receptor-4 (LGR4) and LGR5 
receptors, which in turn increase Wnt-dependent phosphorylation of LRP6 (34, 35). R-spondin 
ligands also enhance Wnt signaling through the clearance of transmembrane E3 ubiquitin ligases 
zinc and ring finger 3 (ZNRF3) and its homologue ring finger 43 (RNF43), which ubiquitinate 
Frizzled and LRP6 and target them for proteasomal degradation (36, 37) (Fig. 2A-B). The 
recruitment of Axin to the plasma membrane leads to disruption of the destruction complex, 
promoting stabilization and cytoplasmic accumulation of β-catenin. Non-phosphorylated β-catenin 
 7 
is translocated to the nucleus where it forms a complex with T cell factor/lymphoid enhancer factor 
(TCF/LEF) transcription factors to mediate expression of target genes (38). 
1.2.2  Non-canonical Wnt Signaling 
 
Figure 3: Non-canonical Wnt Signaling 
(a) In the Planar Cell Polarity (PCP) pathway (left), Wnt ligands bind to a complex consisting of 
certain Frizzled receptors, Ror2, and Dishevelled, which triggers activation of RhoA and ROCK, 
or alternatively activation of Rac and JNK signaling, to regulate cell polarity and migration. In the 
Wnt/calcium pathway (right), Wnt ligands bind to a complex consisting of Frizzled receptors, 
Dishevelled, and G proteins, leading to the activation of PLC, generation of DAG and IP3. DAG 
activates PKC while IP3 promotes increased intracellular calcium levels, leading to activation of 
CaMKII and CaN, which in turn regulate cell migration and proliferation. (b) In the Wnt/TOR 
pathway (left), in the absence of Wnt ligands GSK3β phosphorylates and activates TSC2, which 
in turn inhibits mTORC1 activity. Binding of the Wnt protein to its receptor and co-receptor leads 
to sequestration of the destruction complex, including GSK3β, into multivesicular bodies. This 
prevents activation of TSC2, leading to activation of mTORC1 and promotion of protein 
translation. In the Wnt/STOP pathway (right), the activity of GSK3β promotes phosphorylation 
and proteasomal degradation of a multitude of target proteins. Upon Wnt ligand binding and 
sequestration of GSK3β into multivesicular bodies, these GSK3β-target proteins are no longer 
targeted for degradation and accumulate in the cytoplasm. 
 
 
There are 19 Wnts and 10 Frizzled receptors in the mammalian genome (39), and not all 
of them utilize the same downstream signaling components. Certain Wnt ligands can signal 
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independently of β-catenin, and this form of signaling is referred to as non-canonical Wnt 
signaling. Two classic non-canonical Wnt signaling pathways have been described: the 
Wnt/calcium pathway and the planar cell polarity (PCP) pathway (Fig. 3A).  
In the Wnt/calcium pathway, non-canonical Wnt ligands such as Wnt5a bind to Frizzled 
receptors (Frizzled-2 or Frizzled-7) or with receptor tyrosine kinase-like orphan receptor 2 (Ror2) 
(40) (Fig. 3A). After Wnt binding, a complex forms between Frizzled, Dishevelled and G proteins, 
promoting the activation of Phospho Lipase C (PLC), which cleaves phosphatidylinositol 4,5 
biphosphate (PIP2) into diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3). DAG in turn 
activates Protein Kinase C (PKC) and IP3 promotes increased intracellular calcium levels. This 
increase in calcium activates calcium-calmodulin dependent kinase II (CaMKII) and calcineurin 
(CaN), which in turn regulate cell migration and proliferation (41, 42).  
In the PCP pathway, Wnt ligands bind to the Ror2/Frizzled/Dishevelled complex and 
trigger the activation of Rho-family small GTPases including RhoA and Rac (Fig. 3A). These 
subsequently activate Rho-associated protein kinase (ROCK) and c-Jun N-terminal kinase (JNK), 
which regulate cell polarity and migration (41-43). To add further complexity to Wnt signaling 
pathways, non-canonical Wnt5a can inhibit canonical Wnt/β-catenin signaling by promoting the 
degradation of β-catenin (44).  
More recently, other β-catenin-independent Wnt signaling pathways have been described 
(Fig. 3B). One of these is the Wnt-dependent stabilization of proteins, known as the Wnt/STOP 
pathway (45). The central mediator of this pathway is GSK3β, which was found to phosphorylate 
many additional proteins besides β-catenin and target them for proteasomal degradation (46-49). 
Wnt binding to its co-receptors can trigger the sequestration of GSK3β in multivesicular bodies, 
allowing the cytoplasmic accumulation of GSK3β-target proteins (50-52) (Fig. 3B). It was recently 
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described that Wnt/STOP signaling during mitosis slows protein degradation, stabilizes cell cycle 
effectors such as c-MYC, and promotes increase in cell size as cells prepare to divide (45). 
Wnt/STOP signaling is thought to play a role in many cellular processes including cell division, 
regulation of the cytoskeleton, and DNA remodeling (53).  
Another Wnt signaling pathway independent of β-catenin is Wnt-dependent regulation of 
mechanistic target of rapamycin (mTOR) signaling (Wnt/TOR signaling) (Fig. 3B). In this 
pathway GSK3β phosphorylates and activates tuberous sclerosis complex 2 (TSC2), which in turns 
inhibits the function of mTOR complex 1 (mTORC1). The presence of Wnt ligands prevents 
GSK3β-mediated phosphorylation of TSC2, leading to the activation of the mTORC1 signaling 
pathway and stimulation of protein translation (54). These studies collectively demonstrate that 
Wnt ligands are pleiotropic signaling molecules.  
1.2.3  β-catenin at Adherens Junctions 
In addition to its role in Wnt signaling, β-catenin plays a role in cell-cell adhesion as a 
component of adherens junctions. Adherens junctions are subapical junctions which promote 
homotypic cell-cell adhesion in epithelial tissues (55). A class of transmembrane proteins called 
cadherins perform the extracellular interactions during cell-cell adhesion, and E-cadherin is the 
prototypical cadherin of adherens junctions. The extracellular domain of E-cadherin forms 
calcium-dependent complexes with E-cadherin molecules of neighboring cells to mediate 
homotypic cell-cell adhesion. β-catenin functions in adherens junctions by linking E-cadherin to 
the actin cytoskeleton through binding to α-catenin, which in turn binds directly to actin and to 
actin-binding proteins such as vinculin (56). In addition, β-catenin facilitates the assembly of 
adherens junctions. β-catenin was shown to bind to newly synthesized E-cadherin (57) and 
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promote delivery of E-cadherin from the endoplasmic reticulum to the basal-lateral plasma 
membrane (58). Later, it was shown that binding of β-catenin to E-cadherin blocks a peptide 
sequence which, if exposed, would target E-cadherin for proteasomal degradation (59). However, 
β-catenin is not permanently incorporated into adherens junctions. Tyrosine phosphorylation of β-
catenin at residues Y142, Y654, and Y670 by the activity of hepatocyte growth factor (HGF)/c-
met, Y489 by Abl, and Y654 by the epidermal growth factor receptor (EGFR) and Src may induce 
dissociation of β-catenin from adherens junctions and may activate β-catenin signaling (60-62). β-
catenin may also play a role in the development of tight junctions, which serve to prevent bile from 
the bile canaliculi from mixing with blood in hepatic sinusoids (63). Catenins may participate in 
the trafficking of tight junctional protein zonula occludens-1 (ZO-1) from the cytosol to the plasma 
membrane early in tight junction development (64). Additionally, tight junctional protein claudin-
2 is a transcriptional target of β-catenin (65), and depletion of claudin-2 in a polarized hepatic cell 
line resulted in defects in bile canalicular formation (66).  
1.2.4  Wnt/β-catenin Signaling in Liver Homeostasis 
As hepatocytes are the main parenchymal cell type of the liver, consisting of approximately 
80% of liver mass (67), a great deal is known about the role of Wnt/β-catenin signaling in 
hepatocytes during both homeostasis and liver regeneration. In a baseline liver, hepatocytes 
display molecular heterogeneity depending on their location within the hepatic lobule (68). A liver 
lobule is divided into three zones; hepatocytes near a portal triad (which consists of the portal vein, 
bile ducts, and hepatic artery) are labeled zone 1, hepatocytes surrounding central veins constitute 
zone 3, and hepatocytes in between constitute zone 2 (69). The process of hepatic zonation begins 
in the first few weeks after birth (70). This process serves to compartmentalize opposing metabolic 
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processes, as periportal hepatocytes perform gluconeogenesis, cholesterol biosynthesis, and urea 
metabolism, while pericentral hepatocytes perform glycolysis, bile acid biosynthesis, and 
glutamine synthesis (71). Wnt/β-catenin signaling has proven to be a master regulator of liver 
zonation. Pericentral hepatocytes show active Wnt/β-catenin signaling as demonstrated by 
pericentral-specific expression of Wnt/β-catenin targets Axin2 (72), glutamine synthetase (GS), 
and cytochrome P450 enzymes CYP2E1 and CYP1A2 (73, 74). Importantly, mice with liver-
specific deletion of both LRP5 and LRP6 (68), as well as mice with hepatocyte-specific deletion 
of LGR4 and LGR5 (75), lack liver zonation and fail to express the pericentral metabolic genes. 
Mice with inducible loss of β-catenin in hepatocytes display a periportal phenotype throughout the 
whole liver (76). In contrast, overactivation of β-catenin specifically in hepatocytes due to 
conditional APC deletion led to a pericentral phenotype throughout the entire hepatic lobule (77). 
These results are explained by the finding that HNF4α and β-catenin compete for binding to TCF; 
HNF4α/TCF dictates periportal gene expression while β-catenin/TCF dictates pericentral gene 
expression (76). This hypothesis is supported by the finding that HNF4α-deficient livers show a 
pericentral phenotype (78). Hepatocyte differentiation is also key for metabolic zonation. In mice 
with liver-specific Yes-associated protein (YAP) deletion, there was an expansion of GS-positive 
cells in the pericentral domain. Alternatively, mice with liver-specific deletion of macrophage 
stimulating 1 (Mst1)/Mst2, the kinases responsible for phosphorylation and inactivation of YAP, 
led to disruption of metabolic zonation, with loss of expression of pericentral genes such as GS. 
YAP overexpression led to dedifferentiation of hepatocytes, with downregulation of HNF4α target 
genes and promotion of a stem cell-like phenotype (79). Yap was found to be normally expressed 
in the periportal domain, suggesting an opposing function to Wnt/β-catenin signaling.  
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1.2.5  Wnt/β-catenin Signaling in Liver Regeneration and Metabolic Diseases 
A notable feature of the liver is that normal cell turnover and liver regeneration following 
most models of acute liver injury is mediated by proliferation of existing differentiated hepatocytes 
(80). A well-studied model of liver regeneration is the two-thirds partial hepatectomy (PHx) 
model, where two-thirds of a rat or mouse liver are removed and within days the remaining lobes 
enlarge to replace lost liver mass via mostly cellular hyperplasia and some through cellular 
hypertrophy (81). Wnt/β-catenin signaling is an important driver of liver regeneration in this 
model; within minutes of PHx in the rat there is a transient 2.5-fold increase in β-catenin protein 
and rapid translocation to the nucleus (82). This increase in nuclear β-catenin helps to promote 
hepatocyte proliferation through the expression of target genes such as cell-cycle regulator cyclin 
D1, which shows increased expressed as early as six hours post-PHx (83) (Fig. 4). Mice with 
hepatocyte-specific loss of β-catenin display a delay in regeneration following PHx, as there was 
a two-fold reduction in proliferating hepatocytes at the 40 hour post-PHx time point, which is the 
peak of hepatocyte proliferation in the wild-type mice. However, there was a subsequent increase 
in hepatocyte proliferation three days post-PHx, indicating activation of a compensatory signaling 
pathway (74). Mice lacking both Wnt co-receptors LRP5 and LRP6 in hepatocytes show a similar 
delay in liver regeneration after PHx (68), as do mice lacking both LGR4 and LGR5 in hepatocytes 
(75). Interestingly, non-canonical Wnt signaling was shown to be involved in the conclusion of 
liver regeneration post-PHx. Wnt5a was found to inhibit canonical Wnt/β-catenin signaling in 
cultured primary hepatocytes, and mice with liver-specific deletion of Wntless displayed continued 
hepatocyte proliferation for up to 4 days longer than control littermates due to reduced expression 
of inhibitory Wnt5a between 24-48 hours post-PHx (84) (Fig. 4). This suggests an autocrine 
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Figure 4: Role of Wnt/β-catenin signaling in liver regeneration following surgical resection 
Following surgical resection of liver mass, Wnt/β-catenin signaling is activated to promote liver 
regeneration. Infiltrating inflammatory cells secrete TNFα and IL-6, which in turn promote Wnt 
secretion from macrophages. Additionally, liver sinusoidal endothelial cells secrete Wnt2 and 
HGF, which is also secreted by hepatic stellate cells. Neither biliary epithelial cells nor hepatocytes 
secrete mitogenic Wnts following surgical resection. The secreted Wnt ligands act on hepatocytes 
to promote β-catenin translocation to the nucleus, where it promotes expression of target genes 
such as cyclin D1 to promote hepatocyte proliferation. Following restoration of sufficient liver 
mass, hepatocytes secrete Wnt5a to inhibit canonical Wnt/β-catenin signaling and promote 
termination of liver regeneration. 
  
 14 
mechanism of proliferation termination following acquisition of required hepatocyte mass during 
regeneration.  
A common cause of acute liver injury in patients is overdose of acetaminophen (APAP) 
leading to hepatotoxicity (85). In the liver, APAP is metabolized by the enzymes CYP2E1 and 
CYP1A2 into a reactive metabolite, N-acetyl-p-benzoquinone imine (NAPQI), which covalently 
binds to cellular macromolecules and induces hepatic necrosis (86). Both CYP2E1 and CYP1A2 
are β-catenin target genes, so mice with hepatocyte-specific β-catenin loss are resistant to APAP-
induced hepatotoxicity (73). However, β-catenin may also promote liver regeneration following 
APAP overdose, as liver-specific β-catenin knockout mice given APAP following induction of 
CYP1A2 and CYP2E1 showed significant defects in hepatocyte proliferation following APAP-
induced hepatic necrosis (87).  
A role for Wnt/β-catenin signaling has also been implicated in ischemia/reperfusion injury. 
Under conditions of hypoxia, hypoxia inducible factor-1α (HIF1α) directly competes with TCF4 
for binding to β-catenin, leading to enhancement of HIF1α-mediated transcription and the 
promotion of cell survival (88). Mice with β-catenin-deficient hepatocytes displayed reduced 
HIF1α signaling and were more susceptible to ischemia/reperfusion injury, while mice with 
hepatocyte-specific Wnt1-overexpression had enhanced HIF1α signaling and were protected (89).  
Deficient Wnt/β-catenin signaling may also exacerbate the development of hepatic 
steatosis. Loss-of-function point mutations in LRP6 have been identified in humans with early-
onset cardiovascular disease, hyperlipidemia, and metabolic syndrome traits (90). Mice with 
mutant LRP6 develop fatty liver due to increased AKT/mTOR signaling causing elevated 
hepatocyte lipogenesis, which can be normalized through exogenous Wnt3a treatment (91). 
Additionally, β-catenin has been found to regulate hepatic mitochondrial homeostasis, as mice 
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with β-catenin-deficient hepatocytes subjected to acute ethanol intoxication displayed reduced 
mitochondrial function in addition to impaired Sirtuin 1 (Sirt1)/peroxisome proliferator-activated 
receptor α (PPARα)-signaling, leading to increased steatosis and oxidative damage (92). The role 
of Wnt/β-catenin signaling in hepatic metabolism was further expanded by the discovery of the 
interaction of β-catenin and forkhead box protein O (FOXO) transcription factors. Under 
conditions of oxidative stress, β-catenin binds directly to FOXO and enhances transcription of 
FOXO target genes (93). It was also found that β-catenin modulated hepatic insulin signaling, and 
the association of β-catenin and FOXO1 was promoted in mice under starved conditions. 
Interestingly, β-catenin and FOXO1 promoted the expression of rate-limiting enzymes in hepatic 
gluconeogenesis, and the liver-specific deletion of β-catenin in mice fed a high-fat diet displayed 
increased glucose tolerance due to decreased gluconeogenesis (94). Collectively, these results 
demonstrate the importance of Wnt/β-catenin signaling in hepatic metabolism and could implicate 
a role of this pathway in the pathogenesis of conditions such as non-alcoholic fatty liver disease.  
Wnt/β-catenin may also play a role in bile acid secretion and homeostasis. Hepatocytes are 
responsible for the conversion of cholesterol into bile acids, which are secreted into bile canaliculi 
for eventual transport to the lumen of the small intestine for aid in the digestion of dietary lipids 
and cholesterol (95). Two of the key enzymes in bile acid biosynthesis, CYP7A1 and CYP27, are 
expressed in pericentral hepatocytes, suggesting they are regulated by Wnt/β-catenin signaling 
(96). Mice with liver-specific deletion of β-catenin fed a methionine-choline-deficient diet to 
induce liver injury displayed significant steatohepatitis, accumulation of hepatic cholesterol and 
bile acids, and elevated serum bilirubin, suggesting a defect in bile acid export (97). Furthermore, 
mice with liver-specific deletion of β-catenin displayed dilated and tortuous bile canaliculi and 
reduced bile flow rates, and feeding these mice a diet supplemented with cholic acid to induce bile 
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acid-mediated liver toxicity led to the development of intrahepatic cholestasis and fibrosis (65). 
These results suggest aberrant Wnt/β-catenin signaling may play a role in the development of 
cholestatic liver disease. 
1.3 The Ductular Reaction and BEC-to-Hepatocyte Differentiation 
Adult mammals possess very limited organ repair capabilities, unlike lower vertebrates 
including fish or amphibians (98, 99). During post-natal development, they lose most of their 
competence for regeneration, except for minimal levels of maintenance during tissue homeostasis 
(98, 100, 101). In general, mammalian organs produce non-functional connective tissues after 
injury instead of functional restoration of lost parenchyma (102, 103). While acute and chronic 
deposition of scar tissue is a protective response to reduce organ damage caused by additional 
insults, it results in a progressive loss of function that underlies a majority of chronic diseases, 
particularly in aging populations (99, 103). However, the mammalian liver is a unique organ which 
maintains the ability to regenerate tissue into adulthood at comparable levels to the regenerative 
capacity of fetal liver and the livers of lower vertebrates. The liver can restore lost functional 
parenchyma after various hepatic injuries, including restoration of hepatic mass after surgical 
removal (104, 105). This extraordinary regenerative capacity is mainly based on the self-
replication ability of the two main epithelial cell types: hepatocytes and biliary epithelial cell 
(BECs, also known as cholangiocytes) (104, 105). These two cell populations exit quiescence and 
replicate to compensate for lost functional parenchyma in response to acute/chronic injuries.  
However, regenerative mechanisms following acute liver injury (such as surgical removal 
of liver tissue or damage from hepatotoxic drug overdoses) exhibit distinct phenotypic differences 
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from liver regeneration in the setting of chronic liver disease (CLD). Within a healthy liver, BECs 
are usually confined to the interlobular bile ducts which form the biliary tree, a complex network 
of tubules which function to collect hepatocyte-derived bile and eventually transport it to the 
common bile duct, which drains into the duodenum (106). Hepatocytes secrete bile into the bile 
canaliculi, which connect with the smallest proximal ductules at the ductular-hepatocellular 
junctions known as the canals of Hering (106, 107). The bile ducts are located anatomically near 
the portal vein and hepatic artery in a structure known as the “portal triad”, which is separated by 
linear chords of hepatocytes from the central vein (106) (Fig. 5A, B). However, during many types 
of liver injury there is expansion of cells which express BEC markers, known as reactive BECs, 
from the periportal region into the surrounding parenchyma. This phenomena is termed the 
ductular reaction (DR), defined as “a reaction of ductular phenotype, possibly but not necessarily 
of ductular origin” (107). This definition affords flexibility to the cell-of-origin of the DR, as there 
is evidence that cells besides BECs can give rise to cells of the DR, which will be discussed further 
later in this review. The DR is considered by some to be activation and expansion of liver 
progenitor cells (LPCs), also known as oval cells in rodents, which are bipotent cells capable of 
giving rise to hepatocytes or BECs (105). Another theory is there is no progenitor cell population 
in the liver, but in the context of liver injury hepatocytes and BECs can function as facultative 
stem cells, and the DR is evidence of this cellular plasticity (104). The DR is a complex process 
which has different phenotypes in different injury conditions, but in general is associated with 
infiltration of inflammatory cells, activation of myofibroblasts, and matrix deposition (108). 
Despite the prevalence of DR after liver injury, the origin, fate and exact roles of LPCs in the 
diseased liver are heavily debated and remain largely elusive.  
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Currently, liver transplantation is the only reliable treatment to prolong the lives of patients 
with advanced liver diseases. However, the number of donor livers is not sufficient to match 
increasing demand (109). Therefore, alternative therapeutic options are desperately needed. Given 
the prevalence of DR in human diseased liver and recent findings which suggest LPCs could be a 
reliable source for new hepatocytes in diseased liver, promoting the differentiation of activated 
LPCs into parenchymal liver cells has recently garnered attention as a powerful potential 
therapeutic option for patients with advanced liver diseases. However, the pathophysiologic and 
molecular mechanisms underlying DR and subsequent LPC differentiation still remain largely 
unknown. In this dissertation, we utilize the choline-deficient, ethionine-supplemented (CDE) diet 
as a model of chronic liver injury, and we demonstrated that lack of Wnt/β-catenin signaling in 
hepatocytes impairs hepatocyte proliferation after CDE diet-induced liver injury and promotes 
BECs to differentiate into hepatocytes.  
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Figure 5: Normal and diseased liver architecture. 
(a) The structure of a liver lobule, which consists of three zones. Zone 1 consists of the portal vein, 
bile ducts, and hepatic artery, which together form the “portal triad”. Oxygenated blood from the 
hepatic artery mixes with blood from the portal vein and flows through the hepatic sinusoids 
towards the central vein, which constitutes zone 3. Chords of hepatocytes form the bile canaliculi, 
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which transport hepatocyte-derived bile in the opposite direction of blood flow to the bile ducts. 
The interface between the end of the bile canaliculus and the start of the bile duct is known as the 
Canal of Hering. (b) Normal human liver stained with a pan-cytokeratin (panCK) antibody. The 
arrows denote bile ducts, structures with obvious lumina lined by panCK-positive cells. Scale bar: 
50 µm. (c) Liver from an acute liver failure patient stained with a panCK antibody. A ductular 
reaction (DR) is evidenced by a large increase in the number of panCK-positive cells (arrows). 
Intermediate hepatocytes, or cells which are panCK-positive but exhibit hepatocyte morphology 
(arrowheads), can be observed adjacent to cells of the DR. Scale bar: 50 µm. (d) Liver from a 
patient with nonalcoholic steatohepatitis (NASH)-induced cirrhosis stained with a panCK 
antibody. A DR is evident in the increase in the number of panCK-positive cells, which form bile 
duct-like structures without obvious lumina (arrows). Scale bar: 50 µm. (e) Liver from a patient 
with primary sclerosing cholangitis stained with a panCK antibody. A DR is evident by the 
increase in the number of panCK-positive cells (arrows), which have a distinctly different 
morphology from normal bile ducts. Scale bar: 50 µm. 
1.4 Overview of the Ductular Reaction 
1.4.1  Ductular Reaction in Human Liver Disease 
The activation of the DR is thought to be triggered by impairment of the regenerative 
capacity of the differentiated epithelial cells of the liver during liver injury. In support of this 
theory, analysis of patients diagnosed with acute liver failure or severe liver impairment which 
exhibited severe loss (>50%) of hepatocytes in combination with impaired proliferation of 
remaining hepatocytes developed a robust ductular reaction (Fig. 5C). This study also tracked the 
appearance of intermediate hepatocytes (those which express BEC markers CK7 or CK19) and 
concluded that LPCs appear early but need approximately one week’s time to differentiate to 
hepatocytes (110). In line with this theory, spontaneous recovery of patients with massive hepatic 
necrosis, a condition where nearly all parenchymal cells are acutely lost, is theorized to be due to 
LPC-mediated liver regeneration (reviewed in (111)). There is also evidence of LPC-derived 
hepatocytes in human cirrhosis patients with parenchyma extinction (112). However, even in the 
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setting of acute liver failure, the degree of the DR is positively correlated with liver stiffness and 
hepatic stellate cell (HSC) activation (111, 113), demonstrating the intricate relationship between 
the cells of the DR and the non-parenchymal cells of the liver (reviewed in (114)).  
In chronic liver injury, the degree of the DR positively correlates with disease severity in 
a wide range of pathological settings (111, 115-118). Indeed, in chronic hepatitis C virus (HCV) 
infection, advanced fibrosis stage was associated with higher numbers of activated HSCs and LPCs 
in both adult (119) and pediatric patients (120). In patients with nonalcoholic steatohepatitis 
(NASH), the degree of the DR was strongly correlated with the degree of portal inflammation, 
hepatocyte replicative arrest, and fibrosis stage (Fig. 5D) (121). There were similar findings in 
non-alcoholic fatty liver disease (NAFLD), where the portal inflammatory infiltrate was 
dominated by CD68+ macrophages and CD8+ lymphocytes (122). Furthermore, in patients with 
NASH, expansion of the DR reaction into the centrilobular region was correlated with fibrosis 
stage and fibrosis progression (123). In a study of pediatric NASH patients, the degree of pro-
inflammatory macrophage polarization was correlated with disease severity, DR, and portal 
fibrosis (124).  
Although DR is observed in almost all forms of severe and chronic liver injury, there are 
thought to be disease-specific phenotypic differences. The cells of the DR can differ in 
morphology, ranging from organized ductules with clear lumina to more disorganized strings of 
cells with no visible lumina, and the morphology varies depending on the etiology of the liver 
injury (reviewed in (116)). A recent study characterized the DR in the cholangiopathies primary 
sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) and found that while the DR 
was a prognostic marker in both conditions (Fig. 5E), DR phenotype and activation of signaling 
pathways differed between PSC and PBC (125). Another study used laser capture microdissection 
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to isolate cells of the DR from HCV or PSC patients, and high throughput RNA sequencing 
revealed numerous differences, including a neo-angiogenesis signature in HCV in contrast to a 
profile of oxidative stress-related and pro-inflammatory gene expression in PSC (126).  
There is evidence that LPCs themselves can secrete proinflammatory and profibrogenic 
cytokines (127). In alcoholic hepatitis, the expansion of the DR correlates with disease 
progression, and cells of the DR were found to express chemokines and inflammatory mediators 
promoting neutrophil infiltration in the periportal area (128). A recent study found that activation 
of non-canonical NF-κB signaling via RELB in BECs was important for BEC proliferation during 
the DR in a variety of pathologies including PSC, PBC, NASH, autoimmune hepatitis, viral 
hepatitis, and alcoholic liver disease. In early-stage PBC and PSC, the expression of the cytokine 
lymphotoxin beta increased in BECs and induced RELB activation, and a corresponding mouse 
model found that deletion of RELB reduced inflammatory cell infiltration and expression of 
inflammatory cytokines (129), providing further evidence that cells of the DR can promote 
inflammation.  
A subset of patients with chronic liver disease will go on to develop liver cancer, such as 
hepatocellular carcinoma (HCC), and chronic inflammation is known to be a driver of hepatic 
carcinogenesis (130). There’s a long-standing debate on the role of LPCs in hepatic tumorigenesis 
(131). LPCs are thought to be a potential source of HCC, due to the strong association of the DR 
and progression of chronic liver disease and the fact that up to 50% of human HCC express markers 
of BECs. Additionally, in humans approximately 55% of small cell dysplastic foci are composed 
of LPCs and intermediate hepatocytes (132). Furthermore, a proliferating peritumoral DR was 
found to be a strongly correlated with inflammation and fibrosis, and was an independent 
prognostic factor for disease-free survival after surgical resection of HCC (133, 134). A 
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proliferating peritumoral DR was also found to be correlated with overall survival and disease-free 
survival post-hepatectomy in patients with combined hepatocellular-cholangiocarcinoma (135). 
These data underscore the clear clinical significance of the DR in liver disease, providing the 
impetus to study the role of the DR in liver disease and tumorigenesis in a variety of animal models. 
1.4.2  Evidence for Hepatic Stem Cells in Fetal and Adult Liver 
 
Figure 6: The liver progenitor cell theory. 
(a) During fetal liver development, hepatoblasts give rise to the two primary epithelial cell types 
of the mature liver: hepatocytes and biliary epithelial cells. Studies have identified potential 
markers of hepatoblasts with pluripotent stem cell characteristics, listed above. (b) It is theorized 
that quiescent liver progenitor cells (LPCs), potentially residing the Canal of Hering, are activated 
in the context of severe acute injury or chronic liver injury. These LPCs proliferate and are capable 
of giving rise to both hepatocytes and cholangiocytes, thus contributing to liver repair. 
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While the idea of a LPC population in the liver remains an intensely controversial topic, 
the concept of LPCs has roots in liver development. The liver originates from the foregut 
endoderm, and during hepatic specification there is formation of the liver bud which is composed 
of hepatoblasts, embryonic cells which give rise to both hepatocytes and BECs (for a full review 
of liver development see references (67, 136)). Within the hepatoblasts, several groups have 
reported the existence of a subset of cells with stem cell-like properties, termed hepatic stem cells 
(HpSCs) (Fig. 6A) (67). Cells expressing c-Met and CD49f and negative for c-Kit, CD45, and 
TER119 isolated from E13.5 fetal mouse liver were found to self-renew in culture and give rise to 
hepatocytes and BECs, and found to be multipotent by their capability to differentiate into 
pancreatic ductal and acinar cells or intestinal epithelial cells during in vivo transplantation 
experiments (137). Another group identified that the Dlk-positive cell fraction isolated from E14.5 
fetal mouse liver contained cells that were highly proliferative, could differentiate into BECs and 
hepatocytes in vitro, and gave rise to hepatocytes when transplanted intrasplenically in vivo (138). 
In human fetal liver samples, CD117+/CD34+/CD90- cells were found to express both hepatic and 
biliary markers in vitro (139). Other groups identified cells that express markers such as CD133, 
cytokeratins 8, 18, and 19, CD44H, telomerase, claudin 3, with weak expression of albumin (140); 
additional markers include CD34, CD90, c-kit, EpCAM, c-met, vimentin, and SSEA-4, and these 
cells have displayed over 100 population doublings in culture and the ability to differentiate into 
fat, bone, cartilage, and endothelial cells (141). When AFP+/CK19+/albumin+ HpSCs were 
isolated from E14 rat livers and transplanted into rats subjected to two-thirds 70% partial 
hepatectomy, they transdifferentiated into both hepatocytes and BECs and represented 23.5% of 
total liver mass after 6 months, suggesting continuous proliferation of the donor cells over the 
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duration of the experiment (142). However, the question remains whether HpSCs are confined to 
fetal liver development or persist into adulthood.   
A potential location for HpSCs in the adult liver is in the canals of Hering (Fig. 6B). 
Examination of human postnatal liver samples have revealed that “hybrid” cells in the canal of 
Hering which express HpSC markers (140, 143, 144), such as BECs which weakly express Hnf4α 
and hepatocytes which weakly express Hnf1β (145). In normal adult mice, a small fraction of cells 
expressing markers such as EpCAM, CD133, CD13, and SOX9 have been isolated and reported 
as adult LPCs (146-148), although the efficiency of these cells to form colonies and differentiate 
into hepatocytes in vitro was reduced with age (149). In line with these results, single-cell isolated 
SOX9-positive ductal progenitors formed self-renewing organoids in culture (150). More recently, 
ST14 was identified as a marker of clonogenic cholangiocytes which could give rise to organoids 
that could be serially passaged, although it was not determined if these ST14-positive BECs were 
localized to the canals of Hering (151). Studies using sub-lethal acetaminophen overdose have 
demonstrated through BrdU administration that the cells in the canals of Hering are label-retaining 
cells, a property characteristic of stem cell niches (152, 153). Additionally, cells in the canals of 
Hering have been shown to be regulated by Hedgehog signaling, similar to the progenitor 
compartments of other organs such as skin, bone marrow, and intestine (154). A laminin-
containing basement membrane is present in the canals of Hering (153, 155), and laminin has been 
shown to be important for the proliferation and maintenance of LPCs in culture (156), and laminin 
surrounds LPCs during liver injury in vivo (157, 158). Additionally, morphological studies after 
severe liver injury in mice indicated that LPCs were derived from the canals of Hering (159). 
Taken together, these data suggest there may be a population of LPCs in the adult liver, although 
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their function in liver regeneration has been more clearly elucidated in models of liver injury as 
opposed to studies of homeostatic adult liver. 
1.4.3  Evidence for Liver Progenitor Cells and BEC-to-Hepatocyte Differentiation in 
Rodent Models 
1.4.3.1 Original Description of Oval Cells in Rats 
The first description of what came to be known as putative adult LPCs after hepatic injury 
was a study of liver injury in rats published in the 1950s. In a study cataloguing the histological 
changes following administration of chemical carcinogens in rats, Dr. Emmanuel Farber noted that 
a very early change was the proliferation of “oval cells”, which first appeared in the periportal area 
and over time expanded throughout the entire liver lobule, a phenomenon also described as a 
ductular reaction. These cells were presumed to be of BEC origin (160). It was noted that 
expansion of these cells preceded liver regeneration and it was speculated that oval cells were 
giving rise to a subset of hepatocytes in hyperplastic liver nodules. It was further found that oval 
cells expressed fetal liver markers such as α-fetoprotein (AFP) (161). Studies of azo dye 
carcinogenesis similarly reported transitioning of oval cells into hepatocytes (162, 163), and it was 
suggested that oval cells may function to provide new hepatocytes during prolonged severe liver 
injury. However, the origin and fate of oval cells was intensely controversial (105). Other groups 
performed cell labeling experiments with tritiated thymidine in multiple models of liver injury 
including chemical carcinogenesis, bile duct ligation, and partial hepatectomy in combination with 
carbon tetrachloride administration and argued that oval cells did not give rise to hepatocytes and 
instead underwent removal by cell death (164-166).  
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The study of oval cells was furthered by the development of new rodent models, including 
the Solt-Farber model of hepatocarcinogenesis, in which rats were injected with 2-
acetylaminofluorene (2-AAF) to block hepatocyte proliferation and then subjected to partial 
hepatectomy (PHx), which led to a massive expansion of oval cells (167). Administration of the 
biliary toxin methylene dianiline (DAPM) prior to the 2-AAF/PHx protocol blocked the expansion 
of oval cells and prevented the expression of AFP, providing further evidence that oval cells were 
derived from cholangiocytes (168). Pulse-chase labeling of specifically oval cells with tritiated 
thymidine (169, 170) and careful immunohistochemical analysis (171) in the 2-AAF/PHx model 
demonstrated the conversion of oval cells into hepatocytes, leading to the hypothesis that oval cells 
only give rise to hepatocytes when hepatocyte proliferation is impaired in the context of liver 
injury, which is remains a popular hypothesis for the condition of LPC-to-hepatocyte 
differentiation to this day.  
1.4.3.2 The Choline-Deficient, Ethionine-Supplemented Diet Model 
Another model used to study oval cells in rats involved the combination of the 
hepatocarcinogen ethionine with choline deficiency. Prolonged choline deficiency was known to 
induce liver tumors in rats (172, 173). Ethionine is an analog of methionine and is extremely toxic 
to cells, causing incorporation of ethionine into proteins, reduced protein translation, inhibition of 
DNA replication (174), and prolonged administration of ethionine promotes development of liver 
tumors in rats (160). Administration of a choline-deficient, ethionine-supplemented (CDE) diet in 
rats acutely led to immune infiltration, cell necrosis, fat accumulation, and massive oval cell 
proliferation (175). The CDE diet model has since been adapted for use in mice, where it also gives 
rise to steatohepatitis and oval cell expansion (176). The efficiency and speed of the CDE diet in 
promoting expansion of putative LPCs has made it a widely used model in this field. Sophisticated 
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quantitative liver intravital microscopy revealed compromised blood-bile barrier in mice fed CDE 
diet for four days, which was accompanied by disruption of tight junctions and increase in liver 
injury (177). Deposition of matrix around the portal tract occurs as early as after three days of CDE 
diet and increases over the course of injury, but expansion of the DR begins around day seven of 
CDE diet-induced liver injury and continues to increase over time (158, 178).  
It has been theorized that hepatic injury-mediated inflammatory signaling is required for 
the initiation of the DR. Previously it was shown that a Th1-mediated cellular immune response is 
necessary for DR by demonstrating impaired LPC activation in CDE diet-fed 
immunocompromised mice by genetic deletion of key genes for T-cell-mediated immune 
response, such as CD3, Rag2 and IFNr (179, 180). More recently, it was reported that bone marrow 
cell transplantation or recombinant TWEAK (TNF-like weak inducer of apoptosis) injection is 
sufficient to induce DR in healthy mice without additional hepatic injury (181). This result may 
suggest that hepatic damage-induced macrophage infiltration and secretion of TWEAK is critical 
for triggering DR. However, it must be noted that there is no DR following 2/3 PHx, which also 
induces TWEAK/Fn14 (receptor for Tweak)-mediated innate immune responses (182). Therefore, 
it would be interesting to investigate the immunologic profiles at early stage of the livers with or 
without DR.  
Although it has long been speculated that oval cells give rise to hepatocytes in the CDE 
diet injury model, the advent of lineage tracing technology in mice has allowed researchers to 
directly test this hypothesis. First it was shown that the cells of the DR observed after CDE diet 
feeding are of BEC origin; one group labeled ductal plate cells (an embryonic structure consisting 
of a single-layered sleeve of Sox9-positive cells around the periportal mesenchyme which gives 
rise to cholangiocytes and periportal hepatocytes) with yellow fluorescent protein (YFP) via Sox9-
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CreERT and found that after CDE diet administration the CK19-positive oval cells also expressed 
YFP, indicating ductal plate origin (183). Other lineage tracing systems to label BEC-derived oval 
cells in CDE diet-fed mice include Osteopontin (OPN)-CreERT (155), Foxl1-Cre (184), Hnf1β-
CreERT (185), and Krt19-CreERT  (186-188). While these BECs do not contribute to hepatocytes 
during homeostasis or during toxic or surgical loss of liver mass (150, 155, 186), several groups 
have demonstrated that LPCs give rise to hepatocytes after CDE diet-induced liver injury followed 
by a recovery period on normal chow, with numbers of LPC-derived hepatocytes ranging from 
1.86% (185), 2.45% (155), to 29% in one study where analysis was limited to mice that lost more 
than 14% of their initial body weight upon exposure to CDE diet (184). However, other groups 
performing lineage tracing in the CDE diet model have found that BECs do not significantly 
contribute to hepatocytes. One studying utilizing Sox9-CreERT to label BECs found no BEC-
derived hepatocytes after CDE diet and recovery (150). Another group utilized Krt19-CreERT to 
label BECs and failed to detect BEC-derived hepatocytes after CDE diet and recovery (186). 
Several groups have utilized adeno-associated virus serotype 8 (AAV8), a virus which 
preferentially infects hepatocytes (189), to deliver Cre recombinase driven by a hepatocyte-
specific promoter. With this technique, greater than 99% of hepatocytes can be genetically labeled 
(186, 188-190). In these hepatocyte lineage tracing studies, several groups found no contribution 
of BECs to hepatocytes during CDE diet and recovery (186, 190).  
However, a potential explanation for the very few to no BEC-derived hepatocytes after 
CDE diet-induced liver injury in mice is due to the fact that hepatocyte proliferation is not impaired 
during CDE diet (150, 188, 190). One group utilized the AhCre system to conditionally delete the 
E3 ubiquitin ligase Mdm2 in up to 98% of hepatocytes, leading to overexpression of p21, 
hepatocyte senescence, hepatocyte injury, and widespread DR. LPCs isolated from CDE diet-fed 
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mice were transfected with a GFP plasmid and transplanted into Mdm2 hepatocyte-null mice, and 
after three months GFP-positive hepatocytes and BECs represented approximately 15% of liver 
tissue, suggesting LPC-to-hepatocyte differentiation (191). In a follow-up study, Krt19-CreERT was 
utilized to label BECs, and animals were injected with AAV8-p21 to overexpress p21 in 
hepatocytes followed by CDE diet and recovery, which resulted in approximately 15.3% of 
hepatocytes being derived from BECs. In the same study, the authors used AAV8-thyroid binding 
globulin (TBG)-Cre in order to delete β1 integrin specifically in hepatocytes, which were 
simultaneously labeled with the marker tdTomato. These animals were given methionine, choline-
deficient (MCD) diet to induce liver injury followed by a recovery normal diet, where 20-30% of 
hepatocytes were found to be tdTomato-negative, indicating they did not originate from a pre-
existing hepatocyte. These results were confirmed in Krt19-CreERT mice with tdTomato-labeled 
BECs given RNAi against Itgb1 (β1 integrin) and subjected to MCD diet followed by recovery, 
where tdTomato-positive hepatocytes were observed (187). In a recent study from our group, mice 
with hepatocyte-specific EYFP-labeling and simultaneous deletion of β-catenin via AAV8-TBG-
Cre subjected to CDE diet displayed a profound impairment of hepatocyte proliferation. Following 
recovery on normal diet for two weeks, there was expansion of β-catenin-positive, EYFP-negative 
hepatocytes, accounting for approximately 20% of periportal hepatocytes. Interestingly, between 
three and seven days of recovery on normal diet after CDE diet, very small β-catenin-positive 
hepatocytes were observed, along with β-catenin+/CK19+/Hnf4α+ cells, suggesting BECs in the 
process of differentiating into hepatocytes (Fig. 7B). Positive lineage tracing via Krt19-CreERT 
mice with tdTomato-labeled BECs injected with Ctnnb1 RNAi and placed on CDE diet followed 
by recovery resulted in tdTomato-positive hepatocytes, confirming that BECs were giving rise to 
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hepatocytes in this model (188). All together, these results suggest that when hepatocyte 
proliferation is impaired in the CDE diet model, BECs/LPCs give rise to hepatocytes. 
1.4.3.3 The DDC Diet Model 
Another model that has been used to study potential BEC-to-hepatocyte differentiation is 
the 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet model, which causes porphyrin 
pigment plugs in the biliary tract, leading to bile duct obstruction, DR, cholangitis, and periportal 
fibrosis (192). A notable feature of the DDC diet in addition to the robust proliferation of 
hepatocytes and BECs is the appearance of biphenotypic hepatocytes which express Hnf4α and 
biliary marker A6 (193). However, much like work in the CDE diet, different groups have reported 
conflicting conclusions regarding LPC-to-hepatocyte differentiation. Groups utilizing Krt19-
CreERT mice (186) or Sox9-CreERT mice (150) with labeled BECs found no BEC-derived 
hepatocytes after four weeks of DDC diet-induced liver injury (150) or 2-3 weeks of DDC diet 
followed by recovery on normal diet (186). However, when hepatocyte proliferation was impaired 
through hepatocyte-specific β1 integrin deletion or p21 overexpression and animals were subjected 
to DDC diet and recovery, significant numbers of BEC-derived hepatocytes were observed (187). 
One group lineage traced Lgr5+ cells, and found that while Lgr5 was not readily detectable in 
normal liver, treatment with DDC diet led to labeling of both BECs and hepatocytes. When single 
Lgr5+ cells were isolated, they could be cultured into self-renewing organoids expressing markers 
of both BECs and hepatocytes. These organoids could differentiate to hepatocytes when 
transplanted in vivo, suggesting these Lgr5+ cells marked damage-induced LPCs (194). Excitingly, 
a recent study theorized prolonged exposure to severe liver injury, as is the case for human patients, 
would lead to BEC-derived hepatocytes in wild-type animals. To this end, they subjected Krt19-
CreERT mice with labeled BECs to DDC diet for 24 weeks, and observed approximately 9.1% of 
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hepatocytes were BEC-derived (195). This work has important implications because of the 
appearance of BEC-derived hepatocytes in the absence of genetic manipulation. 
It has also been reported that epigenetic chromatin remodeling plays important roles in 
LPC activation in models such as the DDC diet. Polycomb repressive complexes (PRCs) have 
been reported as crucial regulators of proliferation of hepatoblasts (196, 197) and LPCs (198) via 
repressing Bim1 expression (196). Jalan-Sankrikar et al. suggested hedgehog signaling as an 
upstream regulator of EZH2/PRC during proliferation of LPCs in DDC-fed mice (198). Recently, 
it was reported that chromatin readers, bromodomain and extraterminal (BET) proteins, regulate 
LPC activation in a Myca-dependent manner using both zebrafish and mouse systems (17). 
Altogether, these results may suggest that chromatin modification is necessary for transition of a 
quiescent LPC into active status for further expansion. However, distinct roles for chromatin 
remodeling in reprogramming/dedifferentiation of parenchymal cell and LPCs during regeneration 
remains to be further investigated. 
1.4.3.4 The Thioacetamide Liver Injury Model 
Another model that has been used to study BEC-to-hepatocyte differentiation is the 
thioacetamide (TAA)-induced liver injury model. TAA is metabolized into a toxic metabolite in 
hepatocytes and induces centrilobular hepatic necrosis (199). Chronic administration of TAA in 
drinking water leads to the development of cirrhosis (200). A recent study utilized AAV8-TBG-
Cre to label hepatocytes with tdTomato and simultaneously delete β1 integrin specifically in 
hepatocytes, and when these mice were exposed to TAA for three weeks followed by a recovery 
period on normal diet, 20-30% of hepatocytes were tdTomato negative (187). A more recent study 
subjected Krt19-CreERT mice with labeled BECs to TAA treatment for 24 weeks, and found around 
10% of hepatocytes were BEC-derived. Excitingly, the authors of this study identified bi-
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phenotypic cells with BEC-morphology that expressed CK19 and Hnf4α, which accounted for 
approximately 3.87% of ductular cells. These cells had reduced expression of mature BEC markers 
such as PKCζ and primary cilia, and did not express Lgr5 or AFP, which led the authors to argue 
these cells were BECs directly converting into hepatocytes, as opposed to differentiation through 
a LPC intermediate stage (195). However, expression of more widely accepted LPC markers were 
not assessed in this study, and the renewal capacity of these cells was not tested through in vitro 
culture, so the question remains if these bi-phenotypic cells represent differentiation of mature 
BECs or activation of LPCs. 
1.4.4  Transdifferentiation of Hepatocytes into BECs: Evidence for the Facultative Stem 
Cell Hypothesis 
            An alternative theory to that of LPCs is that there is no “stem cell” population in the liver 
and instead hepatocytes and cholangiocytes serve as facultative stem cells (104, 201), meaning the 
normal cell population dedifferentiates in response to injury. By this theory, cholangiocytes 
directly transdifferentiate into hepatocytes, and vice versa, to mediate liver regeneration when the 
normal proliferation of one of these populations is impaired (Fig. 7A, C). In the case of hepatocyte-
to-cholangiocyte transdifferentiation, this theory is supported by in vitro organoid cultures. Rats 
which do not express the enzyme Dipeptidyl Peptidase IV (DPPIV) were given retrorsine, an agent 
which blocks hepatocyte proliferation, and transplanted with DPPIV-positive hepatocytes, which 
resulted in livers with colonies of donor-derived DPPIV-positive hepatocytes. When organoid 
cultures were derived from these hybrid livers, cells resembling BECs on the surface of the 
organoid culture were found to be DPPIV-positive, indicating hepatocyte origin (202). This 
finding was further confirmed when DPPIV-negative rats were given retrorsine and subjected to  
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Figure 7: The transdifferentiation theory. 
(a) During acute severe or chronic liver injury where hepatocyte function is significantly impaired, 
BECs can directly transdifferentiate into hepatocytes to mediate liver repair. During this process, 
BECs express hepatocyte markers such as Hnf4α. (b) The liver from a mouse fed CDE diet for 
two weeks followed by three days of recovery on normal diet stained for CK19 (green) and Hnf4α 
(red). A transdifferentiating cell which expressed both CK19 and Hnf4α is evident (white arrow). 
Scale bar: 20 µm. (c) Following bile duct paucity or severe injury to BECs, hepatocytes can 
transdifferentiate into BECs, and during this process hepatocytes will express BEC markers such 
as Sox9. Signaling pathways including Tgfβ, YAP, and Notch, and Wnt/β-catenin have been 
identified as playing a role in promoting this process. (d) Liver from a mouse two days post-bile 
duct ligation stained for Sox9 reveals the appearance of hepatocytes which express Sox9 (arrows) 
in comparison to the presence of Sox9 in the BECs lining the bile ducts (arrowheads). 
 
 
PHx followed by transplantation with DPPIV-positive hepatocytes. When these chimeric livers 
were pretreated with DAPM and subjected to bile duct ligation (BDL) (a surgical procedure 
where the common bile duct is ligated, leading to obstructive cholestasis, proliferation of BECs, 
and periportal fibrosis (203)) appearance of DPPIV-positive ductules was observed (204). A 
similar study found that GFP-labeled hepatocytes transplanted into rats after BDL adopted a 
cholangiocyte phenotype, indicating hepatocyte-to-BEC transdifferentiation (205). 
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The DDC diet has also been used to study hepatocyte-to-cholangiocyte differentiation. 
When mice were given AAV8-TBG-Cre to label hepatocytes with YFP and subjected to DDC diet 
or BDL, YFP-positive cells with biliary morphology which expressed BEC markers were detected 
(193). A different group found that SOX9+; EpCAM- negative cells isolated from DDC diet-fed 
mice could be differentiated into hepatocytes or BECs in vitro (206). One study utilized β-
galactosidase-labeled hepatocytes transplanted into mice subjected to retrosine treatment in 
conjunction with PHx to promote engraftment of donor cells, and subsequently induced liver injury 
with CCL4 or DDC diet and observed β-galactosidase-positive BECs (207). Interestingly, a recent 
study where telomerase reverse transcriptase-expressing hepatocytes were labeled with the lineage 
marker tdTomato described the appearance of tdTomato-positive BECs following DDC diet-
induced liver injury (208).   
In terms of signaling pathways that drive hepatocyte-to-BEC transdifferentiation, the 
crucial role of Notch signaling has been confirmed by numerous groups (Fig. 7C). Hepatocyte-
specific overexpression of Notch intracellular domain (NICD) in the absence of injury was 
sufficient to induce hepatocyte-to-BEC conversion, and hepatocyte-specific deletion of Rbpj (the 
principal effector of Notch signaling) in mice fed DDC diet significantly reduced the number of 
hepatocyte-derived BECs, suggesting that Notch signaling is required for hepatocyte 
reprogramming (193). Another group found that the majority of cholangiocytes were derived from 
hepatocytes in chronic DDC diet-induced liver injury, and the ductular reaction in these mice was 
significantly increased with NICD overexpression and significantly reduced via Hes1 deletion 
(209). Notch signaling was also shown to be required for in vitro differentiation of LPCs into 
BECs, and in vivo blockage of Notch receptor cleavage during DDC diet administration reduced 
the extent of the DR, which was attributed to impaired hepatocyte dedifferentiation (210). 
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Importantly, overexpression of Yes-Associated Protein (YAP) in hepatocytes was sufficient to 
dedifferentiate hepatocytes into ductal-like cells, and Notch signaling was found to be a 
downstream target of YAP signaling during the dedifferentiation process (211). Similarly, another 
group described periportal hepatocytes which express SOX9 and differentiate to ductal cells after 
DDC diet-induced liver injury (212). Another signaling pathway putatively involved in 
hepatocyte-to-BEC transdifferentiation is the Wnt/β-catenin signaling pathway. Mice 
overexpressing a stabilized form of β-catenin showed increased hepatocyte expression of BEC 
markers after DDC diet-induced liver injury, and blocking Wnt secretion from BECs via deletion 
of Wntless reduced the number of hepatocytes expressing BEC markers following DDC diet-
induced liver injury (213).  
However, the findings of hepatocyte-to-BEC transdifferentiation during liver regeneration 
are disputed. Some lineage tracing studies performed on mice fed DDC diet or subjected BDL 
detected no evidence of hepatocyte-derived BECs (189). Other groups have found that the 
hepatocytes which adopt a biliary phenotype during injury revert back to the hepatocyte fate upon 
the cessation of injury, arguing that it is hepatocyte metaplasia as opposed to true 
transdifferentiation (214). Interestingly, a recent paper demonstrated the transdifferentiation of 
hepatocytes into BECs in a mouse model of human Alagille syndrome. Mice with Albumin-Cre 
mediated deletion of Rbpj and Hnf6 in both hepatocytes and cholangiocytes are born lacking 
peripheral bile ducts but spontaneously form bile ducts by approximately four months of age. 
Hepatocytes in these mice were labeled with GFP via injection of AAV8 encoding flippase under 
a hepatocyte-specific promoter. The newly-derived BECs were GFP-positive, indicating their 
hepatocyte origin. The authors further proved that this transdifferentiation of hepatocytes into 
BECs required TGFβ signaling, as Albumin-cre+/−;Rbpjf/f; Hnf6f/f; Tgfbr2f/f mice failed to form de 
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novo peripheral bile ducts. These hepatocyte-derived bile ducts were stable throughout life, 
indicating true transdifferentiation as opposed to metaplasia (215).  
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2.0 Bromodomain and Extraterminal Proteins (BET) Proteins Regulate Hepatocyte 
Proliferation in Hepatocyte-Driven Liver Regeneration 
In this section we investigate the role of BET proteins after PHx, a hepatocyte-proliferation 
driven liver regeneration model, by treating C57BL6 mice with BET-inhibitor JQ1 or a vehicle 
control two hours post-PHx and assessing hepatocyte proliferation at 40-45 hours post-PHx, which 
corresponds to the peak of hepatocyte proliferation in mice. We predict that JQ1 will block 
hepatocyte proliferation, and we discuss our results, interpretations, and future directions in detail. 
This study was published in The American Journal of Pathology PMID: 29545201 (216). As first 
author, the publisher Elsevier has granted full permission to reuse the manuscript in this 
dissertation.  
2.1 Paper Summary 
Bromodomain and extraterminal (BET) proteins recruit key components of basic 
transcriptional machinery to promote gene expression. Aberrant expression and mutations in BET 
genes have been identified in many malignancies. Small molecule inhibitors of BET proteins like 
JQ1 have shown efficacy in preclinical cancer models including affecting growth of hepatocellular 
carcinoma. BET proteins also regulate cell proliferation in non-tumor settings. We recently 
showed BET proteins regulate cholangiocyte-driven liver regeneration. Here, we sought to study 
the role of BET proteins in hepatocyte-driven liver regeneration in partial hepatectomy (PHx) and 
acetaminophen (APAP)-induced liver injury models in mice and zebrafish. JQ1 was injected 2 or 
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16 hours post-PHx in mice to determine effect on hepatic injury, regeneration and signaling. Mice 
treated with JQ1 after PHx display increased liver injury and a near-complete inhibition of 
hepatocyte proliferation. Levels of Ccnd1 mRNA and Cyclin D1 protein were reduced in 16 hour 
post-PHx JQ1 injected animals, and even further reduced in 2 hours post-PHx JQ1-injected mice. 
JQ1-treated zebrafish larvae after APAP-induced injury also displayed notably impaired 
hepatocyte proliferation. In both models, Wnt signaling was prominently suppressed by JQ1. Our 
results show BET proteins regulate hepatocyte proliferation-driven liver regeneration and Wnt 
signaling is particularly sensitive to BET protein inhibition. 
2.2 Background 
The liver is a highly regenerative organ which is able to recover from repeated bouts of 
injury through proliferation of the main epithelial cell type of the liver, the hepatocytes (80). 
Alternatively, in conditions of extreme liver injury where proliferation of hepatocytes is impaired, 
biliary epithelial cells (BECs) can give rise to liver progenitor cells (LPCs) which can subsequently 
differentiate into hepatocytes to restore lost cell mass (217, 218). Despite this innate capacity for 
regeneration, chronic liver disease and cirrhosis is the 12th leading cause of death in the United 
States (219). Patients with chronic liver disease and cirrhosis are at a major risk for developing 
hepatocellular carcinoma (HCC), the fifth most common cancer in men worldwide and the second 
leading cause of cancer-related death (220).  The prognosis for HCC is exceedingly poor, with an 
overall 5-year survival rate of 5.1% in the United States, as there are currently no curative therapies 
for advanced HCC (221). Clearly, there is a great need to develop new therapies for HCC and 
underlying chronic liver disease. As failure of endogenous liver regeneration is thought to drive 
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progression in chronic liver disease (222, 223), understanding the mechanisms of liver 
regeneration may lead to the development of new therapies. 
Recently, a class of drugs has been developed which inhibits bromodomain and 
extraterminal (BET) proteins and shows promise in the treatment of cancer and inflammation (3). 
The BET protein family consists of Brd2, Brd3, Brd4, and Brdt which share conserved 
bromodomains, chromatin interaction modules that bind to acetylated lysine residues on histone 
tails (2). Brd4 in particular has been identified as a component of Mediator, a multiprotein complex 
that promotes transcription by interacting with transcription factors (TFs) to recruit and activate 
RNA polymerase II (3, 4). Moreover, Brd4 has been found to occupy the promoters or enhancers 
of virtually all actively transcribed genes in a variety of cells types (8-10). The recently developed 
drug JQ1 displays potent and specific inhibition of Brd4 through competitively binding its 
bromodomains (11). Interestingly, JQ1 has shown potent anti-cancer effects by selectively 
inhibiting oncogenic gene expression in various cancer cells lines and murine models (8, 12, 224). 
The dosage of JQ1 required to inhibit tumors is well-tolerated in mice, despite widespread 
expression of Brd4 in mouse tissues (8, 11, 12). 
Recent reports have additionally implicated a role of Brd4 in liver pathology. Brd4 was 
found to be overexpressed in HCC cell lines compared to normal liver, and knockdown of Brd4 
expression impaired proliferation, migration, and invasion of HCC cells (15, 225, 226). 
Furthermore, treatment with JQ1 reduced cell growth in both HCC cell lines and a xenograft tumor 
model (226). JQ1 treatment was also shown to be protective in a mouse model of carbon 
tetrachloride-induced liver fibrosis through abrogation of cytokine-induced activation of hepatic 
stellate cells (16). These reports would suggest Brd4 inhibitors as a viable treatment option for 
certain liver diseases. However, Brd4 has also been implicated in the promotion of liver 
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regeneration. In a previous study, we showed that JQ1 inhibited BEC-driven liver regeneration in 
both zebrafish and mice (227). However, the role of Brd4 in the more common hepatocyte-driven 
liver regeneration has not been assessed. In the current study, we determine the effect of JQ1 
treatment in two independent models of hepatocyte-driven liver regeneration: partial hepatectomy 
in mice and acetaminophen-overdose in zebrafish. We show that JQ1 is a potent inhibitor of 
hepatocyte proliferation after liver injury. Therefore, the potential use of JQ1 in treatment of liver 
disease must be carefully considered in order to avoid negatively impacting normal liver 
regeneration. 
2.3 Methods 
2.3.1  Animals and Surgery 
All animal experiments and procedures were performed under the guidelines of the 
National Institutes of Health and after approval by the Institutional Animal Use and Care 
Committee at the University of Pittsburgh, School of Medicine. Male C57BL6/J mice (The 
Jackson Laboratory, Bar Harbor, ME) underwent partial hepatectomy as previously described 
(228). Either 2 hours or 16 hours after surgery animals were injected intraperitoneally with 50 
mg/kg JQ1 (ApexBio, Taiwan, Cat# A1910). A stock solution of 50 mg/ml JQ1 was prepared in 
DMSO and subsequently diluted to a working concentration of 5 mg/ml in a solution of 10% 
hydroxypropyl β-cyclodextrin in sterile water (vehicle solution). As a control, mice were injected 
with the vehicle solution alone at the indicated time point after surgery. Animals were also injected 
with either JQ1 or vehicle solution after sham surgeries (where surgery was performed but no liver 
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was removed). At the time of harvest, either 40 – 45 hours or 72 hours after surgery, animals were 
anesthetized with isoflurane and blood was drawn from the inferior vena cava. Subsequently, 
anesthetized mice were euthanized by cervical dislocation. Livers were washed in phosphate 
buffered saline (PBS), flash frozen in liquid nitrogen, and stored at -80℃ until subsequent protein 
and RNA analysis, or alternatively were drop fixed in 10% buffered formalin for 48 hours prior to 
paraffin embedding. Serum aspartate aminotransferase (AST) levels were determined by 
automated methods at the University of Pittsburgh Medical Center clinical chemistry laboratory. 
2.3.2  Immunohistochemistry 
Tissue samples embedded in paraffin were cut into 4 µm sections. Tissue sections were 
deparaffinized in in xylene and hydrated through changes of 100% ethanol followed by 95% 
ethanol, washed in distilled water, and finally washed in PBS. Antigen retrieval was performed by 
microwaving slides in pH 6 sodium citrate buffer (Cyclin D1) or zinc sulfate buffer (PCNA). After 
cooling, endogenous peroxidase activity was blocked through incubation in 3% H2O2 in distilled 
water for 10 minutes. Slides were then washed in PBS and blocking was performed using Super 
Block (ScyTek Laboratories, Logan, UT, AAA500) for 10 minutes (Cyclin D1) or 20 minutes 
(PCNA). Primary antibodies were diluted in 1% bovine serum albumin (BSA) (Fisher 
BioReagents, Pittsburgh, PA, BP1605100) with 0.1% Tween™ 20 (Fisher BioReagents, BP337-
500) in PBS as follows: Cyclin D1 (Abcam, Cambridge, United Kingdom, ab134175, 1:200) and 
PCNA (Santa Cruz, sc-56, 1:5000) and incubated on the slides for 1 hour at room temperature. 
Sections were washed 3 times in PBS and the correct biotinylated anti-rabbit (Vector Laboratories, 
Burlingame, CA, BA-1000, 1:500) or biotinylated anti-mouse (Millipore, Burlington, MA, 
AP181B, 1:700) secondary antibodies were incubated on the tissue sections for 30 minutes. After 
 43 
washing with PBS 3 times, slides were sensitized with the Vectastain® ABC kit (Vector 
Laboratories, PK-6101) for 30 minutes. Sections were washed 3 times with PBS and color was 
developed with the DAB Peroxidase Substrate Kit (Vector Laboratories, SK-4100) followed by 
quenching in distilled water for 5 minutes. Sections were counterstained in hematoxylin (Thermo 
Scientific, Pittsburgh, PA, 7211) for approximately 8 – 20 seconds and washed under running tap 
water for 5 minutes. Slides were then dehydrated in changes of alcohol (70%, 95%, 100%) 
followed by xylene and coverslips were applied with Cytoseal™ XYL (Thermo Scientific, 8312-
4). Images were taken on Axioskop 40 (Zeiss, Oberkochen, Germany) inverted brightfield 
microscope. 
2.3.3  Protein Extraction and Western Blots 
Whole-cell lysates of liver tissue were prepared using RIPA buffer containing fresh 
protease and phosphatase inhibitors (Thermo Scientific, Prod# 1861282) as described previously 
(229). Gel electrophoresis was performed with 30 µg of protein run on precast 7.5% 
polyacrylamide gels (BioRad, Hercules, CA, Cat# 456-1025) and transferred onto nitrocellulose 
membranes using the Trans-Blot® Turbo™ Transfer kit (BioRad, Cat# 170-4270). Membranes 
were blocked in 5% milk (LabScientific, Highlands, NJ, Cat# M0841) in Blotto blocking buffer 
(0.15 M NaCl, 0.02 M Tris pH 7.5, 0.1% Tween in dH2O) for 30 minutes at room temperature. 
Primary antibodies were diluted in 5% milk/Blotto as follows: Cyclin D1 (Thermo Scientific, RB-
9041-P; 1:200), β-catenin (BD Biosciences, San Jose, CA, 610154; 1:1000), and GAPDH (Santa 
Cruz Biotechnology, Dallas, TX, sc-25778, 1:1000) and incubated on membranes at 4℃ 
overnight. Membranes were washed in Blotto for 15 minutes prior to incubation with the correct 
HRP-conjugated mouse (Millipore, AP308P; 1:10,000) or rabbit (Thermo Scientific, Cat# 31460, 
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1:20,000) secondary antibodies diluted in 5% milk/Blotto for 1 hour at room temperature. 
Membranes were then washed for 15 minutes in Blotto prior to exposure with SuperSignal® West 
Pico Chemiluminescent Substrate (Thermo Scientific, Prod# 34080) for 3 minutes at room 
temperature. The resulting bands were viewed by autoradiography. 
2.3.4  RNA Isolation and Real-Time PCR 
Cellular RNA was isolated by homogenizing liver tissue in TRIzol™ Reagent (Thermo 
Scientific, Cat# 15596026), followed by a cholorform extraction, precipitating nucleic acid with 
isopropanol at -20℃, and dissolving the resulting dried nucleic acid pellet in nuclease-free water 
(QIAGEN, Hilden, Germany, Cat# 129117). DNase treatment was performed with the DNA-
free™ Kit (Ambion, Pittsburgh, PA, AM1906) according to manufacturer instructions. 
Approximately 1 µg of RNA was reverse-transcribed using SuperScript® III (Invitrogen, 
Carlsbad, CA, 18080-044). Real-time PCR was performed on a StepOnePlus™ Real-Time PCR 
System (Applied Biosystems, Foster City, CA, Cat# 4376600) using the Power SYBR® Green 
PCR Master Mix (Applied Biosystems, 4367660) with the mouse-specific primers listed Table 1. 
Fold changes in gene expression were calculated after normalizing target gene expression to the 
average of two housekeeping genes (Gapdh and Rn18s) using the ΔΔ-Ct method. 
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Table 1: Sequence of Real Time PCR primers used in the study in mice. 
Gene Forward Primer Reverse Primer 
Ccnd1  5’-TTTCTTTCCAGAGTCATCAAGTGT-3’ 5’-TGACTCCAGAAGGGCTTCAA-3’ 
Ctnnb1  5’-GGGTCCTCTGTGAACTTGCTC-3’ 5’-
TTCTTGTAATCCTGTGGCTTGTCC-
3’ 
Axin2 5’-GAGAGTGAGCGGCAGAGC-3‘ 5’-CGGCTGACTCGTTCTCCT-3’ 
Regucalcin  5’-CGATTCAATGATGGGAAGGT-3’ 5’-CGTTTCCTCAGCCATGGTA-3’ 
Lect2 5’-CCCACAACAATCCTCATTTCA-3’ 5’-GTTAGCCCATGGTCCTGCTA-3’ 
Brd4 5’-TTCAGCACCTCACTTCGACC-3’ 5’-CTGGTGTTTTTGGCTCCTGC-3’ 
Gapdh 5’-AACTTTGGCATTGTGGAAGG-3’ 5’-ACACATTGGGGGTAGGAACA-3’ 
Rn18s 5’-GTAACCCGTTGAACCCCATT-3’ 5’-CCATCCAATCGGTAGTAGCG-3’ 
 
2.3.5  Cell Culture 
HepG2 liver tumor cells were grown to approximately 30 – 40% confluency in Eagle's 
Minimum Essential Medium (ATCC®, Manassas, VA, Cat# 30-2003) supplemented with 10% 
fetal bovine serum (Gemini Bio-Products, West Sacramento, CA, Cat# 100-106) and penicillin-
streptomycin (ATCC®, 30-2300) and then serum starved overnight. Cells were transfected with 
800 ng TopFlash (Millipore, 21-170) or the p65 reporter (gift from Dr. David Geller (230)) and 
200 ng Renilla in Opti-MEM media (Gibco, Gaithersburg, MD, Cat# 31985-070) using the 
Lipofectamine® 3000 Transfection Kit (Invitrogen, L3000-008) according to manufacturer 
instructions. After 5 hours incubation with transfection reagents, 0.25 µm, 0.5 µm, or 1 µm JQ1, 
or DMSO alone as a control, in EMEM media supplemented with 4% FBS and penicillin-
streptomycin was added to the cells. Treated cells were harvested 24 hours later and luciferase 
activity was measured using the Dual-Luciferase® Reporter Assay System (Promega, Madison, 
WI, Cat# E1960) and normalized to Renilla levels.  
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For siRNA experiments, HepG2 or Hep3B hepatocellular carcinoma cells were seeded at 
a density of 200,000 cells/well in 6-well plates. After 48 hours of culture, cells were transfected 
with Silencer® Select BRD4 siRNA S23901 (Ambion, 4390824) or Silencer® Select Negative 
Control #2 siRNA (Ambion, 4390847) in Opti-MEM media (Gibco, 31985-070) using the 
Lipofectamine® RNAiMAX kit (Invitrogen, 13778-150) and incubated for 24 hours at 37℃. Next, 
TopFlash transfections were performed as described earlier, and luciferase activity was measured 
24 hours post-TopFlash transfection. 
2.3.6  Zebrafish Studies 
Experiments were performed with approval of the Institutional Animal Care and Use 
Committee (IACUC) at the University of Pittsburgh.  Embryos and adult fish were raised and 
maintained under standard laboratory conditions (231).  We used the following transgenic lines: 
Tg(fabp10a:CFP-nfsB)s931 (232),   Tg(EPV.Tp1-Mmu.Hbb:hist2h2l-mCherry)s939 (233), and 
Tg(fabp10a:mAGFP-gmnn,cryaa:ECFP)pt608 (227) [referred to here as Tg(fabp10a:CFP), 
Tg(Tp1:H2B-mCherry), and Tg(fabp10a:mAGFP-gmnn), respectively] and Tg(OTM:d2EGFP)kyu2 
(234).  Liver injury was induced by treating Tg(fabp10a:CFP) larvae with 10 mM acetaminophen 
(APAP) from 3.5 to 5 dpf for 36 hours.  The 10 mM APAP working solution was freshly made by 
dissolving APAP powder in egg water supplemented with 0.2% dimethyl sulfoxide (DMSO) and 
0.2 mM 1-phenyl 2-thiourea (PTU).  Hepatocyte ablation was performed by treating 
Tg(fabp10a:CFP) larvae with 10 mM metronidazole (Mtz) in egg water supplemented with 0.2% 
dimethyl sulfoxide (DMSO) and 0.2 mM PTU.  For BET inhibition, larvae were treated with 3 μM 
JQ1 or 50 μM iBET151 from R0h to R48h, and fabp10a:CFP expression was imaged using the 
Leica M205 FA epifluorescence microscope (227).  To quantify liver size and Wnt/β-catenin 
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activity, corrected total cell fluorescence (CTCF) of fabp10a:CFP and OTM:d2EGFP, 
respectively, was measured using the ImageJ software as previously described (235). 
2.3.7  Zebrafish Whole-Mount Confocal Microscopy  
Whole-mount immunostaining was performed as previously described (236), using the 
following antibodies: mouse anti-Alcam (1:20; ZIRC, Eugene, OR) and Alexa Fluor 647-
conjugated secondary antibodies (1:500; Life Technologies, Grand Island, NY).  Zeiss LSM700 
confocal microscope was used to obtain image data and confocal stacks were analyzed using the 
Zen 2009 software.  All figures, labels, arrows, scale bars, and outlines were assembled or drawn 
using the Adobe Illustrator (version CS5) software. 
2.3.8  Zebrafish qPCR 
Total RNA was extracted from 50 dissected livers using the RNeasy Mini Kit (Qiagen, 
Valencia, CA); cDNA was synthesized from the RNA using the SuperScript® III First-Strand 
Synthesis SuperMix (Life Technologies, Grand Island, NY) according to the kit protocols.  qPCR 
was performed as previously described (237), using the Bio-Rad iQ5 qPCR machine with the iQTM 
SYBR Green Supermix (Bio-Rad, Hercules, CA).  Fold changes were calculated after normalizing 
target gene expression to eef1a1l1 using the ΔΔ-Ct method.  At least three independent 
experiments were performed.  The zebrafish-specific primers used for qPCR are listed in Table 2. 
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Table 2: Sequence of Real Time PCR primers used in the study in zebrafish. 
Gene Forward Primer Reverse Primer 
brd4 5’-GGCCCCTTCTTCCTTCAACC-3’ 5’-TGTAGAATGCGCTCTCTAGGC-3’ 
ccnd1 5’-GGAACTGCTGGCGCTTAAATA-3’ 5’-GACTTGCGAGAGGAAGTTGG-3’ 
pcna 5’-ATCTGGATGTGGAGCAGCTT-3’ 5’-TGTGACCGTCTTGGACAGAG-3’ 
myca 5’-TATTGTTAACCCGCCCCCAC-3’ 5’-ATGCATTCACCAGCAGTCCA-3’ 
axin2 5’-GGCTACAGGTCCTACAGAC-3’ 5’-GCTTGTAAGGAGGAATGGC-3’ 
eef1α1l1 5’-CTGGAGGCCAGCTCAAACAT-3’ 5’-
ATCAAGAAGAGTAGTACCGCTAGC
ATTAC-3’ 
2.3.9  Statistical Analyses 
Statistical analysis was performed with GraphPad Prism software (version 7). For analyses 
concerning only two groups, a two-tailed Student’s t-test was performed, with p < 0.05 considered 
significant. For analyses concerning more than two groups, a one-way ANOVA test was 
performed, with p < 0.05 considered significant. For survival curves, a Gehan-Breslow-Wilcoxon 
test was performed, with p < 0.05 considered significant. 
2.4 Results 
2.4.1  JQ1 Administration 16 Hours Post-Partial Hepatectomy Impairs Cyclin D1 
Expression and Hepatocyte Proliferation at 40 Hours. 
To determine if JQ1 would have an impact on hepatocyte proliferation-driven liver 
regeneration, we utilized the mouse partial hepatectomy (PHx) model, a common model of liver 
regeneration where two-thirds of the liver is surgically removed and remaining hepatocytes 
proliferate to restore lost liver mass (81). In order to allow time for mice to recovery from the 
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surgery prior to injection, we administered a single injection of JQ1 at 16 hours post-PHx. We 
harvested mice within the 40 – 45 hours post-PHx window, which is the peak of DNA synthesis 
in mouse hepatocytes after PHx (238, 239) (Fig. 8A). JQ1-injected mice at 40 hours post-PHx 
displayed significantly elevated levels of serum liver injury marker aspartate aminotransferase 
(AST) compared to control mice injected with the vehicle solution (10% hydroxypropyl β-
cyclodextrin in distilled water) (Fig. 8B). When hepatocyte proliferation was assessed by 
immunohistochemistry (IHC) for proliferating cell nuclear antigen (PCNA) (240), there were 
many PCNA-positive hepatocytes in vehicle-injected animals, whereas JQ1-injected animals had 
very few PCNA-positive hepatocytes (Fig. 8C). Cyclin D1, which is involved in promoting the 
G1/S phase transition in the cell cycle, is known to be highly upregulated in order to drive 
hepatocyte proliferation after PHx in mice (241, 242). We detected robust hepatocyte expression 
of Cyclin D1 in vehicle-injected mice post-PHx, while JQ1-injected mice displayed a marked 
reduction in Cyclin D1 staining (Fig. 8C). Cyclin D1 was also dramatically reduced at both the 
gene expression (Fig. 8D) and protein levels (Fig. 8E) in JQ1-injected animals. 
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Figure 8: Injection of JQ1 16 hours post-PHx impairs liver regeneration. 
(a) Schematic for experimental plan for injection of JQ1 (50 mg/kg) or vehicle solution 16 hours 
post-PHx, followed by harvest at 40-45 hours post-PHx. (b) Serum AST levels are significantly 
elevated in JQ1-injected mice compared to vehicle-injected controls 40 hours post-PHx (t-test, * 
= p < 0.05). (c) IHC for PCNA and Cyclin D1 reveals significantly reduced hepatocyte 
proliferation and Cyclin D1 expression in JQ1-injected mice (scale bar 50 µm, PV = portal vein, 
CV = central vein). (d) Significantly reduced Ccnd1 gene expression in JQ1-injected mice (t-test, 
* = p < 0.05). (e) No reduction in total β-catenin levels but a significant reduction in Cyclin D1 
protein levels are evident in JQ1-injected mice. (f) Significant reduction in Rgn gene expression in 
JQ1-injected mice (t-test, * = p < 0.05). (g) Significant reduction in Axin2 gene expression in JQ1-
injected mice (t-test, ** = p < 0.01). (h) Significant reduction in Lect2 gene expression in JQ1-
injected mice (t-test, ** = p < 0.01). Error bars are mean + SD. 
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2.4.2  JQ1 Administration 16 hours Post-Partial Hepatectomy Impairs Expression of 
Additional Wnt Target Genes in Addition to Cyclin D1. 
Cyclin D1 is a known target of the Wnt/β-catenin signaling pathway (243, 244), and mice 
with liver-specific deletion of β-catenin display dramatically reduced Cyclin D1 levels and a delay 
in liver regeneration post-PHx (229). Therefore, we hypothesized JQ1 may be inhibiting Wnt/β-
catenin signaling in post-PHx mice. Indeed, in JQ1-injected mice there were significant decreases 
in gene expression of β-catenin targets regucalcin (Rgn) (245) (Fig. 8F), Axin2 (72) (Fig. 8G), and 
leukocyte cell-derived chemotaxin 2 (Lect2) (246) (Fig. 8H) compared to vehicle-injected controls 
at 40 hours post-PHx. However, there was no reduction in total protein levels of β-catenin in JQ1-
injected mice (Fig. 8E), suggesting JQ1 is inhibiting transcription of β-catenin target genes rather 
than directly inhibiting expression of β-catenin. 
2.4.3  An Earlier Administration of JQ1 at 2 Hours After Partial Hepatectomy Completely 
Prevents Cyclin D1 Expression and Hepatocyte Proliferation Leading to 
Enhanced Injury and Mortality at 40 Hours. 
Previous reports have shown that Cyclin D1 can be induced as early as 12 hours post-PHx 
in mice (247, 248), so we decided to administer JQ1 at 2 hours post-PHx (Fig. 9A) rather than 16 
hours post-PHx to investigate if this would completely abrogate any increases in Cyclin D1. We 
again chose to harvest tissue at the peak of hepatocyte proliferation (40-45 hours post-PHx). As a 
control, we injected mice with either JQ1 or the vehicle solution 2 hours after a sham surgery and 
harvested at 40 hours post-surgery to assess the effects on JQ1 on a non-injured liver. Injection of 
JQ1 had no effect on the gross appearance of sham animal livers (Fig. 9B). However, JQ1  
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Figure 9: Injection of JQ1 2 hour post-PHx impairs liver regeneration. 
(a) Schematic for experimental design of injecting JQ1 (50mg/kg) or vehicle solution 2 hour post-
PHx and harvesting at 40-45 hours post-PHx. (b) No effect on the gross morphology of livers from 
JQ1-injected sham surgery animals. (c) Striking discoloration of the livers of JQ1-injected animals 
40 hours post-PHx. (d) Reduced survival of animals injected with JQ1 2 hours post-PHx (Gehan-
Breslow-Wilcoxon test, * = p < 0.05, Vehicle n = 12, JQ1 n = 17). (e) No increase in serum AST 
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in JQ1-injected sham animals, but a significant increase in serum AST in JQ1-injected PHx 
animals compared to vehicle-injected PHx mice (one-way ANOVA, ** = p < 0.01). (f) IHC 
staining for PCNA and Cyclin D1 reveals robust staining in vehicle-injected controls, but virtually 
no staining in JQ1-injected mice 40 hours post-PHx (scale bar 50 µm, PV = portal vein, CV = 
central vein). (g) Dramatic upregulation of Ccnd1 gene expression in vehicle-injected animals 
post-PHx, but no upregulation in JQ1-injected animals (one-way ANOVA, **** = p < 0.0001). 
(h) No change in Brd4 expression after either PHx or JQ1 injection. (i) Reduced Cyclin D1 protein 
in JQ1 injected animals compared to vehicle-injected controls, but no reduction in total β-catenin 
protein levels. Error bars are mean + SD. 
 
 
injection 2 hours post-PHx resulted in severe liver injury, with the livers from JQ1-injected animals 
40 hours post-PHx exhibiting striking discoloration (Fig. 9C). Animals injected with JQ1 2 hours 
post-PHx had significantly reduced survival compared to vehicle-injected controls, with 30% of 
mice exhibiting notable morbidity requiring euthanasia at or before 45 hours post-PHx (Fig. 9D). 
Although there was no increase in serum AST in JQ1-injected animals that underwent sham 
surgery, JQ1-injected PHx mice displayed significantly elevated serum AST levels compared to 
vehicle-injected PHx animals (Fig. 9E). While in vehicle-injected animals there was robust 
hepatocyte expression of PCNA and Cyclin D1, in mice injected with JQ1 2 hours post-PHx there 
were almost no PCNA-positive hepatocytes in addition to extremely little Cyclin D1 staining (Fig. 
9F). In accordance with these results, Ccnd1 gene expression was significantly upregulated in 
vehicle-injected PHx mice compared to sham controls, but this upregulation was completely absent 
in mice injected with JQ1 2 hours post-PHx (Fig. 9G). Additionally, levels of Cyclin D1 protein 
were dramatically lower in JQ1-injected mice compared to vehicle-injected controls after PHx, 
while levels of β-catenin were not reduced (Fig. 9I). Expression of Brd4 was not significantly 
altered in JQ1-injected mice (Fig. 9H), demonstrating that JQ1 does not induce compensatory 
upregulation of Brd4.  
Another factor known to play a critical role in promoting cell cycle progression is the E2f2 
transcription factor, which has been shown to be required for hepatocyte proliferation after PHx  
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Figure 10: E2f2-driven transcription is inhibited in JQ1-injected animals after PHx. 
(a) Expression of E2f2 is significantly reduced in JQ1-injected mice after PHx (one-way ANOVA, 
* = p < 0.05). (b) Expression of Cdc6 is induced in vehicle-injected but not JQ1-injected mice after 
PHx (one-way ANOVA, ** = p < 0.01, *** = p < 0.001). (c) Expression of p21 is further increased 
in JQ1-injected mice after PHx. (d) Expression of Mcm3 is induced in vehicle-injected but not 
JQ1-injected mice after PHx (one-way ANOVA, * = p < 0.05). (e) Expression of Mcm5 is induced 
in vehicle-injected but not JQ1-injected mice after PHx (one-way ANOVA, ** = p < 0.01). (f) 
Expression of Ccne1 is induced in vehicle-injected but not JQ1-injected mice after PHx (one-way 
ANOVA, ** = p < 0.01). Error bars are mean + SD. 
 
 
(249). Additionally, E2F2 has been shown to be a direct target of JQ1-mediated BRD4 inhibition 
in human liver cancer cells (250). Therefore, we investigated if E2f2 signaling was inhibited in 
our JQ1-injected mice after PHx. Although there was no increase in E2f2 expression in vehicle-
injected mice after PHx compared to sham controls, we observed a decrease in E2f2 expression in 
JQ1-injected animals after PHx (Fig. 10A). We next assessed expression of E2f2 target genes 
known to be involved in cell cycle progression. Expression of E2f2 targets Cdc6 and Mcm3, which 
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are induced in late G1 phase (251), were dramatically induced in vehicle-injected mice after PHx, 
and this increase was blocked in JQ1-injected animals (Fig. 10B and D). Disruption of E2f2 
signaling can lead to the induction of p21 (251), and indeed there was an increase in p21 expression 
in JQ1-injected mice after PHx compared to vehicle-injected controls (Fig. 10C). Additional E2f2 
targets mcm5 and ccne1 (249, 251) were induced in vehicle-injected animals after PHx, but this 
induction was blocked in JQ1-injected animals (Fig. 10E and F). Interestingly, expression of E2f2 
targets genes was largely unaffected in JQ1-injected mice which underwent sham surgery (Fig. 
10). Thus our data indicates that JQ1, in addition to inhibiting β-catenin target gene expression, is 
inhibiting expression of E2f2-driven target genes after PHx, resulting in cell cycle arrest. 
Collectively, these results show that injection of JQ1 2 hours post-PHx nearly completely 
abrogates hepatocyte proliferation and liver regeneration, but JQ1 injection is well tolerated in 
animals in the absence of liver injury. 
2.4.4  Earlier JQ1 Administration after Hepatectomy Impairs Expression of Additional 
Wnt Target Genes, Which was Validated In Vitro. 
We wanted to confirm that the hepatic expression of β-catenin target genes that were 
downregulated in animals injected with JQ1 16 hours post-PHx were also downregulated in the 
mice injected with JQ1 2 hours post-PHx. Expression of Rgn was significantly reduced in JQ1-
injected PHx animals compared to both JQ1-injected sham and vehicle-injected PHx mice (Fig. 
11A). Similarly, gene expression of Lect2 was significantly reduced in JQ1-injected PHx mice 
reduced compared to both JQ1-injected sham and vehicle-injected PHx animals (Fig. 11B). 
Expression of Axin2 tended to be lower in JQ1-injected PHx mice compared to vehicle-injected 
PHx animals (Fig. 11C). There was no significant change in Ctnnb1 gene expression in mice  
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Figure 11: β-catenin-driven transcription is sensitive to JQ1 inhibition. 
(a) Rgn gene expression in significantly reduced in JQ1-injected mice compared to vehicle-
injected controls post-PHx (one-way ANOVA, ** = p < 0.01, *** = p < 0.001). (b) Lect2 gene 
expression is significantly reduced in JQ1-injected mice post-PHx (one-way ANOVA, * = p < 
0.05, **** = p < 0.0001). (c) Expression of Axin2 tended to be lower in JQ1-injected mice post-
PHx. (d) No change in the gene expression of Ctnnb1 was observed in JQ1-injected mice. (e) 
HepG2 cells transfected with a TCF/LEF luciferase reporter and treated with JQ1 for 24 hours 
showed a dose-dependent decrease in reporter activity after JQ1 treatment. Data is the pooled 
results of three independent experiments (one-way ANOVA, *** = p < 0.001, **** = p < 0.0001). 
(f) HepG2 cells transfected with a p65 luciferase reporter and treated with JQ1 for 24 hours showed 
a reduction of reporter activity after 1 µm JQ1 treatment. Data is pooled results of three 
independent experiments (one-way ANOVA, * = p < 0.05). Error bars are mean + SD. 
 
injected with JQ1 2 hours post-PHx compared to mice injected with the vehicle solution (Fig. 
11D).  
To determine if JQ1 could directly inhibit β-catenin-driven transcriptional activity, we 
transfected HepG2 cells, which has constitutively active β-catenin owing to a deletion affecting 
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exon-3 of the CTNNB1 gene, with a TopFlash luciferase reporter. JQ1 was able to, in a dose-
dependent manner, significantly inhibit β-catenin-TCF/LEF reporter activity (Fig. 11E). To 
determine if β-catenin-driven transcriptional activity is especially sensitive to inhibition by JQ1 
treatment, we tested the effect of JQ1 on the NFκB signaling pathway, another pathway implicated 
in liver regeneration after PHx due to the observed activation of the NFκB subunit p65/RelA within 
30 minutes of PHx in mice and rats (252, 253). When HepG2 cells transfected with a p65 luciferase 
reporter were treated with JQ1, at the highest concentration of JQ1 there was only a 50% reduction 
in reporter activity (Fig. 11F), compared to up to a 90% reduction in β-catenin-TCF/LEF reporter 
activity. These results suggest β-catenin-driven transcriptional activity is particularly sensitive to 
inhibition by JQ1. 
To determine if the JQ1-mediated reduction in β-catenin-TCF/LEF reporter activity was 
specifically due to inhibition of BRD4 activity, we treated two liver tumor cell lines, HepG2 and 
Hep3B, with BRD4 siRNA and subsequently measured TCF/LEF reporter activity. We first 
validated that we achieved robust knockdown of BRD4 expression in our siRNA-treated cells (Fig. 
12A). Interestingly, HepG2 cells treated with BRD4 siRNA showed no reduction in TCF/LEF 
reporter activity (Fig. 12B). As HepG2 cells have constitutively-active mutant β-catenin, we 
speculated that reduction in BRD4 expression levels may not be sufficient to reduce signaling 
driven by mutant β-catenin protein. Therefore, we treated Hep3B cells, a hepatocellular carcinoma 
cell line with wild-type β-catenin, with BRD4 siRNA. In Hep3B cells we saw a modest but 
significant reduction in TCF/LEF reporter activity (Fig. 12C), which was roughly on-par with the 
reduction of TCF/LEF reporter activity seen in HepG2 cells with low-dose JQ1 treatment (Fig. 
11E). As JQ1 is known to inhibit the bromodomains of BET proteins (11), and the BET family 
proteins share conserved bromodomains (2), we assessed the expression levels of BRD2 and  
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Figure 12: BRD4 siRNA reduces TCF/LEF transcriptional activity in Hep3B cells. 
(a) BRD4 siRNA treatment dramatically reduces BRD4 expression in both HepG2 and Hep3B 
cells (two-way ANOVA, **** = p < 0.0001). (b) No reduction in TCF/LEF reporter activity in 
HepG2 cells treated with BRD4 siRNA. Data is pooled results of five independent experiments. 
(c) Significant reduction in TCF/LEF reporter activity in Hep3B cells treated with BRD4 siRNA. 
Data is pooled from four independent experiments (t-test, * = p < 0.05). (d) No change in 
expression of BRD2 in cells treated with BRD4 siRNA. (e) Slight reduction in the expression of 
BRD3 in cells treated with BRD4 siRNA (two-way ANOVA, ** = p < 0.01). 
 
BRD3 in our liver cancer cells to determine if there was compensatory upregulation of other 
members of the BET protein family upon BRD4 knockdown. The expression of BRD2 was 
unchanged by BRD4 siRNA treatment (Fig. 12D), while the expression level of BRD3 was slightly 
reduced in both HeG2 and Hep3B cells (Fig. 12E). It is possible that BRD2 and BRD3 would able 
to partially compensate for BRD4 transcriptional activity, while all BET proteins would be 
inhibited by high-dose JQ1 treatment, offering a potential explanation for the relatively minor 
effects of BRD4 siRNA on TCF/LEF reporter activity. Overall, our data suggest that JQ1-
inhibition of BRD4 is at least partially responsible for the reduction in β-catenin-driven 
transcriptional activity in a wild-type β-catenin setting. 
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2.4.5  A Single Early Dose of JQ1 2 Hours Post-Hepatectomy is Insufficient to Have an 
Impact on Cyclin D1 Expression and Hepatocyte Proliferation at 72 Hours 
Post-Hepatectomy. 
To determine the extent to which a single dose of JQ1 can block liver regeneration, we 
injected mice with JQ1 or the vehicle solution 2 hours post-PHx and assessed the level of liver 
regeneration at 72 hours post-PHx (Fig. 13A). The 70% of JQ1-injected animals that survived to 
72 hours post-PHx showed serum liver injury marker AST levels that were comparable with 
vehicle-injected animals (Fig. 13B). Robust proliferation of hepatocytes was evident via PCNA 
IHC in both vehicle and JQ1-injected mice (Fig. 13C). There was also appearance of Cyclin D1 
staining in the hepatocytes of JQ1-injected mice at this time point (Fig. 13C), which was 
accompanied by an upregulation of Ccnd1 gene expression in the JQ1-injected mice (Fig. 13D). 
Most likely this induction of liver regeneration coincides with the clearance of JQ1 from the mice, 
as our previous work demonstrated that liver regeneration in zebrafish resumed after washout of 
JQ1 (227). 
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Figure 13: Induction of liver regeneration in JQ1-injected animals 72 hours post-PHx. 
(a) Schematic of experimental design, with a 50 mg/kg JQ1 injection (or vehicle injection) 2 hours 
post-PHx and harvest at 72 hours post-PHx. (b) Serum AST levels are normalizing in both JQ1 
and vehicle-injected mice 72 hours post-PHx. (c) PCNA staining reveals robust hepatocyte 
proliferation in both vehicle and JQ1-injected mice 72 hours post-PHx, and Cyclin D1 staining is 
present in hepatocytes in both vehicle and JQ1-injected animals 72 hours post-PHx (scale bar 50 
µm). (d) Upregulation of Ccnd1 gene expression is present in both vehicle and JQ1-injected 
animals 72 hours post-PHx (one-way ANOVA, * = p < 0.05). Error bars are mean + SD. 
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2.4.6  BET Protein Inhibition also Impairs Hepatocyte Proliferation and Liver Size in a 
Zebrafish Model of Hepatic Injury and Hepatocyte-Mediated Regeneration. 
To further validate the effect of BET protein inhibition on hepatocyte-driven liver 
regeneration, we next used a zebrafish model in which N-acetyl-p-aminophenol (APAP) overdose 
induces liver damage and subsequent regeneration (254, 255).  The APAP overdose model has 
been widely used in rodents (256) and zebrafish (254, 255, 257), because it mimics human APAP-
induced acute liver failure (ALF), the most common cause of ALF in the United States (256, 258). 
As previously reported (254, 255), treating zebrafish larvae with APAP greatly reduced liver size 
and following APAP washout liver size gradually recovered (Fig. 14A and B). We first determined 
whether hepatocytes solely or together with BECs contribute to regenerating hepatocytes in the 
APAP-induced injury model. As a positive control for BEC contribution to regenerating 
hepatocytes, we used our previous model of BEC-driven liver regeneration (232), in which 
Tg(fabp10a:CFP-NTR) zebrafish, which express nitroreductase (NTR) fused with cyan 
fluorescent protein (CFP) specifically in hepatocytes via the hepatocyte-specific fabp10a promotor 
(Fig. 14C). NTR metabolizes the prodrug metronidazole (Mtz) into a cytotoxic compound, 
resulting in the ablation of NTR-expressing cells. Thus treating Tg(fabp10a:CFP-NTR) larvae with 
Mtz induces hepatocyte-specific cell death.  In this model, near-complete ablation of hepatocytes 
induces the dedifferentiation of BECs into LPCs, which subsequently differentiate into either 
hepatocytes or BECs (232).  Given the BEC-restricted Notch activity in the zebrafish liver (259), 
in order to mark BECs, we used a Notch reporter line, Tg(Tp1:H2B-mCherry), which expresses 
H2B-mCherry fusion proteins under the promoter containing the Notch-responsive element (233).  
Due to the prolonged stability of H2B-mCherry proteins, this line also reveals BEC-derived cells 
even after Notch signaling is turned off. In Mtz-treated larvae after 24 hours of recovery (R24h),  
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Figure 14: BET inhibition impairs hepatocyte-driven liver regeneration in zebrafish. 
(a) Scheme illustrating the periods of APAP treatment (I, injury) and liver regeneration (R). An 
arrow indicates analysis stage. (b) Epifluorescence images showing fabp10a:CFP expression in 
the untreated larvae or larvae treated with APAP. (c) Scheme illustrating the periods of APAP or 
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Mtz treatment and liver regeneration. (d) Confocal images showing the expression of Alcam 
(green), Tp1:H2B-mCherry (red), and fabp10a:CFP-NTR (grey) in regenerating livers at R24h.  
Arrows point to BEC-derived hepatocytes, which weakly express Tp1:H2B-mCherry.   (e) Scheme 
illustrating the periods of APAP and BET inhibitor treatments.  Arrows indicate analysis stages.  
(f) Epifluorescence images showing fabp10a:CFP expression in the regenerating larvae treated 
with two different BET inhibitors, iBET151 and JQ1.  Arrows point to the liver.  (g) Quantification 
of fabp10a:CFP expression in the regenerating larvae treated with DMSO or BET inhibitors, as 
shown in (d) (one-way ANOVA, * = p < 0.05, ** = p < 0.01, *** = p < 0.001).  Error bars: ± SEM; 
scale bars: 100 µm. 
 
all hepatocytes weakly expressed Tp1:H2B-mCherry (Fig. 14D, arrows) but not mature BEC 
marker Alcam as previously reported (232), indicating hepatocytes with BEC origin.  However, in 
APAP-treated larvae at R24h no hepatocytes expressed Tp1:H2B-mCherry (Fig. 14D), revealing 
that liver regeneration in the zebrafish APAP-induced injury model is hepatocyte- but not BEC-
driven. To inhibit BET proteins, we used two different BET inhibitors, JQ1 (11) and iBET151 
(13), which both block BET proteins by specifically binding to acetyl-recognizing BET pockets. 
Treatment with JQ1 or iBET151 immediately following 36-hour APAP treatment (R0h) 
significantly reduced liver size after 24 or 48 hours of recovery (R24h and R48h, respectively), as 
assessed by hepatocyte-specific fabp10a:CFP expression (Fig. 14E-G), supporting the positive 
role of BET proteins in hepatocyte-driven liver regeneration.   
Given the reduced liver size in BET-inhibited larvae (Fig. 14G) and the role of BET 
proteins in proliferation (227), we examined hepatocyte proliferation using the 
Tg(fabp10a:mAGFP-gmnn) line that expresses geminin fused with monomeric Azami green 
fluorescent proteins in hepatocytes (227). As geminin is degraded in G0 and G1 phases (260), this 
line reveals proliferating hepatocyte in S/G2/M phases (227). Hepatocyte proliferation was greatly 
increased in APAP-treated larvae compared with control larvae at 5 days post-fertilization (dpf) 
(Fig. 15B and C). JQ1 treatment significantly reduced the hepatocyte proliferation induced by 
APAP overdose (Fig. 15B and C), suggesting the crucial role of BET proteins in hepatocyte  
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Figure 15: BET inhibition reduces hepatocyte proliferation in the zebrafish APAP-induced injury model.   
(a) Scheme illustrating the periods of APAP and JQ1 treatments and analysis stages (arrows).  (b) 
Confocal images showing the hepatic expression of fabp10a:CFP (grey, hepatocytes), Tp1:H2B-
mCherry (red, BECs) and fabp10a:mAGFP-gmnn (green, proliferating hepatocytes).  (c) 
Quantification of the number of mAGFP-gmnn+ cells, as shown in (B) (one-way ANOVA, ** = p 
< 0.01, **** = p < 0.0001).  (d-h) qPCR data showing the relative expression levels of ccnd1, 
pcna, myca, brd4 and axin2 among uninjured control livers at 5 dpf and DMSO- and JQ1-treated 
regenerating livers at R12h (one-way ANOVA, * = p<0.05).  Error bars, ± SEM; scale bar, 100 
μm. 
 
proliferation during regeneration. This proliferation phenotype was further supported by the 
reduced expression of ccnd1 (Fig. 15D), consistent with our mouse data (Fig. 8D). However, other 
proliferation-related genes, such as pcna and myca, were not significantly reduced in JQ1-treated 
livers (Fig. 15E and F). brd4 expression was significantly upregulated in APAP-treated livers 
compared with untreated control livers (Fig. 15G), as observed in a zebrafish BEC-driven liver 
regeneration model (227). Additionally, similar to the mouse PHx model (Fig. 8G), expression of 
Wnt/β-catenin signaling target axin2 tended to be lower in JQ1-treated larvae after APAP overdose 
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(Fig. 15H). Altogether, these zebrafish data together with our mouse data strongly support the 
observation that BET proteins regulate hepatocyte-driven liver regeneration. 
2.4.7  BET Inhibition Represses Wnt/β-catenin Signaling in APAP-Treated Zebrafish 
Livers.   
 
Figure 16: BET inhibition reduces Wnt/β-catenin signaling in the zebrafish APAP-induced injury model. 
(a) Scheme illustrating the periods of APAP and JQ1 treatments and analysis stage (arrow). (b) 
Confocal images showing the hepatic expression of OTM:d2EGFP (green, Tcf/Lef reporter 
activity) in regenerating larvae at R12h. Dotted white line outlines the liver. (c) Quantification of 
OTM:d2EGFP expression in the regenerating larvae treated with DMSO or JQ1, as shown in (b) 
(t-test, * = p < 0.05).  Error bars, ± SEM; scale bar, 100 μm. 
 
 
Given the crucial role of Wnt/β-catenin signaling in liver regeneration induced by APAP 
overdose (87, 254) and the reduced expression of Wnt target genes ccnd1 and axin2 in JQ1-treated 
regenerating zebrafish livers (Fig. 15D and H), we hypothesized that BET inhibition could 
suppress Wnt/β-catenin signaling in livers injured by APAP treatment. To test this hypothesis, we 
used a Wnt reporter zebrafish line, Tg(OTM:d2EGFP), which expresses destabilized GFP under a 
promoter containing six copies of Tcf/Lef binding site (234), meaning that the level of GFP 
expression is driven by β-catenin signaling.  GFP expression was significantly reduced in JQ1-
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treated regenerating livers compared with DMSO-treated control livers (Fig. 16A-C).  These 
zebrafish data together with the in vitro data (Fig. 11 and 12) suggest that BET proteins regulate 
hepatocyte-driven liver regeneration by regulating Wnt/β-catenin signaling in addition to other 
signaling pathways. 
2.5 Discussion 
BET protein inhibitors, such as JQ1, have been proposed for use in the treatment of a 
variety of conditions due to their ability to inhibit oncogenic gene expression (8, 12, 224), reduce 
inflammation (261, 262), and protect against liver fibrosis (16). Adding to their therapeutic 
potential, effective anti-neoplastic doses of JQ1 are well tolerated in animals despite the 
widespread activity of Brd4 in nearly every tissue type (8, 11, 12). JQ1 has also been shown to be 
effective in reducing cell growth in a tumor xenograft HCC model (226), which may suggest BET 
protein inhibitors to be a potential treatment for liver cancer. However, BET proteins also play a 
role in biliary-driven liver regeneration (227). In the current study, we show that JQ1-mediated 
inhibition of BET proteins significantly blocks hepatocyte proliferation in two independent models 
of hepatocyte-driven liver regeneration. Since the majority of HCC cases occur in the patients with 
chronic liver diseases which in turn are characterized by ongoing regeneration, inadvertent 
suppression of regeneration during HCC treatment may adversely affect hepatic function. Hence, 
our findings suggest the use of BET proteins in the treatment of liver pathologies must be carefully 
considered, as BET protein inhibitors are liable to inhibit the regeneration of normal liver tissue.  
Two-thirds partial hepatectomy in rodents is widely used to study the mechanisms of 
hepatocyte proliferation during liver regeneration (81) and is a useful model for the study of 
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temporal changes in gene expression during liver regeneration. In our study, we used either early 
(2 hours post-PHx) or late (16 hours post-PHx) injections of JQ1 to study the effects of BET 
protein inhibition on hepatocyte proliferation. In both instances, injection of JQ1 resulted in a near 
total block of hepatocyte proliferation with significant reduction in expression of cell cycle-
regulator Cyclin D1, suggesting that transcriptional activation of pro-regeneration genes occurs 
even many hours after the initial injury. We additionally observed impaired induction of E2f2 
downstream targets involved in cell cycle progression, further demonstrating the complete block 
of hepatocyte proliferation in JQ1-injected mice after PHx.  
Our second model to study the role of BET proteins in hepatocyte proliferation was APAP 
overdose, as APAP-induced ALF is the most common cause of ALF in the United States (256, 
258). We performed APAP overdose experiments in zebrafish, as their large clutch sizes, growth 
in water, optical transparency, and fully developed livers by 5 dpf (263) make them ideal for drug 
treatment studies. Consistent with our results from our mouse PHx study, we found that JQ1-
treated zebrafish larvae displayed significant reductions in hepatocyte proliferation and Cyclin D1 
expression during recovery from APAP overdose. Interestingly, in comparison to our mouse PHx 
model, we detected a large increase in brd4 expression in zebrafish larvae during recovery from 
APAP overdose. This finding suggests BET proteins are important regulators of liver regeneration 
in this model, although there are presently very few studies on the role of BET proteins in liver 
regeneration after acetaminophen injury. Thus, our work presents an opportunity to study signaling 
pathways under the control of BET proteins during liver regeneration. 
A signaling pathway well-known to be active in promoting liver regeneration (68, 87, 229) 
in addition to being an oncogenic driver in subsets of liver cancer (264-267) is the Wnt/β-catenin 
signaling pathway. Our results demonstrate that Wnt/β-catenin signaling targets, such as Cyclin 
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D1, are significantly reduced in JQ1-treated animals after liver injury. In this respect, mice injected 
with JQ1 post-PHx are reminiscent of liver-specific β-catenin knockout animals subjected to 
partial hepatectomy, which show an early lag in hepatocyte proliferation in conjunction with 
reduced Cyclin D1 levels (229). Furthermore, activation of Wnt/β-catenin signaling is thought to 
promote liver regeneration after APAP-induced liver injury (87, 254), and our zebrafish results 
demonstrate that JQ1 is a potent inhibitor of hepatocyte proliferation and Wnt/β-catenin signaling 
after APAP overdose. Additionally, our in vitro experiments revealed that Wnt/β-catenin signaling 
was sensitive to inhibition by JQ1. Our in vitro data showed that knockdown of BRD4 in Hep3B 
cells with wild-type β-catenin leads to a reduction in TCF/LEF reporter activity, suggesting the 
ability of JQ1 to impair β-catenin signaling is mediated at least partially through inhibition of 
BRD4. However, treatment of HepG2 cells with high doses of JQ1 led to a robust decrease in 
TCF/LEF reporter activity, suggesting that other BET proteins such as BRD2 and BRD3 may also 
play a role in regulating β-catenin signaling, although this hypothesis remains to be tested. 
Together, these data suggest JQ1 as a potent inhibitor of Wnt/β-catenin signaling. However, these 
results must be considered in a cell type-specific context, as JQ1 had minimal effect on β-
catenin/TCF-mediated transcription in colorectal cancer cells (268). This raises the interesting 
question of whether JQ1 would be especially effective in treating liver cancer with activating β-
catenin mutations, as these cancers have been shown to be sensitive to inhibition of β-catenin 
(267). Although we have demonstrated that JQ1 is capable of inhibiting normal liver regeneration, 
with careful dose titration BET inhibitors may be capable of inhibiting oncogenic Wnt signaling 
without impinging signaling pathways required for normal hepatic function. As tumors tend to be 
addicted to several oncogenic signaling pathways, such as Met and Wnt/β-catenin signaling, while 
normal liver regeneration occurs through many redundant signaling mechanisms, low doses of 
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BET inhibitors may be able to selectively inhibit oncogenic Wnt/β-catenin signaling while sparing 
compensatory regeneration mechanisms in normal liver. 
The sensitivity of Wnt/β-catenin signaling to JQ1 may be due in part to proficiency of BET 
inhibitors to reduce BRD4 enhancer occupancy at super enhancers (8), or large enhancers with 
multiple TF binding sites, high levels of Mediator occupancy, and high levels of associated gene 
expression (269-271). Interestingly, super enhancers in colorectal cancer were found to be 
occupied by TCF4 and thus were sensitive to perturbation of oncogenic Wnt signaling (272), and 
TF targets of Wnt signaling were found to be enriched for super enhancers in embryonic stem cells 
(271). Additionally, Cyclin D1 was found to be regulated by a super enhancer in a model of Ewing 
sarcoma (273). These data suggest that super enhancers under the control of the Wnt/β-catenin 
signaling pathway may regulate the expression of genes activated during hepatocyte-driven liver 
regeneration, such as Cyclin D1, although this hypothesis remains to be tested. Very little is known 
about the role of super enhancer-driven gene expression during liver regeneration, and our model 
of JQ1 treatment post-PHx may provide a useful platform for the identification of these important 
signaling mechanisms. 
In conclusion, our work has identified the key role of BET proteins in multiple models of 
hepatocyte-driven liver regeneration. Additionally, we have identified the Wnt/β-catenin signaling 
pathway, a known important driver of liver regeneration (68, 229), to be sensitive to JQ1-mediated 
BET protein inhibition resulting in an abrogation of hepatocyte proliferation. Although more work 
remains to be done to identify the mechanism behind JQ1-mediated inhibition of Wnt/β-catenin 
signaling, our work has important implications for the clinical use of BET inhibitors. As these 
drugs are herein demonstrated to be potent inhibitors of normal liver regeneration, their potential 
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use to treat liver pathologies must be carefully considered, as patients may become more 
susceptible to liver failure under a regimen of BET protein inhibitors.  
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3.0 Hepatocyte-Specific β-Catenin Deletion during Severe Liver Injury Provokes 
Cholangiocytes to Differentiate into Hepatocytes 
In this section, we describe how mice with hepatocyte-specific deletion of β-catenin 
exposed to choline deficient, ethionine-supplemented diet-induced liver injury develop severe 
liver injury with an impairment of hepatocyte proliferation. We further describe how in the β-
catenin knockout mice BECs transdifferentiate into hepatocytes to mediate liver regeneration using 
both negative and positive lineage tracing models. The work in this section was published in 
Hepatology, PMID 30215850 (188). As first author, the publisher John Wiley & Sons has granted 
full permission to reuse the manuscript in this dissertation. 
3.1 Paper Summary 
Liver regeneration after injury is normally mediated by proliferation of hepatocytes, 
although recent studies have suggested biliary epithelial cells (BECs) can differentiate into 
hepatocytes during severe liver injury when hepatocyte proliferation is impaired. We investigated 
the effect of hepatocyte-specific β-catenin deletion in recovery from severe liver injury and BEC-
to-hepatocyte differentiation. To induce liver injury, we administered choline-deficient, ethionine-
supplemented (CDE) diet to three different mouse models, the first being mice with deletion of β-
catenin in both BECs and hepatocytes (Albumin-Cre; Ctnnb1flox/flox mice). In our second model, 
we performed hepatocyte lineage tracing by injecting Ctnnb1flox/flox; Rosa-stopflox/flox-EYFP mice 
with the adeno-associated virus serotype 8 encoding Cre recombinase under the control of the 
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thyroid binding globulin promoter (AAV8-TBG-Cre), a virus which infects only hepatocytes. 
Finally, we performed BEC lineage tracing via Krt19-CreERT; Rosa-stopflox/flox-tdTomato mice. To 
observe BEC-to-hepatocyte differentiation, mice were allowed to recover on normal diet following 
CDE diet-induced liver injury. Livers were collected from all mice and analyzed by quantitative 
real-time polymerase chain reaction, western blotting, immunohistochemistry, and 
immunofluorescence. We show that mice with lack of β-catenin in hepatocytes placed on the CDE 
diet develop severe liver injury with impaired hepatocyte proliferation, creating a stimulus for 
BECs to differentiate into hepatocytes. In particular, we use both hepatocyte and BEC lineage 
tracing to show that BECs differentiate into hepatocytes, which go on to repopulate the liver during 
long-term recovery. Conclusion: β-catenin is important for liver regeneration after CDE diet-
induced liver injury, and BEC-derived hepatocytes can permanently incorporate into the liver 
parenchyma to mediate liver regeneration. 
3.2 Background 
Despite the liver’s capacity for regeneration, chronic liver disease and cirrhosis is the 12th 
leading cause of death in the United States (219). This significant morbidity is attributable to lack 
of treatments for advanced liver disease besides liver transplantation, for which there is a severe 
shortage of donor organs (274). Often, hepatocytes and biliary epithelial cells (BECs) can replicate 
to replenish their respective cell types and eventually restore hepatic mass following injury. 
However, livers of patients with chronic liver disease exhibit ductular reaction (116, 275, 276), 
with the degree of BEC expansion correlating with disease severity (115, 277). The role of ductular 
reaction in liver regeneration (LR) remains controversial, although studies are beginning to show 
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BECs may be giving rise to hepatocytes. Indeed, experimentally, when endogenous hepatocyte 
proliferation is impaired, reactive BECs (183, 194) can differentiate into hepatocytes to mediate 
repair (80, 218). Alternatively, hepatocytes can differentiate into BECs, which can then be 
incorporated into biliary ductules (208, 215) and may revert back to hepatocytes when injury is 
withdrawn (214). There is evidence of BEC-to-hepatocyte differentiation in both humans (104, 
112) and animal models of liver injury where hepatocyte proliferation is blocked (171, 187, 191) 
or after near total loss of hepatocytes (232).  
The choline-deficient, ethionine-supplemented (CDE) diet is a well-known liver injury diet 
which induces proliferation of reactive BECs (175, 176). Recent lineage tracing studies have 
demonstrated limited contribution of BECs to hepatocytes in CDE diet fed mice (150, 190, 278), 
leading to the conclusion that BECs do not contribute significantly to the restoration of hepatocyte 
mass after chronic liver injury. However, the CDE diet does not block hepatocyte proliferation 
(190), and thus is unable to provide the correct milieu for BEC-to-hepatocyte transdifferentiation. 
Since the Wnt/β-catenin signaling pathway is a major driver of hepatocyte proliferation during LR 
(68, 279), we investigated if CDE diet-induced injury to conditional β-catenin knockout mice will 
necessitate BEC-mediated liver repair. We utilized multiple mouse models to perform hepatocyte 
and BEC lineage tracing in mice that underwent modulation of β-catenin expression and were 
administered CDE diet. Our results demonstrate that loss of β-catenin in hepatocytes during CDE 
diet-induced liver injury indeed impairs hepatocyte proliferation, triggering the expansion of BECs 
which subsequently differentiate into hepatocytes. We have successfully established a model 
which will lend itself well to the study of the mechanisms of BEC expansion and differentiation. 
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3.3 Methods 
3.3.1  Mouse strains, Viral Infections, Tamoxifen Administration, In Vivo RNAi, and Diet 
All animals are housed in temperature and light-controlled facilities and are maintained in 
accordance with the Guide for Care and Use of Laboratory Animals and the Animal Welfare Act. 
Albumin-Cre;Ctnnb1flox/flox  mice or KO1 and wild-type littermate controls (WT1) (74) were 
maintained on a C57BL/6 background. Ctnnb1flox/flox;Rosa-stopflox/flox-EYFP reporter mice were 
generated through breeding Ctnnb1flox/flox mice with Rosa-stopflox/flox-EYFP mice (Jackson 
Laboratories). Krt19-CreERT;Rosa-stopflox/flox-tdTomato reporter mice were described previously 
(191). To label hepatocytes and generate KO2 mice, 23–25 day-old Ctnnb1flox/flox;Rosa-stopflox/flox-
EYFP mice were injected intraperitoneally with 1x1012 genome copies (GCs) of adeno-associated 
virus serotype 8 encoding Cre recombinase under the hepatocyte-specific thyroid binding globulin 
promoter (AAV8-TBG-Cre) (Penn Vector Core) followed by a 12 days (12d) washout period. To 
generate WT2 mice, the same AAV8-TBG-Cre was injected into or Ctnnb1+/+;Rosa-stopflox/flox-
EYFP mice. To label BECs, Krt19-CreERT;Rosa-stopflox/flox-tdTomato mice were given 3 doses of 
12.5 mg/kg tamoxifen during postnatal week 1, followed by 2 weeks (2W) washout. For the liver 
injury time point, 4–5w-old mice were given choline-deficient diet (Envigo Teklad Diets) 
supplemented with 0.15% ethionine drinking water (Acros Organics, 146170100) for 2-3w (Krt19-
CreERT;Rosa-stopflox/flox-tdTomato mice). For recovery time points, animals were switched back to 
normal chow diet for 3d up to 6 months (6m) after 2W of CDE diet. For in vivo knockdown of β-
catenin expression, both C57BL6/NJ (Charles River) and Krt19-CreERT; Rosa-stopflox/flox-tdTomato 
mice were given biweekly or weekly subcutaneous injections of 5 mg/kg GalXC-Ctnnb1 (Dicerna 
Pharmaceuticals) starting 1W prior to CDE diet administration and continuing throughout CDE 
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diet and recovery periods. GalXC is a Dicerna Pharmaceuticals Ctnnb1 RNAi conjugated to 
hepatocyte targeting ligand N-acetylgalactosamine, which allows for hepatocyte-specific 
knockdown of target gene expression (280). Serum biochemistry analysis was performed by 
automated methods at the University of Pittsburgh Medical Center clinical chemistry laboratory. 
All studies were performed according to the guidelines of the National Institutes of Health and the 
University of Pittsburgh Institutional Animal Use and Care Committee.  
3.3.2  Immunohistochemistry 
Tissue samples were drop-fixed in 10% buffered formalin for 48 hours prior to paraffin 
embedding. Samples were cut into 4 µm sections, deparaffinized, and washed with PBS. For 
antigen retrieval, samples were microwaved for 12 minutes in pH6 sodium citrate buffer (Cyclin 
D1, PanCK, GS, CD45) or Tris-EDTA buffer (Ki67), or were pressure cooked for 20 minutes in 
pH6 sodium citrate buffer (β-catenin), Dako Target Retrieval Solution (Dako, S1699) (CK19, 
EpCAM), or pH9 EDTA buffer (αSMA). After cooling, samples were placed in 3% H2O2 for 10 
minutes to quench endogenous peroxide activity. After washing with PBS, slides were blocked 
with Super Block (ScyTek Laboratories, AAA500) for 10 minutes or 10% goat serum in PBS for 
10 minutes (GS, p21). The primary antibodies were incubated at the following concentrations in 
antibody diluent (PBS + 1% BSA (Fisher BioReagents, BP1605-100) with 0.1% Tween™ 20 
(Fisher BioReagents, BP337-500)): GS (Sigma G2781, 1:1500), Ki67 (Thermo Scientific RM-
9106-S, 1:100), PanCK (Dako Z0622, 1:200), Cyclin D1 (Abcam ab134175, 1:200), β-catenin 
(Abcam ab32572, 1:100) for one hour at room temperature or at 4℃ overnight: p21 (Santa Cruz 
sc-471, 1:25), EpCAM (Biolegend 118201, 1:50), CK19 (DSHB TROMA III, 1:10). Samples were 
washed with PBS three times and incubated with the appropriate biotinylated secondary antibody 
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(Vector Laboratories) diluted 1:500 or 1:1000 (GS) in antibody diluent for 30 minutes at room 
temperature. Samples were washed with PBS three times and sensitized with the Vectastain® ABC 
kit (Vector Laboratories, PK-6101) for 30 minutes. Following three washes with PBS color was 
developed with DAB Peroxidase Substrate Kit (Vector Laboratories, SK-4100), followed by 
quenching in distilled water for five minutes. Slides were counterstained with hematoxylin 
(Thermo Scientific, 7211), dehydrated to xylene and coverslips applied with Cytoseal™ XYL 
(Thermo Scientific, 8312-4). For H&E staining, samples were deparaffinized and stained with 
hematoxylin (Thermo Scientific, 7211) and eosin (Thermo Scientific, 71204), followed by 
dehydration to xylene and application of a coverslip. For Sirius Red staining, samples were 
deparaffinized and incubated for one hour in Picro-Sirius Red Stain (American MasterTech, 
STPSRPT), washed twice in 0.5% acetic acid water, dehydrated to xylene, and coversliped. Images 
were taken on a Zeiss Axioskop 40 inverted brightfield microscope. Images for tiling were taken 
on a Zeiss Axio Observer.Z1 microscope and assembled utilizing ZEN Imaging software. 
3.3.3  Immunofluorescence  
Tissue samples were drop fixed in 10% buffered formalin overnight, cryopreserved in 30% 
sucrose in PBS overnight, frozen in OCT compound (Sakura, 4583) and stored at -80℃ or 
alternatively were paraffin embedded after formalin fixation. Cryopreserved samples were cut into 
5 µm sections, allowed to air-dry, and then washed in PBS, while paraffin-embedded samples were 
cut into 4 µm sections and deparaffinized to PBS. Antigen retrieval was performed through 
pressure cooking for 20 minutes with Dako Target Retrieval Solution (Dako, S1699) or through 
microwaving in pH 6 sodium citrate buffer (PanCK, RFP, CYP2D6, GS, CK19). After cooling, 
slides were washed with PBS and permeabilized with 0.1% Triton X-100 in PBS for 20 minutes 
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at room temperature. Samples were washed three times with PBS and then blocked with 2% 
Donkey serum in 0.1% Tween™ 20 in PBS (antibody diluent) for 30 minutes at room temperature. 
Antibodies were diluted as follows: β-catenin (Abcam ab32572, 1:100), PanCK (Dako Z0622, 
1:200), Hnf4α (Santa Cruz sc-6556, 1:50), GFP (Abcam ab13970, 1:200), CK19 (DSHB TROMA-
III-s, 29 µg/ml), PCNA (Santa Cruz sc-56, 1:1000), RFP (Rockland 600-401-379, 1:200), GS 
(Abcam ab73593, 1/200), CYP2D6 (Gift from R. Wolfe, University of Dundee, 1/500) in antibody 
diluent and incubated at 4℃ overnight. Samples were washed three times in PBS and incubated 
with the proper fluorescent secondary antibody (AlexaFluor 488/555/647, Invitrogen) diluted 
1:800 in antibody diluent for two hours at room temperature. Samples were washed three times 
with PBS and incubated with DAPI (Sigma, B2883) for 1 minute. Samples were washed three 
times with PBS and mounted with fluromount (SouthernBiotech) or ProLongTM Gold antifade 
reagent (Invitrogen, P10144). Images were taken on a Nikon Eclipse Ti epifluorescence 
microscope or a Zeiss LSM700 confocal microscope.  
3.3.4  Western Blotting 
To extract protein, whole liver tissue was homogenized in RIPA buffer as previously 
described (74). Protein was separated on pre-cast 4-20% or 7.5% polyacrylamide gels (Bio-Rad) 
and transferred to a nitrocellulose membrane using the Trans-Blot Turbo Transfer System (Bio-
Rad). Membranes were blocked for 30 minutes with 5% skim milk (LabScientific, Cat# M0841) 
or 5% BSA in Blotto buffer (0.15 M NaCl, 0.02 M Tris pH 7.5, 0.1% Tween in dH2O), and 
incubated with primary antibodies at 4℃ overnight at the following concentrations: β-catenin (BD 
Biosciences 610154, 1:1000 in 5% milk), Active β-catenin (Cell Signaling cs-4270, 1:800 in 5% 
BSA), Cyclin D1 (Thermo Fisher RB-9041-P, 1:200 in 5% milk), GS (Santa Cruz sc-74430, 
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1:2000 in 5% milk), p21 (Santa Cruz sc-271532, 1:50 in 5% milk), αSMA (Abcam ab5694, 1:1000 
in 5% milk), GAPDH (Santa Cruz sc-25778, 1:1000 in 5% milk). Membranes were washed in 
Blotto buffer and incubated with the appropriate HRP-conjugated secondary antibody for 1 – 3 
hours at room temperature. Membranes were washed with Blotto buffer, and bands were developed 
utilizing SuperSignal® West Pico Chemiluminescent Substrate (Thermo Scientific, Prod# 34080) 
and visualized by autoradiography. 
3.3.5  RT-PCR 
Whole liver was homogenized in TRIzol™ (Thermo Scientific, Cat# 15596026), treated 
with chloroform, and nucleic acid was precipitated with isopropanol. Cellular DNA was digested 
with DNA-free™ Kit (ambion, AM1906), and RNA was reverse-transcribed into cDNA using 
SuperScript® III (Invitrogen, 18080-044). Real-time PCR was performed in technical triplicate on 
a StepOnePlus™ Real-Time PCR System (Applied Biosystems, Cat# 4376600) using the Power 
SYBR® Green PCR Master Mix (Applied Biosystems, 4367660). Target gene expression was 
normalized to the average of two housekeeping genes (Gapdh and Rn18s), and fold change was 
calculated utilizing the ΔΔ-Ct method. Primers are listed in Table 3. 
 
Table 3: List of primers used in the Hepatology study 
Gene Forward Primer (5’ – 3’) Reverse Primer (5’ – 3’) 
Ccnd1  TTTCTTTCCAGAGTCATCAAGTGT TGACTCCAGAAGGGCTTCAA 
Ctnnb1  ACTTGCCACACGTGCAATTC AAGGTTGTGCAGAGTCCCAG 
Col1a1 TCCGGCTCCTGCTCCTCTTA GTATGCAGCTGACTTCAGGGATGT 
Acta2 CCGAGATCTCACCGACTACC TCCAGAGCGACATAGCACAG 
Sox9 GTGCAAGCTGGCAAAGTTGA TGCTCAGTTCACCGATGTCC 
Krt19 CCAGGAAGCCCACTACAACAA TCGAGGGAGGGGTTAGAGTAAA 
Gapdh AACTTTGGCATTGTGGAAGG ACACATTGGGGGTAGGAACA 
Rn18s GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
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3.3.6  Statistics  
For analysis of serum biochemistry between two groups, a two-tailed t-test was performed. 
For analysis of gene expression data between more than two groups, a one-way ANOVA was 
performed. For analysis of cell counts, such as proliferating hepatocytes, a Mann-Whitney U Test 
was performed. For analysis of change in body weight over time, a two-way ANOVA was 
performed. A p<0.05 was considered significant, and plots are mean ±SD. All statistical analysis 
and graph generation was performed using GraphPad Prism 7 software. 
3.4 Results 
3.4.1  β-catenin is Important for LR after CDE Diet-Induced Liver Injury 
To test whether lack of β-catenin in hepatocytes impairs hepatocyte proliferation in a 
chronic liver injury setting, we placed KO1 mice (74) lacking β-catenin in hepatocytes and BECs, 
and WT1 mice on CDE diet for 2W (Fig. 17A). KO1 showed severe histological abnormalities 
including steatohepatitis (Fig. 17F), with gross liver morphology displaying pale and smaller livers 
(Fig. 17B). Serum liver injury markers, alanine aminotransferase (ALT) (Fig. 17C), serum 
aspartate aminotransferase (AST) (Fig. 18D), and bilirubin (Fig. 17D) were significantly elevated 
in KO1 compared to WT1 on CDE diet. There was no difference in serum alkaline phosphatase 
(ALP) levels in WT1 and KO1 mice (Fig. 18E). Both WT1 and KO1 displayed characteristic 
expansion of reactive BECs, which are positive for BEC-marker CK19 (Fig. 18A), although KO1 
displayed a more robust BEC expansion as determined by increased expression of BEC markers 
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Figure 17: KO1 mice display severe liver injury and impaired hepatocyte proliferation after CDE diet. 
(a) Four-week-old male WT1 and KO1 mice were placed on CDE diet for 2W to induce liver 
injury. (b) Gross liver morphology reveals small and pale livers in KO1 mice after 2W of CDE 
diet. (c) Serum liver injury marker alanine aminotransferase (ALT) is significantly elevated in 
KO1 mice after CDE diet compared to both WT1 mice and baseline normal diet (ND) levels (t-
test, ** = p < 0.01). (d) Serum bilirubin is significantly elevated in KO1 mice after CDE diet 
compared to both WT1 mice and baseline normal diet (ND) levels (t-test, **** = p < 0.0001). (e) 
 81 
Quantification of hepatocyte proliferation in mice after 2W of CDE diet reveals significantly 
impaired hepatocyte proliferation in KO1 mice (Mann-Whitney U test, ** = p < 0.01). (f) KO1 
mice display prominent steatohepatitis and few Ki67 or Cyclin D1-positive hepatocytes (scale bar 
50 µm). (g) Hepatic Ccnd1 gene expression is upregulated after 2W of CDE diet, but is impaired 
in KO1 mice (One-way ANOVA, * = p < 0.05). (h) Whole liver lysates display dramatically 
reduced levels of β-catenin and active β-catenin in KO1 mice while WT1 animals exhibit 
upregulation of both proteins after CDE diet. 
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Figure 18: KO1 mice develop fibrosis and a robust BEC response after two weeks of CDE diet. 
(a) IHC staining reveals loss of β-catenin expression in both hepatocytes and BECs in KO1 mice. 
Additionally, KO1 mice display robust expansion of BECs by CK19 staining, fibrosis by Sirius 
Red, an increase in p21-positive hepatocytes compared to WT1 mice, and TUNEL-positive cells 
in both WT1 and KO1 mice after two weeks of CDE diet (scale bar 50 µm). PV = portal vein. (b) 
KO1 mice display an increase in Col1a1 gene expression (one-way ANOVA, p = 0.0575). (c) KO1 
mice display a significant increase in Acta2 (α-smooth muscle actin) gene expression compared to 
WT1 mice (one-way ANOVA, p < 0.01). (d) Elevated serum AST levels in KO1 mice compared 
to WT1 mice after two weeks of CDE diet (t-test, p = 0.0762). (e) No difference in serum ALP 
levels in KO1 and WT1 mice after two weeks of CDE diet. (f) KO1 mice display a significant 
increase in Krt19 gene expression compared to WT1 mice (one-way ANOVA, p < 0.05) and KO1 
mice on normal diet (one-way ANOVA, p < 0.05). (g) KO1 mice display a significant increase in 
Sox9 gene expression compared to WT1 mice (one-way ANOVA, p < 0.01) and KO2 mice on 
normal diet (one-way ANOVA, p < 0.05). (h) KO1 mice on CDE diet for two weeks express less 
Cyclin D1, more p21, and more α-smooth muscle actin (molecular weight 42 kDa) compared to 
WT1 littermates. 
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Krt19 and Sox9 (Fig. 18F, G). KO1 also displayed increased fibrosis by Sirius Red staining (Fig. 
18A) and increased expression of pro-fibrotic genes Col1a1 (Fig. 18B) and Acta2 (Fig. 18C, H). 
We detected increased cell death as evidenced by TUNEL staining (Fig. 18A) and increased 
hepatocyte senescence in KO1 as evidenced by an increase in p21-positive hepatocytes (Fig. 18A) 
and increased levels of p21 protein (Fig. 18H) compared to WT1. Collectively, we detect severe 
liver injury in KO1 mice on CDE diet. 
To determine if there was a defect in LR in KO1, we assessed hepatocyte proliferation via 
Ki67 and Cyclin D1 IHC (Fig. 17F). While WT1 displayed robust hepatocyte proliferation and 
Cyclin D1 expression especially in periportal hepatocytes, KO1 displayed significantly impaired 
hepatocyte proliferation (Fig. 17E) and reduced Ccnd1 expression (Fig. 17G) and protein (Fig. 
18H). As expected, low levels of β-catenin protein were observed in KO1 livers, likely due to non-
parenchymal cells (Fig. 17H). However, there was no expression of active-β-catenin 
(hypophosphorylated) in KO1 mice even after CDE diet (Fig. 17H). Alternatively, there was 
increased total and active-β-catenin levels in WT1 mice on CDE diet compared to normal diet 
(Fig. 17H). This suggests activation of β-catenin signaling is contributing to hepatocyte 
proliferation, and deletion of β-catenin leads to impaired hepatocyte proliferation and defective 
LR after CDE diet. 
3.4.2  Lack of β-catenin in Hepatocytes Impairs Hepatocyte Proliferation and Promotes 
Injury from the CDE Diet 
As KO1 mice on CDE diet displayed severe liver injury, impaired hepatocyte proliferation, 
and robust expansion of BECs, we hypothesized BEC differentiation to hepatocytes would be 
activated to mediate restoration of hepatocyte mass. To test this hypothesis we generated KO2 
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mice (186). Genes in the Rosa locus are ubiquitously expressed, but prior to Cre recombination a 
floxed stop codon inactivates expression of the Rosa-driven enhanced yellow fluorescence protein 
(EYFP) reporter gene (281). AAV8 infects only hepatocytes, and greater than 99% of hepatocytes 
can be permanently labeled with EYFP after AAV8-TBG-Cre injection (186, 189, 190). We 
administered a single injection of AAV8-TBG-Cre and allowed 12d washout before administering 
CDE diet (Fig. 19A) to allow for clearance of residual viral genome (282). In KO2, hepatocytes 
lack β-catenin expression and are permanently labeled with EYFP (Fig. 19B). Importantly, BECs 
are not infected with AAV8 and thus retain β-catenin and do not express EYFP. Therefore, 
hepatocytes originating from BECs will be negative for EYFP and express β-catenin (Fig. 19F). 
As controls, WT2 mice showed EYFP-labeled hepatocytes that retain β-catenin expression. IHC 
confirmed β-catenin expression in hepatocytes in WT2 mice but not in KO2 mice (Fig. 20A). 
KO2 on CDE diet, like KO1, showed severe liver injury reflected by significantly increased 
serum AST (Fig. 19C), serum ALT (Fig. 20D), and bilirubin levels (Fig. 19D) as compared to 
WT2. WT2 mice on CDE diet initially lost weight but began to recover after 5–7d. In contrast, 
KO2 mice continued to lose weight over the course of CDE diet administration (Fig. 19E), 
suggesting failure to recover from injury. Both WT2 and KO2 mice displayed expansion of BECs 
(Fig. 20A), confirmed by increased Krt19 (Fig. 20F) and Sox9 (Fig. 20G) expression. KO2 and 
WT2 mice developed fibrosis after 2W of CDE diet evident by increased Sirius Red staining (Fig. 
20A) and increased expression of Col1a1 (Fig. 20B) and Acta2 (Fig. 20C). KO2 mice on CDE diet 
also displayed increased p21-positive hepatocytes (Fig. 20A) and overall p21 protein levels (Fig. 
20H).  
When hepatocyte proliferation was assessed by Ki67 staining, WT2 mice also displayed 
robust periportal hepatocyte proliferation, which was nearly absent in KO2 mice (Fig. 19G-H). 
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Figure 19: KO2 mice display severe liver injury and impaired hepatocyte proliferation after CDE diet-
induced liver injury. 
(a) 24-25 day old male Ctnnb1flox/flox; Rosa-stopflox/flox-EYFP or Ctnnb1+/+; Rosa-stopflox/flox-EYFP 
mice were injected with AAV8-TBG-Cre to generate KO2 and WT2 mice respectively, followed 
by 12ds of wash-out on normal diet before 2W of CDE diet. (b) Schematic of cell labeling after 
AAV8-TBG-Cre injection, only hepatocytes (maroon hexagons) will be labeled with EYFP and 
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will lose β-catenin expression (black outline). BECs (green circles) will not be altered by AAV8-
TBG-Cre injection. (c) Serum liver injury marker aspartate aminotransferase (AST) is significantly 
elevated in KO2 mice after CDE diet compared to WT2 mice (t-test, **** = p < 0.0001). (d) Serum 
bilirubin is significantly elevated in KO2 mice after CDE diet compared to WT2 mice (t-test, **** 
= p < 0.0001). (e) KO2 mice lose significantly more body weight compared to WT2 mice after 
CDE diet (WT2 n = 22, KO2 n =11, Two-way ANOVA, **** = p < 0.0001). (f) Schematic of fate-
tracing showing that any BECs that give rise to hepatocytes will be negative for EYFP and will 
express β-catenin. (g) IHC shows many Ki67-positive hepatocytes in WT2 mice but not in KO2 
after CDE diet (scale bar 50 µm). (h) Quantification reveals fewer Ki67-positive hepatocytes in 
KO2 mice after CDE diet (Mann-Whitney U Test, ** = p < 0.01). (i) Hepatic Ccnd1 gene 
expression is significantly elevated in WT2 mice after CDE diet, but impaired in KO2 mice (One-
way ANOVA, ** = p < 0.01). (j) No BEC-derived hepatocytes (EYFP-negative, β-catenin-
positive) were evident in either WT2 or KO2 mice after 2W of CDE diet (scale bar 50 µm).  
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Figure 20: KO2 mice develop fibrosis and a robust BEC response after two weeks of CDE diet. 
(a) IHC staining reveals a lack of β-catenin expression in hepatocytes in KO2 mice. Additionally, 
Pan-cytokeratin staining reveals a robust BEC response, Sirius Red the development of fibrosis, 
and p21 staining reveals an increase in p21-positive hepatocytes in KO2 mice after two weeks of 
CDE diet compared to WT2 mice (scale bar 50 µm). (b) WT2 and KO2 mice display an increase 
in Col1a1 gene expression of two weeks of CDE diet. (c) WT2 and KO2 mice display an increase 
in Acta2 (α-smooth muscle actin) gene expression after two weeks of CDE diet. (d) Significantly 
elevated serum ALT levels in KO2 mice after two weeks of CDE diet (t-test, p < 0.01). (e) No 
difference in serum ALP levels in WT2 and KO2 mice after two weeks of CDE diet. (f) WT2 and 
KO2 mice display an increase in Krt19 gene expression after two weeks of CDE diet. (g) WT2 
and KO2 mice display an increase in Sox9 gene expression after two weeks of CDE diet. (h) KO2 
mice do not display an increase in total β-catenin levels but do show an increase in active β-catenin 
after two weeks of CDE diet compared to KO2 mice on normal diet. KO2 mice also display less 
Cyclin D1 and more p21 expression compared to WT2 mice after two weeks of CDE diet.  
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WT2 mice, like WT1, displayed increased Ccnd1 gene (Fig. 19I) and protein expression (Fig. 20H) 
after CDE diet, which was significantly abrogated in KO2. This suggests severely impaired 
hepatocyte proliferation in KO2 mice after 2W of CDE diet. We did not detect any β-catenin-
positive, EYFP-negative hepatocytes in KO2 (Fig. 19J), suggesting no BEC-derived hepatocytes 
(Fig. 19F) were present at this time. Corroborating this observation, we did not detect an increase 
in total β-catenin levels in KO2 mice after 2W of CDE diet in comparison to KO2 mice left on 
normal diet. However, we did detect active β-catenin in KO2 mice on CDE diet, which was absent 
in KO2 mice on normal diet (Fig. 20H). This suggests active-β-catenin is present in β-catenin-
positive BEC compartment, and that BEC differentiation into hepatocytes had yet to occur. 
3.4.3  Defective Hepatocyte Proliferation in KO2 Mice Drives BEC-to-Hepatocyte 
Differentiation after CDE Diet-Induced Hepatic Injury 
To facilitate BEC-driven repair, we next administered CDE diet to WT2 and KO2 mice for 
2W followed by recovery on normal diet for 2W (184, 187, 191) (Fig. 21A). Both WT2 and KO2 
displayed normal serum ALT (Fig. 21C), although KO2 displayed slightly elevated serum bilirubin 
(Fig. 21D) and ALP (Fig. 21E) compared to WT2. Excitingly, in KO2 mice we detected clusters 
of β-catenin-positive, EYFP-negative cells which stained positively for hepatocyte marker Hnf4α 
(Fig. 21G), indicating BEC-derived hepatocytes (Fig. 21B). We did not detect expansion of EYFP- 
negative hepatocytes in WT2 mice, suggesting that BECs do not give rise to hepatocytes in animals 
when hepatocyte proliferation is not impaired, consistent with previous reports (190, 214, 278). 
An alternative explanation for these cells is that they were hepatocytes which escaped initial Cre 
recombination, which could result in EYFP-negative, β-catenin-positive hepatocytes. However, 
we would predict the efficiency of AAV8-TBG-Cre to be the same in both WT2 and KO2 mice. 
 89 
 
Figure 21: BEC-derived hepatocytes appear in KO2 but not WT2 mice following recovery after CDE diet. 
(a) 24-25 day old male Ctnnb1flox/flox; Rosa-stopflox/flox-EYFP or Ctnnb1+/+; Rosa-stopflox/flox-EYFP 
mice were injected with AAV8-TBG-Cre to generate KO2 and WT2 mice respectively, followed 
by 12ds of wash-out on normal diet before 2W of CDE diet followed by another 2W of recovery 
on normal chow. (b) Schematic of fate tracing depicting BECs that give rise to hepatocytes will be 
negative for EYFP and will express β-catenin. (c) Serum ALT levels normalize after 2W of 
recovery post-CDE diet in both WT2 and KO2 mice. (d) Serum bilirubin levels are reduced in 
KO2 mice compared to immediate post-CDE diet injury levels, but still significantly elevated in 
comparison to WT2 mice following 2W of recovery (t-test, ** = p < 0.01).  (e) Serum ALP levels 
are significantly elevated in KO2 compared to WT2 mice after CDE 2W and 2W of recovery (t-
test, *** = p < 0.001). (f) Over 99% of hepatocytes are EYFP-positive in WT2 and KO2 mice both 
prior to injury (Normal Diet 12ds) and after 2W of CDE diet-induced liver injury (CDE 2W). After 
recovery on normal diet following CDE diet, approximately 20% of periportal hepatocytes are 
EYFP-negative in KO2 mice while there is no reduction in EYFP-positive hepatocytes in WT2 
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mice. (g) Hnf4α-positive hepatocytes which are negative for EYFP and positive for β-catenin 
appear in KO2 mice after CDE diet and recovery. No EYFP-negative hepatocytes are apparent in 
WT2 mice (scale bar 50 µm). 
 
Therefore, we quantified the number of EYFP-positive/negative hepatocytes in our WT2 and KO2 
mice over the course of CDE diet injury and recovery (Fig. 21F). First, we quantified the number 
of EYFP-positive hepatocytes in WT2 and KO2 mice 12d after injection with AAV8-TBG-Cre, 
corresponding to the initial labeling efficiency before the onset of liver injury. We found that 
greater than 99% of hepatocytes were EYFP-positive, consistent with previous reports (190, 278). 
After 2W of CDE diet, the percentage of EYFP-negative hepatocytes was not significantly 
increased in either WT2 or KO2. However, after 2W of recovery after CDE diet-induced liver 
injury, in KO2 mice approximately 20% of periportal hepatocytes were EYFP-negative, whereas 
the percentage of EYFP-negative hepatocytes in WT2 mice did not increase (Fig. 21F).  
Correspondingly, tiled images (and serial higher magnification images from a representative area) 
from KO2 mice of representative lobes stained for β-catenin revealed no clusters of β-catenin-
positive hepatocytes after 2W of CDE diet (Fig. 22A, B), whereas after 2W of CDE diet followed 
by 2W of recovery on normal diet many clusters of β-catenin-positive hepatocytes were evident 
across the entire lobe (and serial higher magnification images from a representative area) (Fig. 
22C, D). Likewise, hepatic Ctnnb1 expression tended to increase in KO2 mice after CDE diet and 
recovery, although it was still significantly lower than WT2 mice. In age- matched control mice 
left on normal diet for 6W after AAV8-TBG-Cre injection, hepatic gene expression of Ctnnb1 was 
greatly reduced in KO2 mice compared to WT2 mice (Fig. 22E), indicating lack of repopulation 
of β-catenin-positive hepatocytes in the absence of liver injury. These results, in combination with 
lack of expansion of EYFP-negative hepatocytes in WT2 after CDE diet injury and recovery, 
support BEC-to-hepatocyte conversion in KO2 over expansion of Cre-recombinase escaped cells. 
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Figure 22: Expansion of β-catenin-positive hepatocytes occurs only after recovery on normal diet. 
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(a) Tiled β-catenin IHC staining of an entire lobe from the liver of a KO2 mouse after 2 weeks of 
CDE diet reveals dramatic expansion of β-catenin-positive BECs, but no clusters of β-catenin-
positive hepatocytes. (b) Serial magnifications of a representative area from Figure S3A (open 
box) verifies dramatic expansion of β-catenin-positive BECs, but no clusters of β-catenin-positive 
hepatocytes (50x, 100x, 200x, 400x). (c) Tiled β-catenin IHC staining of an entire lobe from the 
liver of a KO2 mouse after 2 weeks of CDE diet followed by 2 weeks of recovery on normal diet 
reveals clusters of β-catenin-positive hepatocytes appearing across the entire lobe. (d) Serial 
magnifications of a representative area from Figure S3C (open box) verifies clusters of β-catenin-
positive hepatocytes appearing in close association with ductules (50x, 100x, 200x, 400x). (e) 
Expression of Ctnnb1 is dramatically reduced in KO2 mice compared to WT2 mice on normal diet 
for 6 weeks. After 2 weeks of CDE diet followed by 2 weeks of recovery on normal diet, expression 
of Ctnnb1 is trending upward in KO2 mice, although it is still significantly reduced compared to 
WT2 levels (one-way ANOVA, ** = p < 0.01. **** = p < 0.0001). 
 
3.4.4  BEC-Derived β-catenin-Positive Hepatocytes are More Proliferative than 
Endogenous Hepatocytes 
            Analysis of hepatic sections from KO2 mice after 2W of recovery on normal chow 
following 2W of CDE diet showed that nearly all β-catenin-positive hepatocytes were located in 
clusters adjacent to BECs in the periportal region (Fig. 22B). This may also explain the lack of 
reappearance of pericentral β-catenin target glutamine synthetase (GS) (68, 283) in KO2 mice at 
this time (Fig. 23C). The reactive BEC response was extensive after 2W of CDE diet and recovery, 
as evidenced by large numbers of EpCAM-positive BECs (Fig. 24A). The extent of BEC 
expansion was similar in WT2 and KO2, as indicated by comparable hepatic expression of BEC 
markers Krt19 (Fig. 24B) and Sox9 (Fig. 24C). There was ongoing fibrosis in both WT2 and KO2 
as evidenced by Sirius Red staining even after 2W recovery on normal diet (Fig. 24A), which is 
likely due to ongoing reactive BEC response, which is known to secrete profibrogenic cytokines 
(127). This level of fibrosis also indicated that repair of CDE diet-induced liver injury was not 
complete after 2W of recovery on normal diet. 
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Figure 23: β-catenin-positive hepatocytes preferentially proliferate to restore lost hepatocyte mass. 
(a) The majority of BEC-derived β-catenin-positive hepatocytes in a given cluster are PCNA-
positive (scale bar 50 µm). (b) Quantification of PCNA reveals β-catenin-positive hepatocytes are 
significantly more proliferative than surrounding β-catenin-negative hepatocytes (Mann-Whitney 
U test, ** = p < 0.01). (c) There is an increase in total β-catenin, active β-catenin, and Cyclin D1 
levels in KO2 mice after CDE diet and recovery compared to KO2 mice left on normal diet. Since 
all BEC-derived hepatocytes are located in the periportal region, there is no re-expression of 
pericentral β-catenin target GS. (d) IHC staining for β-catenin reveals no β-catenin-positive 
hepatocytes in KO2 mice after 2W on CDE diet with 0 days of recovery. However, a few β-catenin-
positive hepatocytes are visible after 3 days of recovery (red arrow), with clusters of β-catenin-
positive hepatocytes increasing in size from 7 days recovery to 14 days recovery on normal diet 
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(scale bar 50 µm). (e) β-catenin-positive cells which express both BEC marker CK19 and 
hepatocyte marker Hnf4α can be found in KO2 mice after 2W on CDE diet followed by 7 days of 
recovery on normal diet (scale bar 10 µm). 
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Figure 24: Robust BEC response in WT2 and KO2 mice after CDE diet and recovery. 
(a) There is sustained fibrosis and a continued BEC response in both WT2 and KO2 mice after 
CDE diet and recovery. Rare EpCAM-positive cells with hepatocyte morphology are detectable in 
KO2 mice (black arrows). Additionally, clusters of presumable BEC-derived hepatocytes (red 
arrows) are strongly Cyclin D1 positive in KO2 mice (scale bar 50 µm). (b) The level of Krt19 
gene expression is comparable between WT2 and KO2 mice after 2 weeks of CDE diet followed 
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by 2 weeks of recovery on normal diet. (c) The level of Sox9 gene expression is comparable 
between WT2 and KO2 mice after 2 weeks of CDE diet followed by 2 weeks of recovery on 
normal diet. (d) The majority of BECs are negative for EYFP in WT2 and KO2 mice after CDE 
diet and recovery. However, rare EYFP cells positive for BEC markers are detectable in both WT2 
and KO2 mice, potentially suggesting hepatocyte-to-BEC transdifferentiation (scale bar 50 µm). 
PV = portal vein. 
 
To determine if BEC-derived, β-catenin-positive hepatocytes were driving restoration of 
hepatocyte mass in KO2 mice after CDE diet-induced liver injury, we performed triple 
immunofluorescence for Hnf4α, β-catenin, and proliferating cell nuclear antigen (PCNA) (Fig. 
23A). Within a given cluster of β-catenin-positive hepatocytes in KO2, the majority of β-catenin-
positive hepatocytes stained positively for PCNA. Indeed, periportal β-catenin-positive 
hepatocytes were significantly more proliferative than surrounding β-catenin-negative hepatocytes 
in KO2 (Fig. 23B). Likewise, clusters of periportal hepatocytes in KO2 were strongly Cyclin D1-
positive in comparison to surrounding hepatocytes (Fig. 24A, red arrows). KO2 also displayed 
increased total Cyclin D1 protein compared to WT2 after 2W of CDE diet and recovery (Fig. 23C). 
There was also a noticeable increase in total and active-β-catenin in KO2 after recovery in 
comparison to age-matched KO2 left on normal diet for 6W (Fig. 23C), indicating repopulation 
by β-catenin-positive cells in KO2 during repair. Collectively, these results demonstrate BEC-
derived β-catenin-positive hepatocytes are preferentially proliferating to replenish lost hepatic 
mass in KO2 mice.  
3.4.5  BEC Differentiation to Hepatocytes Occurs Early in Recovery on Normal Diet    
To determine if the BEC-derived hepatocytes after 2W of recovery on normal diet express 
BEC markers, we performed triple immunofluorescence with a wide-spectrum cytokeratin 
antibody (PanCK) in addition to EYFP and hepatocyte marker Hnf4α (Fig. 24D). EYFP-negative 
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hepatocytes were PanCK-negative (Fig. 24D, white arrowhead), and as expected the majority of 
cytokeratin-positive BECs were negative for EYFP. Interestingly, rare EYFP-positive BECs were 
observed in both WT2 and KO2 mice (Fig. 24D, white arrows), potentially indicating hepatocyte-
to-BEC transdifferentiation after CDE diet-induced liver injury. When we performed staining for 
a second BEC marker, EpCAM, we observed rare cells with hepatocyte-like morphology which 
were EpCAM-positive in KO2 mice (Fig. 24A, black arrows). This finding correlates with the 
observations of EpCAM-positive hepatocytes in human patients with BEC expansion after severe 
liver injury (104).  These results demonstrate that after 2W of recovery on normal diet, the majority 
of BEC-derived hepatocytes in KO2 mice do not express BEC markers. 
To further explore the timing of BEC-to-hepatocyte differentiation during recovery from 
CDE diet, we harvested KO2 mice after 3d or 7d of recovery on normal diet post-CDE diet (Fig. 
25A). Excitingly, very few small β-catenin-positive hepatocyte-like cells are evident after 3d 
recovery, which grow into small clusters of β-catenin-positive cells with hepatocyte morphology 
after 7d recovery (Fig. 23D, red arrows). These clusters are even larger following 2W of recovery 
on normal diet, suggesting potential clonal expansion of BEC-derived, β-catenin-positive 
hepatocytes. Interestingly, serum ALT levels are dramatically reduced following 3d of recovery 
on normal diet (Fig. 25B), while both serum bilirubin and ALP levels remain elevated after 3d of 
recovery and only begin to normalize after 7d or 14d of recovery, respectively (Fig. 25C-D), 
potentially suggesting abatement of acute liver injury may be required for expansion of these cells. 
Similar serum liver injury profiles and appearance of small β-catenin-positive hepatocytes were 
also observed in female KO2 mice after CDE diet and three days of recovery (data not shown), 
suggesting BEC-to-hepatocyte differentiation also occurs in female mice following recovery from 
CDE diet-induced liver injury. 
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Figure 25: Expansion of BEC-derived, β-catenin-positive hepatocytes during early recovery on normal diet. 
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(a) Schematic of KO2 mice placed on normal diet for two weeks and then allowed to recovery on 
normal diet for either 0, 3, 7, or 14 days. (b) Serum ALT levels are elevated in KO2 mice on CDE 
diet for 2 weeks, but are dramatically reduced as early as 3 days after recovery on normal diet 
(One-way ANOVA, ** p < 0.01, **** p < 0.0001). (c) Serum bilirubin levels are elevated in KO2 
mice on CDE diet for 2 weeks, and only begin to show a reduction after 7 days of recovery on 
normal diet (One-way ANOVA, **** p < 0.0001). (d) Serum ALP levels are elevated in KO2 
mice on CDE diet for 2 weeks and begin to show a reduction after two weeks of recovery on 
normal diet (One-way ANOVA, **** p < 0.0001). (e) After 2 weeks of CDE diet, β-catenin-
positive cells are positive for BEC-marker CK19 but negative for Hnf4α (scale bar 20 µm). (f) As 
early as 3 days of recovery following CDE diet-induced liver injury, β-catenin-positive cells which 
express CK19 and weakly express Hnf4α (white arrow) can be detected (scale bar 20 µm). (g) 
After 7 days of recovery on normal diet following CDE diet-induced liver injury, there are clusters 
containing multiple β-catenin-positive, Hnf4α-positive hepatocytes (white arrows, scale bar 20 
µm). 
 
We next investigated the expression of Hnf4α in these putative transdifferentiating BECs 
over time. After 2W of CDE diet, virtually all β-catenin-positive cells were positive for CK19 and 
negative for Hnf4α (Fig. 25E). However, as early as after 3d of recovery we detected β-catenin-
positive cells which were CK19-positive and weakly positive for Hnf4α (Fig. 25F). After 7d of 
recovery on normal diet, rare β-catenin-positive cells were observed which were strongly positive 
for both CK19 and Hnf4α (Fig. 23E). At this time point, clusters containing β-
catenin+/Hnf4α+/CK19+ hepatocytes were evident (Fig. 25G). The rarity of the β-
catenin+/Hnf4α+/CK19+ cells in combination with the increased proliferation of β-catenin-
positive hepatocytes suggests that few BECs differentiate into hepatocytes, which subsequently 
proliferate to restore lost hepatocyte mass in KO2 mice.  
3.4.6  BEC-Derived Hepatocytes Repopulate the Liver during Long-Term Recovery 
Previous studies have demonstrated that transdifferentiated cells, such as hepatocyte-
derived BECs, may revert back to their original cell type when liver injury has abated (214). 
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Alternatively, it has been shown that with persistent need for transdifferentiated cells, such as in 
mice which lack the intrahepatic biliary system, hepatocyte-to-BEC conversion is permanent and 
stable for life (215). To determine if BEC-derived hepatocytes would persist and further repopulate 
the liver, KO2 mice were allowed to recover on normal diet for either 3 or 6 months (6m) after 
CDE diet (Fig. 26A). As a control, we traced WT2 and KO2 mice for 6m on normal diet to 
determine the persistence of EYFP labeling in the absence of injury. Serum ALT levels were 
normal in both WT2 and KO2 (Fig. 26B, C). Interestingly, KO2 mice left on normal diet for 6m 
showed minor elevation of bilirubin compared to WT2 (Fig. 26C). KO2 mice after long-term 
recovery from CDE diet showed extensive expansion of EYFP-negative, β-catenin-positive 
hepatocytes (Fig. 26E), as evidenced by central veins that were partially or completely GS-positive 
(Fig. 27A). When we quantified the number of EYFP-positive hepatocytes, we found that in 
control WT2 and KO2 left on normal diet for 6m there was no significant expansion of EYFP-
negative hepatocytes, similar to WT2 after long-term recovery from CDE diet (Fig. 26D). 
However, in KO2 after 3m of recovery from CDE diet up to 70% of hepatocytes were EYFP-
negative, and this number remained stable after 6m of recovery. In control KO2 mice left on 
normal diet for 6m, virtually all EYFP-positive hepatocytes were β-catenin-negative (Fig. 27B) as 
confirmed by β-catenin IHC (Fig. 27C). Hepatic expression of Ctnnb1 was significantly reduced 
in KO2 mice left on normal diet for 6m compared to control WT2 mice, while expression of 
Ctnnb1 in KO2 after recovery from CDE diet began to approach WT2 levels (Fig. 27D). The lack 
of expansion of EYFP-negative hepatocytes in WT2 mice even after 6m of recovery post-CDE 
diet, combined with the lack of expansion of EYFP-negative hepatocytes in KO2 left on normal 
diet, further supports our hypothesis that BEC-derived hepatocytes repopulate the liver in KO2 
after CDE diet-induced liver injury. 
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Figure 26: β-catenin-positive hepatocytes repopulate the majority of the liver during long-term recovery. 
(a) After CDE diet treatment, WT2 and KO2 mice were allowed to recover on normal diet for 
either 3 or 6 months. As a control, WT2 and KO2 mice which were never exposed to CDE diet 
were traced for 6 months after AAV8 injection. (b) Serum ALT levels are normal in both WT2 
and KO2 mice after long-term recovery on normal diet. (c) Serum bilirubin levels are normal in 
both WT2 and KO2 mice on long-term recovery on normal diet, although serum bilirubin is 
slightly elevated in control KO2 mice kept on normal diet for 6 months (one-way ANOVA, * = p 
< 0.05). (d) There is no significant expansion of EYFP-negative hepatocytes in control WT2 and 
KO2 mice left on normal diet for 6 months (blue bars), or in WT2 mice exposed to CDE diet for 
2W and allowed to recover on normal diet for up to 6 months. However, in KO2 mice up to 70% 
of hepatocytes are EYFP negative after 6 months of recovery on normal diet following CDE diet-
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induced liver injury. (e) Expansion of EYFP-negative hepatocytes is only evident in KO2, not 
WT2, mice after 6 months of recovery on normal diet following CDE diet-induced liver injury.  
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Figure 27: Expansion of EYFP-negative hepatocytes occurs only after exposure to CDE diet in KO2 mice. 
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(a) Expression of GS partially reappears in KO2 mice after CDE diet-induced liver injury and 
either 3 or 6 months of recovery on normal diet. (b) Virtually all hepatocytes are EYFP-positive 
in both control WT2 and KO2 mice left on normal diet for 6 months (scale bar 50 µm). (c) Tiled 
IHC β-catenin staining of a lobe from a KO2 mouse left on normal diet for 6 months after AAV8 
injection reveals virtually no β-catenin-positive hepatocytes. (d) There is dramatically reduced 
hepatic Ctnnb1 expression in control KO2 mice left on normal diet for 6 months compared to WT2 
controls. However, in KO2 mice placed on CDE diet followed by up to 6 months of recovery on 
normal diet the level of hepatic Ctnnb1 expression is approaching WT2 levels (one-way ANOVA, 
*** = p < 0.001).  
 
3.4.7  In Vivo Ctnnb1 RNAi Impairs Hepatocyte Proliferation after CDE Diet-Induced 
Liver Injury 
To prove BECs were indeed giving rise to hepatocytes in our model, we sought to perform 
direct lineage tracing of BECs utilizing tamoxifen-inducible Krt19-Cre to label BECs with the 
reporter tdTomato. However, usage of Cre recombinase to label BECs precluded the usage of Cre 
recombinase to delete Ctnnb1 specifically in hepatocytes. To achieve labeling of BECs with a 
reporter and simultaneous knockdown of Ctnnb1 expression in hepatocytes, we utilized GalXC 
(280). To validate that GalXC injection would recapitulate the phenotype of CDE diet-fed mice 
with genetic hepatocyte-specific Ctnnb1 deletion, we performed weekly subcutaneous injections 
of GalXC in mice fed CDE diet. The first injection was performed 1W before CDE diet exposure 
to ensure reduced β-catenin levels in hepatocytes at the time of CDE diet administration (Fig. 
28A).  
Real-time PCR analysis demonstrated significant reduction of hepatic Ctnnb1 gene 
expression in GalXC-injected mice compared to PBS-injected control mice on CDE diet (Fig. 
28B). GalXC-injected mice fed CDE diet for 2W displayed significantly elevated serum ALT (Fig. 
28C), AST (Fig. 28D), and bilirubin levels (Fig. 28F) compared to control PBS-injected mice. We 
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Figure 28: Hepatocyte-specific in vivo Ctnnb1 RNAi induces severe liver injury and a block of hepatocyte 
proliferation in CDE diet-fed mice. 
(a) C57BL6/NJ mice were placed on CDE diet for 2W. Mice were given weekly subcutaneous 
injections of GalXC or PBS one week prior to CDE diet administration and throughout the course 
of CDE diet feeding. (b) RT-PCR analysis of Ctnnb1 gene expression in whole liver lysates of 
GalXC or PBS-injected mice on CDE diet (t-test, ** = p < 0.01). (c) Significantly elevated serum 
ALT levels in GalXC-injected mice compared to PBS controls (t-test, ** = p < 0.01). (d) 
Significantly elevated serum AST levels in GalXC-injected mice compared to PBS controls (t-test, 
** = p < 0.01). (e) Whole liver lysate reveals reduction in total β-catenin and active β-catenin, as 
well as complete loss of β-catenin-target GS in GalXC-injected mice on CDE diet. (f) Significantly 
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elevated serum bilirubin levels in GalXC-injected mice compared to PBS controls (t-test, **** = 
p < 0.0001). (g) Quantification reveals significantly fewer Ki67-positive hepatocytes in GalXC-
injected mice compared to PBS-injected controls (Mann-Whitney U test, * = p < 0.05). (h) IHC 
staining reveals robust Ki67 staining of hepatocytes in PBS but not GalXC-injected animals. 
Cyclin D1 staining is significantly reduced in GalXC-injected mice, which also display a lack of 
hepatocyte-specific β-catenin staining (scale bar 50 µm). 
 
additionally confirmed reduction in both total and active β-catenin protein levels, as well as loss 
of expression of β-catenin downstream target GS, in GalXC-injected mice on CDE diet (Fig. 28E). 
Staining for Ki67 displayed robust hepatocyte proliferation in PBS-injected controls but not 
GalXC-injected mice on CDE diet (Fig. 28H), which was confirmed by quantification (Fig. 28G). 
There was also a notable decrease in Cyclin D1 staining in the livers of GalXC-injected mice on 
CDE diet (Fig. 28H). Finally, IHC for β-catenin confirmed loss of β-catenin expression specifically 
in hepatocytes of GalXC-injected mice (Fig. 28H). Collectively, these results demonstrate that 
GalXC-injected mice display increased liver injury and impairment of hepatocyte proliferation. 
3.4.8  BECs Give Rise to Hepatocytes in Ctnnb1 RNAi-Treated Mice after CDE Diet-
Induced Liver Injury 
Having proven that injection of GalXC was sufficient to block hepatocyte proliferation in 
mice on CDE diet, we developed a mouse model of Krt19-CreERT+/--driven BEC lineage tracing 
(191) in combination with hepatocyte-specific Ctnnb1 knockdown. To label BECs, tamoxifen 
was injected in Krt19-CreERT+/- mice during postnatal week one, followed by a two-week 
washout period to ensure elimination of any residual tamoxifen (Fig. 29A). Next, these mice 
were given weekly injections of GalXC throughout the course of CDE diet and recovery (Fig. 
29A). In this model, BEC-derived hepatocytes can be directly traced as they will be tdTomato-
positive (Fig. 29B). Prior to CDE diet administration, we verified that early postnatal tamoxifen 
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administration labeled only BECs and not surrounding hepatocytes (Fig. 30A), implying that any 
tdTomato-positive hepatocytes would have to arise from a pre-existing tdTomato-positive BEC. 
We additionally determined the Krt19-CreERT+/- recombination efficiency in BECs in this model 
to be approximately 50% (Fig. 30B). After CDE diet and recovery, serum liver injury markers 
were approaching normal levels in both PBS and GalXC-injected mice (Fig. 30B-D). Excitingly, 
clusters of tdTomato-positive hepatocytes which were also Hnf4α-positive (Fig. 29C) and 
CYP2D6-positive (Fig. 31A) were evident in the GalXC-injected mice but not in the mice 
injected with PBS as a control. Quantification revealed that approximately 6% of hepatocytes 
were tdTomato-positive in GalXC-injected mice after CDE diet and recovery (Fig. 29D).  
Immunofluorescence of β-catenin was strongly detected in the hepatocytes of PBS-injected 
mice but was significantly reduced in GalXC-injected mice (Fig. 29E). Importantly, tdTomato- 
positive hepatocytes were located adjacent to clusters of β-catenin-positive BECs in GalXC- 
injected mice. Finally, clusters of tdTomato-positive hepatocytes in GalXC-injected mice would 
occasionally extend all the way to the central vein, resulting in localized re-expression of β-catenin 
target GS (Fig. 31B). All together, these results demonstrate that BECs give rise to hepatocytes 
when hepatocyte proliferation is impaired, which was achieved in our model through the loss of 
β-catenin expression in hepatocytes in mice exposed to CDE diet-induced liver injury (Fig. 31C). 
3.5 Discussion 
The role of BECs in mediating LR has remained controversial, as several studies have 
reported a limited role for BEC differentiation to hepatocytes (150, 190, 278). Recent studies have 
demonstrated widespread hepatocyte senescence (191), hepatocyte ablation (232), impaired 
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Figure 29: BEC-derived hepatocytes appear in GalXC but not PBS treated mice following recovery period 
after CDE diet. 
(a) Krt19-CreERT+/- mice were given tamoxifen during postnatal week 1, followed by a 2 week 
washout. Mice were given subcutaneous injections of either GalXC or PBS one week prior to CDE 
diet administration, and injected weekly throughout the course of the experiment. Mice remained 
on CDE diet for 3 weeks followed by a 2 week recovery on normal diet. (b) After tamoxifen 
administration, BECs will be labeled with tdTomato, and GalXC injections induce hepatocyte-
specific knockdown of Ctnnb1 expression. Therefore, a BEC-derived hepatocyte will be 
tdTomato-positive and re-express β-catenin. (c) In control PBS-injected mice after CDE diet and 
recovery, BECs but not hepatocytes are tdTomato-positive. In GalXC-injected mice clusters of 
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tdTomato-positive, Hnf4α-positive hepatocytes are evident, demonstrating BEC-to-hepatocyte 
conversion (scale bar 100 µm). (d) Quantification of tdTomato, Hnf4α double-positive cells 
reveals significantly more BEC-derived hepatocytes in GalXC-injected mice compared to PBS-
injected controls (t-test, * = p < 0.05).  (e) In control PBS-injected mice, both BECs and 
hepatocytes are β-catenin-positive, but only BECs are tdTomato-positive. In GalXC-injected mice, 
hepatocytes lose cytoplasmic β-catenin-staining and clusters of tdTomato-positive hepatocytes 
(white arrows) are located periportally (scale bar 100 µm). 
 
 
 
Figure 30: BEC-derived hepatocytes begin to repopulate the liver in GalXC-injected mice. 
(a) After tamoxifen administration, only CK19-positive BECs are labeled with tdTomato. 
Expression of tdTomato is not detected in mice that do not express Cre recombinase (scale bar 100 
µm). (b) Quantification of recombination efficiency of CK19-positive cells following tamoxifen 
injections. (c) Serum ALT levels are normalizing in GalXC-injected mice after CDE diet and 
recovery. (d) Serum Bilirubin levels are normalizing in GalXC-injected mice after CDE diet and 
recovery. (e) Serum AST levels are normalizing in GalXC-injected mice after CDE diet and 
recovery. 
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Figure 31: BEC-derived hepatocytes express mature hepatocyte markers. 
(a) BEC-derived tdTomato-positive hepatocytes are positive for hepatocyte marker CYP2D6 in 
GalXC-injected mice (scale bar 100 µm). (b) BEC-derived tdTomato-positive hepatocytes in 
GalXC-injected mice extend all the way to the central vein, resulting in re-expression of β-catenin-
target GS (scale bar 100 µm). (c) Schematic illustrating key findings: when hepatocyte 
proliferation is intact (β-catenin WT hepatocytes) after CDE diet-induced liver injury, liver 
regeneration is driven by hepatocyte proliferation. When mice with hepatocyte-specific loss of β-
catenin are subjected to CDE diet, BEC-to-hepatocyte differentiation occurs to facilitate liver 
regeneration. 
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hepatocyte proliferation (187), or prolonged exposure to severe liver injury (195) can trigger 
differentiation of BECs to hepatocytes. Interestingly, a previous study reported ductular reaction 
and BEC-to-hepatocyte differentiation in aged Albumin-Cre β-catenin KO livers (284), suggesting 
expression of β-catenin in hepatocytes is important for long-term liver health. Here, we 
demonstrate that hepatocyte-specific loss of β-catenin expression in combination with CDE diet-
induced liver injury triggers severe impairment of hepatocyte proliferation and leads to 
unequivocal repopulation of liver with BEC-derived hepatocytes.  
Genetic loss of β-catenin in hepatocytes led to extensive injury in the CDE diet model with 
robust expansion of BECs in both male and female mice (data not shown). Further, knockdown of 
Ctnnb1 expression in hepatocytes via siRNA also impaired hepatocyte proliferation after CDE 
diet. Intriguingly, BEC expansion occurred normally despite β-catenin loss in these cells in 
Albumin-Cre Ctnnb1 KO mice on CDE diet. However, the appearance of active-β-catenin in KO2 
mice, which retained β-catenin expression in BECs, suggests activation of β-catenin signaling in 
this compartment during CDE diet. This observation is in accordance with previous findings that 
activation of β-catenin in reactive BECs promotes differentiation towards the hepatocyte lineage 
(210). In our model, appearance of BEC-derived hepatocytes was evident as early as 3d of recovery 
on basal diet after 2W of CDE diet, when cells positive for both BEC and hepatocyte markers 
could be observed. Excitingly, Hnf4α+/CK19+ cells have also been observed in a recent study 
demonstrating BEC-derived hepatocytes during long-term severe liver injury (195). Our results 
suggest that differentiation of BECs to hepatocytes is limited or impaired during ongoing injury 
and that a period of recovery is necessary to allow BEC differentiation to hepatocytes, as also 
shown elsewhere (184, 187, 191).  
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Greater than 99% of hepatocytes were labeled with EYFP after AAV8-TBG-Cre injection, 
and after 6 months of normal diet the numbers of EYFP-negative hepatocytes in both WT2 and 
KO2 mice were not significantly increased. Additionally, over 99% of hepatocytes were still 
EYFP-positive in both WT2 and KO2 mice after 2W of CDE diet, suggesting no significant 
population of hepatocytes escaping initial Cre-recombination, as these cells would express β-
catenin and would be expected to have a proliferative advantage during CDE diet-induced liver 
injury. In this negative tracing model, we found that after recovery, approximately 20% of 
periportal hepatocytes were BEC-derived. Interestingly, in our positive lineage tracing model, we 
found only 6% of hepatocytes were BEC-derived. This is attributable to the fact that initially only 
around 50% of BECs were labeled with tdTomato in this model, suggesting potentially 12% of 
hepatocytes were BEC-derived in our model after factoring in the limited recombination 
efficiency. Furthermore, newly BEC-derived hepatocytes may be susceptible to GalXC-mediated 
Ctnnb1 knockdown, potentially reducing their proliferation during recovery from CDE diet, 
further reducing tdTomato-positive hepatocyte numbers.    
Although our data convincingly proves the differentiation and long-term survival of BEC-
derived hepatocytes, much remains to be elucidated about both the long-term effects of BEC-
derived hepatocytes on liver health and the mechanisms underlying BEC-to-hepatocyte 
differentiation. For instance, it will be interesting to determine if BEC-derived hepatocytes are 
equally as adept at promoting resolution of liver injury, such as resolution of fibrosis. Additionally, 
while factors that promote ductular reaction are better known (285), our knowledge of the factors 
promoting BEC differentiation to hepatocytes is much more limited. Since our model establishes 
a clear timeline for BEC differentiation to hepatocytes, it will be invaluable in determining the 
factors that underlie this process. For example, as we have demonstrated the importance of β-
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catenin signaling in LR, this would potentially allow promotion of BEC-to-hepatocyte 
differentiation while circumventing activation of oncogenic β-catenin signaling in patients. 
Additionally, it will be important to determine the threshold of hepatic impairment that triggers 
BEC-to-hepatocyte differentiation, as this may lead to the development of biomarkers for patients 
with severe liver disease that are amenable to such treatments. These would be important steps in 
developing regenerative medicine therapies for the treatment of chronic liver disease.  
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4.0 Concluding Remarks and General Discussion 
4.1 Significance 
Chronic liver disease is a major public health concern which is growing in magnitude. In 
2013, chronic liver disease and cirrhosis was the 12th leading cause of death in the United States 
(286). Chronic liver disease (CLD) has many causes including viral hepatitis, alcoholic hepatitis, 
primary biliary cirrhosis, and non-alcoholic fatty liver disease (NAFLD) (222, 287, 288). Patients 
with CLD are at risk for progression to cirrhosis and/or liver failure (222, 223, 289, 290), 
conditions where the only available treatment is a liver transplant (222, 290). The scarcity of donor 
organs and mortality of patients on the waiting list means there is a great need to develop 
alternative treatments for CLD (291). Liver progenitor cells (LPCs), bipotent cells arising from the 
biliary epithelial cell (BEC) compartment, are thought to differentiate into hepatocytes to mediate 
liver regeneration only when hepatocyte proliferation is impaired (80, 175, 176, 218). In this 
dissertation, we have identified an important role for BET protein signaling in promoting 
hepatocyte proliferation after acute liver injury (216). This will be important knowledge to keep 
in mind when designing therapies involving the use of BET inhibitors, as this treatment may put 
patients at higher risk of developing liver failure with the use of over-the-counter medicines that 
contain acetaminophen.  
The mechanisms of LPC-mediated liver regeneration are poorly understood. Expansion of 
LPCs is observed in a wide range of human patients with both chronic (116, 275, 276) and acute 
liver injury (292). Therapies promoting LPC differentiation to hepatocytes could have major 
clinical benefits, as impairment of endogenous hepatocyte proliferation is thought to promote 
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progression of CLD (222). β-catenin signaling, which is important for both normal liver 
development (70, 293, 294) and regeneration after liver injury (74, 82, 97), has been implicated in 
the differentiation of LPCs to hepatocytes (210).  In this dissertation, we have identified lack of β-
catenin in hepatocytes during exposure to severe liver injury as a mechanism of impairing 
hepatocyte proliferation, leading to BEC-to-hepatocyte differentiation (188). This suggests that 
patients with innately impaired liver Wnt/β-catenin signaling may be at a higher risk of developing 
severe liver injury and progressing to cirrhosis in the context of chronic liver disease, also this 
hypothesis remains to be tested with clinical specimens. 
4.2 Future Directions: Wnt/β-catenin Signaling 
As more knowledge about the role of Wnt/β-catenin signaling in liver biology is obtained, 
it is becoming clear that Wnt/β-catenin signaling is involved in almost every aspect of liver 
function, from liver development to metabolism to regeneration. This review has also illustrated 
the diverse roles of Wnt/β-catenin signaling in nearly every cell type in the liver. As this signaling 
pathway can promote both liver injury and regeneration, therapies targeting Wnt/β-catenin 
signaling must be carefully evaluated to consider both the disease context and the targeted cell 
type. The pleiotropic nature of this signaling pathway would also necessitate the development of 
delivery methods that would minimize off-target effects of undesirable Wnt/β-catenin signaling 
inhibition in non-target cell types.  
Despite all that is known about Wnt/β-catenin signaling in liver biology, there is clearly 
still much to be discovered. For example, very little is understood about which Wnt ligands interact 
with which Frizzled receptors in many cell type and disease contexts. As there are 19 Wnts and 10 
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Frizzled receptors in the mammalian genome (39), this a problem of almost dizzying complexity. 
Additionally, the role of non-canonical Wnt signaling is liver homeostasis, disease, and 
regeneration is poorly understood. Finally, the role of Wnt/β-catenin signaling in the pathobiology 
of conditions such as steatohepatitis (92, 97), cholestasis (65), and hepatic fibrosis (295, 296) in 
human patients will need to be investigated further, as experiment evidence has implicated a role 
for Wnt/β-catenin signaling in the etiology of these conditions. Undoubtedly, future research will 
continue to identify new and exciting roles for Wnt/β-catenin signaling in liver pathobiology and 
regeneration.  
4.3 Future Directions: BEC-to-Hepatocyte Differentiation 
The current body of literature clearly indicates that there is remarkable cellular plasticity 
within the epithelial cells of the liver during hepatic injury, such that under specific circumstances 
the hepatocytes and BECs can change their cellular fate to mediate liver regeneration. Whether 
this cell type conversion is direct transdifferentiation or goes through a “progenitor cell” 
intermediate remains to be definitively elucidated. It also remains to be proven if there are certain 
subsets of hepatocytes and BECs which are more primed to undergo cell fate changes, and if this 
were the case, whether these subsets of cell are facultative stem cells or represent a progenitor cell 
compartment is an argument of semantics. Based on their diverse origin and their dynamic cellular 
fate in diseased liver, LPC-specific markers (or a marker which is absent in mature BECs and 
hepatocytes but expressed in a cell undergoing a cell fate conversion) are not currently available. 
Therefore, it is not feasible to distinguish LPC activation and BEC proliferation/hyperplasia to 
repair damage to biliary structures. Although several markers are suggested as LPC markers, such 
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as Foxl1 (184), Lgr5 (297), Trop2 (147) and Ncam (298), these genes are not usable for detecting 
all LPC populations, as expression of these markers is most likely context-dependent. There is no 
doubt that identification of LPC-specific markers would greatly advance this field; however, it 
remains challenging to identify concrete markers for LPCs applicable to multiple disease 
conditions.   
It also remains to be seen if targeting LPCs for differentiation into hepatocytes represents 
a viable therapeutic strategy for chronic liver disease. Only a subset of patients with chronic liver 
disease will progress to end-stage liver disease and liver cancer, and the role or function of LPCs 
during disease progression remains unknown. Most studies have focused on proving the 
phenomena of cell fate conversion and sought to identify the molecular mechanisms underlying 
this process. While these experiments are essential for developing druggable targets, few studies 
have examined the long-term consequences of promoting LPC differentiation. Since the DR is 
well known to promote fibrogenesis and inflammation, is simply targeting the cells of the DR for 
conversion to hepatocytes enough to induce a restorative hepatic microenvironment? Can this 
process be achieved with enough specificity and efficiency to produce a measurable effect? 
Currently the technology for targeting BECs, the main cell type of the DR, is severely limited, 
which serves as a major roadblock to the development of new therapeutics. Many studies involved 
in promoting LPC differentiation to hepatocytes have removed the underlying liver injury to allow 
recovery and enhance LPC differentiation. This is a very unrealistic scenario in clinical practice, 
so more work will be necessary to determine the efficiency of LPC differentiation in the context 
of ongoing liver injury.  
In conclusion, the liver is a remarkable organ with a diverse array of regenerative responses 
to hepatic injury. It remains to be determined if activation of LPCs, or activation of BECs and 
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hepatocytes as facultative stem cells, is a viable alternative liver regeneration mechanism to 
proliferation of the endogenous epithelial cells of the liver. Nonetheless, advances in this field and 
identification of new mechanisms of liver regeneration hold great promise towards the 
development of therapies for patients with chronic liver disease.  
 119 
Appendix A  
A.1 Publications 
Russell JO, Ko S, Molina LM, Monga SP. 2019. Liver progenitor cells and cell plasticity in liver 
injury and repair: knowns and unknowns. Submitted to Annual Reviews of Pathology. 
 
Russell JO, Ko S, Monga SP, Shin D. 2019. Notch Inhibition Promotes Differentiation of Liver 
Progenitor Cells into Hepatocytes via sox9b Repression in Zebrafish. Stem Cells International. 
 
Min Q, Molina L, Li J, Adebayo Michael AO, Russell JO, Preziosi ME, Singh S, Poddar M, Matz-
Soja M, Ranganathan S, Bell AW, Gebhardt R, Gaunitz F, Yu J, Tao J, Monga SP. 2019. β-Catenin 
and yes-associated protein 1 cooperate in hepatoblastoma pathogenesis. Am J Pathol  
 
Adebayo Michael AO, Ko S, Tao J, Moghe A, Yang H, Xu M, Russell JO, Pradhan-Sundd T, Liu 
S, Singh S, Poddar M, Monga JS, Liu P, Oertel M, Ranganathan S, Singhi A, Rebouissou S, 
Zucman-Rossi J, Ribback S, Calvisi D, Qvartskhava N, Görg B, Häussinger D, Chen X, Monga 
SP. 2019. Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers 
Driven by β-Catenin Mutations. Cell Metab  
 
Ko S, Russell JO, Tian J, Gao C, Kobayashi M, Feng R, Yuan X, Shao C, Ding H, Poddar M, 
Singh S, Locker J, Weng HL, Monga SP, Shin D. 2019. Hdac1 Regulates Differentiation of 
Bipotent Liver Progenitor Cells During Regeneration via Sox9b and Cdk8. Gastroenterology 156: 
187-202.e14 
 
Zhang R, Kikuchi AT, Nakao T, Russell JO, Preziosi ME, Poddar M, Singh S, Bell AW, England 
SG, Monga SP. 2018. Elimination of Wnt secretion from stellate cells is dispensable for zonation 
and development of liver fibrosis following hepatobiliary injury. Gene Expr  
 
Russell JO, Lu WY, Okabe H, Abrams M, Oertel M, Poddar M, Singh S, Forbes SJ, Monga SP. 
2018. Hepatocyte-specific β-catenin deletion during severe liver injury provokes cholangiocytes 
to differentiate into hepatocytes. Hepatology  
 
Pradhan-Sundd T, Vats R, Russell JO, Singh S, Michael AA, Molina L, Kakar S, Cornuet P, 
Poddar M, Watkins SC, Nejak-Bowen KN, Monga SP, Sundd P. 2018. Dysregulated bile 
transporters and impaired tight junctions during chronic liver injury in mice. Gastroenterology  
 
Russell JO, Ko S, Saggi HS, Singh S, Poddar M, Shin D, Monga SP. 2018. Bromodomain and 
Extraterminal (BET) Proteins Regulate Hepatocyte Proliferation in Hepatocyte-Driven Liver 
Regeneration. Am J Pathol 188: 1389-405 
 
 120 
Russell JO, Monga SP. 2018. Wnt/β-Catenin Signaling in Liver Development, Homeostasis, and 
Pathobiology. Annu Rev Pathol 13: 351-78 
 
Pradhan-Sundd T, Zhou L, Vats R, Jiang A, Molina L, Singh S, Poddar M, Russell J, Stolz DB, 
Oertel M, Apte U, Watkins S, Ranganathan S, Nejak-Bowen KN, Sundd P, Monga SP. 2018. Dual 
catenin loss in murine liver causes tight junctional deregulation and progressive intrahepatic 
cholestasis. Hepatology 67: 2320-37 
 
Ko S, Choi TY, Russell JO, So J, Monga SPS, Shin D. 2016. Bromodomain and extraterminal 
(BET) proteins regulate biliary-driven liver regeneration. J Hepatol 64: 316-25 
 
Cranz-Mileva S, MacTaggart B, Russell J, Hitchcock-DeGregori SE. 2015. Evolutionarily 
conserved sites in yeast tropomyosin function in cell polarity, transport and contractile ring 
formation. Biol Open 4: 1040-51 
 
Delgado E, Okabe H, Preziosi M, Russell JO, Alvarado TF, Oertel M, Nejak-Bowen KN, Zhang 
Y, Monga SP. 2015. Complete response of Ctnnb1-mutated tumours to β-catenin suppression by 
locked nucleic acid antisense in a mouse hepatocarcinogenesis model. J Hepatol 62: 380-7 
 
Cranz-Mileva S, Pamula MC, Barua B, Desai B, Hong YH, Russell J, Trent R, Wang J, Walworth 
NC, Hitchcock-DeGregori SE. 2013. A molecular evolution approach to study the roles of 
tropomyosin in fission yeast. PLoS One 8: e76726 
 
A.2 Funding 
• T32 training grant: Cellular Approaches to Tissue Engineering and Regeneration (NIH 
T32EB0010216), 2015-2017 
 
• F31 fellowship: Elucidating the role of β-catenin signaling in liver progenitor cell-mediated 
liver regeneration (NIH/NIDDK 1F31DK115017-01), 2017-2019 
 
 121 
Bibliography 
1. Russell JO, Monga SS. 2017. Wnt/β-Catenin Signaling in Liver Development, 
Homeostasis, and Pathobiology. Annu Rev Pathol  
2. Dhalluin C, Carlson JE, Zeng L, He C, Aggarwal AK, Zhou MM. 1999. Structure and 
ligand of a histone acetyltransferase bromodomain. Nature 399: 491-6 
3. Shi J, Vakoc CR. 2014. The mechanisms behind the therapeutic activity of BET 
bromodomain inhibition. Mol Cell 54: 728-36 
4. Jiang YW, Veschambre P, Erdjument-Bromage H, Tempst P, Conaway JW, Conaway RC, 
Kornberg RD. 1998. Mammalian mediator of transcriptional regulation and its possible 
role as an end-point of signal transduction pathways. Proc Natl Acad Sci U S A 95: 8538-
43 
5. Wu SY, Chiang CM. 2007. The double bromodomain-containing chromatin adaptor Brd4 
and transcriptional regulation. J Biol Chem 282: 13141-5 
6. Zhou Q, Li T, Price DH. 2012. RNA polymerase II elongation control. Annu Rev Biochem 
81: 119-43 
7. Adelman K, Lis JT. 2012. Promoter-proximal pausing of RNA polymerase II: emerging 
roles in metazoans. Nat Rev Genet 13: 720-31 
8. Lovén J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, Bradner JE, Lee TI, Young 
RA. 2013. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 
153: 320-34 
9. Anand P, Brown JD, Lin CY, Qi J, Zhang R, Artero PC, Alaiti MA, Bullard J, Alazem K, 
Margulies KB, Cappola TP, Lemieux M, Plutzky J, Bradner JE, Haldar SM. 2013. BET 
bromodomains mediate transcriptional pause release in heart failure. Cell 154: 569-82 
10. Zhang W, Prakash C, Sum C, Gong Y, Li Y, Kwok JJ, Thiessen N, Pettersson S, Jones SJ, 
Knapp S, Yang H, Chin KC. 2012. Bromodomain-containing protein 4 (BRD4) regulates 
RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem 287: 
43137-55 
11. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, 
Hickman TT, Felletar I, Philpott M, Munro S, McKeown MR, Wang Y, Christie AL, West 
N, Cameron MJ, Schwartz B, Heightman TD, La Thangue N, French CA, Wiest O, Kung 
AL, Knapp S, Bradner JE. 2010. Selective inhibition of BET bromodomains. Nature 468: 
1067-73 
 122 
12. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, 
Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, 
Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung 
AL, Bradner JE, Mitsiades CS. 2011. BET bromodomain inhibition as a therapeutic 
strategy to target c-Myc. Cell 146: 904-17 
13. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, Robson 
SC, Chung CW, Hopf C, Savitski MM, Huthmacher C, Gudgin E, Lugo D, Beinke S, 
Chapman TD, Roberts EJ, Soden PE, Auger KR, Mirguet O, Doehner K, Delwel R, Burnett 
AK, Jeffrey P, Drewes G, Lee K, Huntly BJ, Kouzarides T. 2011. Inhibition of BET 
recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478: 
529-33 
14. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, 
Wunderlich M, Taylor MJ, Johns C, Chicas A, Mulloy JC, Kogan SC, Brown P, Valent P, 
Bradner JE, Lowe SW, Vakoc CR. 2011. RNAi screen identifies Brd4 as a therapeutic 
target in acute myeloid leukaemia. Nature 478: 524-8 
15. Wang YH, Sui XM, Sui YN, Zhu QW, Yan K, Wang LS, Wang F, Zhou JH. 2015. BRD4 
induces cell migration and invasion in HCC cells through MMP-2 and MMP-9 activation 
mediated by the Sonic hedgehog signaling pathway. Oncol Lett 10: 2227-32 
16. Ding N, Hah N, Yu RT, Sherman MH, Benner C, Leblanc M, He M, Liddle C, Downes M, 
Evans RM. 2015. BRD4 is a novel therapeutic target for liver fibrosis. Proc Natl Acad Sci 
U S A 112: 15713-8 
17. Ko S, Choi TY, Russell JO, So J, Monga SPS, Shin D. 2016. Bromodomain and 
extraterminal (BET) proteins regulate biliary-driven liver regeneration. J Hepatol 64: 316-
25 
18. Kimelman D, Xu W. 2006. beta-catenin destruction complex: insights and questions from 
a structural perspective. Oncogene 25: 7482-91 
19. Behrens J, Jerchow BA, Würtele M, Grimm J, Asbrand C, Wirtz R, Kühl M, Wedlich D, 
Birchmeier W. 1998. Functional interaction of an axin homolog, conductin, with beta-
catenin, APC, and GSK3beta. Science 280: 596-9 
20. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, Zhang Z, Lin X, He X. 2002. Control 
of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108: 837-
47 
21. Amit S, Hatzubai A, Birman Y, Andersen JS, Ben-Shushan E, Mann M, Ben-Neriah Y, 
Alkalay I. 2002. Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular 
switch for the Wnt pathway. Genes Dev 16: 1066-76 
22. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. 1997. beta-catenin is a target for the 
ubiquitin-proteasome pathway. EMBO J 16: 3797-804 
 123 
23. Hart M, Concordet JP, Lassot I, Albert I, del los Santos R, Durand H, Perret C, Rubinfeld 
B, Margottin F, Benarous R, Polakis P. 1999. The F-box protein beta-TrCP associates with 
phosphorylated beta-catenin and regulates its activity in the cell. Curr Biol 9: 207-10 
24. Barrott JJ, Cash GM, Smith AP, Barrow JR, Murtaugh LC. 2011. Deletion of mouse Porcn 
blocks Wnt ligand secretion and reveals an ectodermal etiology of human focal dermal 
hypoplasia/Goltz syndrome. Proc Natl Acad Sci U S A 108: 12752-7 
25. Zhai L, Chaturvedi D, Cumberledge S. 2004. Drosophila wnt-1 undergoes a hydrophobic 
modification and is targeted to lipid rafts, a process that requires porcupine. J Biol Chem 
279: 33220-7 
26. Bänziger C, Soldini D, Schütt C, Zipperlen P, Hausmann G, Basler K. 2006. Wntless, a 
conserved membrane protein dedicated to the secretion of Wnt proteins from signaling 
cells. Cell 125: 509-22 
27. Bartscherer K, Pelte N, Ingelfinger D, Boutros M. 2006. Secretion of Wnt ligands requires 
Evi, a conserved transmembrane protein. Cell 125: 523-33 
28. Bhanot P, Brink M, Samos CH, Hsieh JC, Wang Y, Macke JP, Andrew D, Nathans J, Nusse 
R. 1996. A new member of the frizzled family from Drosophila functions as a Wingless 
receptor. Nature 382: 225-30 
29. Wehrli M, Dougan ST, Caldwell K, O'Keefe L, Schwartz S, Vaizel-Ohayon D, Schejter E, 
Tomlinson A, DiNardo S. 2000. arrow encodes an LDL-receptor-related protein essential 
for Wingless signalling. Nature 407: 527-30 
30. Pinson KI, Brennan J, Monkley S, Avery BJ, Skarnes WC. 2000. An LDL-receptor-related 
protein mediates Wnt signalling in mice. Nature 407: 535-8 
31. Tamai K, Semenov M, Kato Y, Spokony R, Liu C, Katsuyama Y, Hess F, Saint-Jeannet 
JP, He X. 2000. LDL-receptor-related proteins in Wnt signal transduction. Nature 407: 
530-5 
32. Tamai K, Zeng X, Liu C, Zhang X, Harada Y, Chang Z, He X. 2004. A mechanism for 
Wnt coreceptor activation. Mol Cell 13: 149-56 
33. MacDonald BT, Tamai K, He X. 2009. Wnt/beta-catenin signaling: components, 
mechanisms, and diseases. Dev Cell 17: 9-26 
34. Carmon KS, Gong X, Lin Q, Thomas A, Liu Q. 2011. R-spondins function as ligands of 
the orphan receptors LGR4 and LGR5 to regulate Wnt/beta-catenin signaling. Proc Natl 
Acad Sci U S A 108: 11452-7 
35. de Lau W, Barker N, Low TY, Koo BK, Li VS, Teunissen H, Kujala P, Haegebarth A, 
Peters PJ, van de Wetering M, Stange DE, van Es JE, Guardavaccaro D, Schasfoort RB, 
Mohri Y, Nishimori K, Mohammed S, Heck AJ, Clevers H. 2011. Lgr5 homologues 
associate with Wnt receptors and mediate R-spondin signalling. Nature 476: 293-7 
 124 
36. Hao HX, Xie Y, Zhang Y, Charlat O, Oster E, Avello M, Lei H, Mickanin C, Liu D, 
Ruffner H, Mao X, Ma Q, Zamponi R, Bouwmeester T, Finan PM, Kirschner MW, Porter 
JA, Serluca FC, Cong F. 2012. ZNRF3 promotes Wnt receptor turnover in an R-spondin-
sensitive manner. Nature 485: 195-200 
37. Koo BK, Spit M, Jordens I, Low TY, Stange DE, van de Wetering M, van Es JH, 
Mohammed S, Heck AJ, Maurice MM, Clevers H. 2012. Tumour suppressor RNF43 is a 
stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature 488: 665-9 
38. Cadigan KM, Nusse R. 1997. Wnt signaling: a common theme in animal development. 
Genes Dev 11: 3286-305 
39. Vincan E, Barker N. 2008. The upstream components of the Wnt signalling pathway in the 
dynamic EMT and MET associated with colorectal cancer progression. Clin Exp 
Metastasis 25: 657-63 
40. Oishi I, Suzuki H, Onishi N, Takada R, Kani S, Ohkawara B, Koshida I, Suzuki K, Yamada 
G, Schwabe GC, Mundlos S, Shibuya H, Takada S, Minami Y. 2003. The receptor tyrosine 
kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway. Genes Cells 8: 
645-54 
41. Sastre-Perona A, Santisteban P. 2012. Role of the wnt pathway in thyroid cancer. Front 
Endocrinol (Lausanne) 3: 31 
42. Pez F, Lopez A, Kim M, Wands JR, Caron de Fromentel C, Merle P. 2013. Wnt signaling 
and hepatocarcinogenesis: molecular targets for the development of innovative anticancer 
drugs. J Hepatol 59: 1107-17 
43. Nishita M, Enomoto M, Yamagata K, Minami Y. 2010. Cell/tissue-tropic functions of 
Wnt5a signaling in normal and cancer cells. Trends Cell Biol 20: 346-54 
44. Topol L, Jiang X, Choi H, Garrett-Beal L, Carolan PJ, Yang Y. 2003. Wnt-5a inhibits the 
canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradation. J Cell 
Biol 162: 899-908 
45. Acebron SP, Karaulanov E, Berger BS, Huang YL, Niehrs C. 2014. Mitotic wnt signaling 
promotes protein stabilization and regulates cell size. Mol Cell 54: 663-74 
46. Fuentealba LC, Eivers E, Ikeda A, Hurtado C, Kuroda H, Pera EM, De Robertis EM. 2007. 
Integrating patterning signals: Wnt/GSK3 regulates the duration of the BMP/Smad1 signal. 
Cell 131: 980-93 
47. Kim NG, Xu C, Gumbiner BM. 2009. Identification of targets of the Wnt pathway 
destruction complex in addition to beta-catenin. Proc Natl Acad Sci U S A 106: 5165-70 
48. Koch S, Acebron SP, Herbst J, Hatiboglu G, Niehrs C. 2015. Post-transcriptional Wnt 
Signaling Governs Epididymal Sperm Maturation. Cell 163: 1225-36 
 125 
49. Xu C, Kim NG, Gumbiner BM. 2009. Regulation of protein stability by GSK3 mediated 
phosphorylation. Cell Cycle 8: 4032-9 
50. Kim H, Vick P, Hedtke J, Ploper D, De Robertis EM. 2015. Wnt Signaling Translocates 
Lys48-Linked Polyubiquitinated Proteins to the Lysosomal Pathway. Cell Rep 11: 1151-9 
51. Taelman VF, Dobrowolski R, Plouhinec JL, Fuentealba LC, Vorwald PP, Gumper I, 
Sabatini DD, De Robertis EM. 2010. Wnt signaling requires sequestration of glycogen 
synthase kinase 3 inside multivesicular endosomes. Cell 143: 1136-48 
52. Vinyoles M, Del Valle-Perez B, Curto J, Vinas-Castells R, Alba-Castellon L, Garcia de 
Herreros A, Dunach M. 2014. Multivesicular GSK3 sequestration upon Wnt signaling is 
controlled by p120-catenin/cadherin interaction with LRP5/6. Mol Cell 53: 444-57 
53. Acebron SP, Niehrs C. 2016. beta-Catenin-Independent Roles of Wnt/LRP6 Signaling. 
Trends Cell Biol 26: 956-67 
54. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, 
Stankunas K, Wang CY, He X, MacDougald OA, You M, Williams BO, Guan KL. 2006. 
TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and 
GSK3 to regulate cell growth. Cell 126: 955-68 
55. Wheelock MJ, Johnson KR. 2003. Cadherins as modulators of cellular phenotype. Annu 
Rev Cell Dev Biol 19: 207-35 
56. D'Souza-Schorey C. 2005. Disassembling adherens junctions: breaking up is hard to do. 
Trends Cell Biol 15: 19-26 
57. Hinck L, Näthke IS, Papkoff J, Nelson WJ. 1994. Dynamics of cadherin/catenin complex 
formation: novel protein interactions and pathways of complex assembly. J Cell Biol 125: 
1327-40 
58. Chen YT, Stewart DB, Nelson WJ. 1999. Coupling assembly of the E-cadherin/beta-
catenin complex to efficient endoplasmic reticulum exit and basal-lateral membrane 
targeting of E-cadherin in polarized MDCK cells. J Cell Biol 144: 687-99 
59. Huber AH, Stewart DB, Laurents DV, Nelson WJ, Weis WI. 2001. The cadherin 
cytoplasmic domain is unstructured in the absence of beta-catenin. A possible mechanism 
for regulating cadherin turnover. J Biol Chem 276: 12301-9 
60. Lilien J, Balsamo J. 2005. The regulation of cadherin-mediated adhesion by tyrosine 
phosphorylation/dephosphorylation of beta-catenin. Curr Opin Cell Biol 17: 459-65 
61. Monga SP, Mars WM, Pediaditakis P, Bell A, Mulé K, Bowen WC, Wang X, Zarnegar R, 
Michalopoulos GK. 2002. Hepatocyte growth factor induces Wnt-independent nuclear 
translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes. Cancer 
Res 62: 2064-71 
 126 
62. Zeng G, Apte U, Micsenyi A, Bell A, Monga SP. 2006. Tyrosine residues 654 and 670 in 
beta-catenin are crucial in regulation of Met-beta-catenin interactions. Exp Cell Res 312: 
3620-30 
63. Kojima T, Yamamoto T, Murata M, Chiba H, Kokai Y, Sawada N. 2003. Regulation of the 
blood-biliary barrier: interaction between gap and tight junctions in hepatocytes. Med 
Electron Microsc 36: 157-64 
64. Rajasekaran AK, Hojo M, Huima T, Rodriguez-Boulan E. 1996. Catenins and zonula 
occludens-1 form a complex during early stages in the assembly of tight junctions. J Cell 
Biol 132: 451-63 
65. Yeh TH, Krauland L, Singh V, Zou B, Devaraj P, Stolz DB, Franks J, Monga SP, Sasatomi 
E, Behari J. 2010. Liver-specific β-catenin knockout mice have bile canalicular 
abnormalities, bile secretory defect, and intrahepatic cholestasis. Hepatology 52: 1410-9 
66. Son S, Kojima T, Decaens C, Yamaguchi H, Ito T, Imamura M, Murata M, Tanaka S, 
Chiba H, Hirata K, Sawada N. 2009. Knockdown of tight junction protein claudin-2 
prevents bile canalicular formation in WIF-B9 cells. Histochem Cell Biol 131: 411-24 
67. Gordillo M, Evans T, Gouon-Evans V. 2015. Orchestrating liver development. 
Development 142: 2094-108 
68. Yang J, Mowry LE, Nejak-Bowen KN, Okabe H, Diegel CR, Lang RA, Williams BO, 
Monga SP. 2014. β-catenin signaling in murine liver zonation and regeneration: a Wnt-
Wnt situation! Hepatology 60: 964-76 
69. Behari J. 2010. The Wnt/β-catenin signaling pathway in liver biology and disease. Expert 
Rev Gastroenterol Hepatol 4: 745-56 
70. Lemaigre FP. 2009. Mechanisms of liver development: concepts for understanding liver 
disorders and design of novel therapies. Gastroenterology 137: 62-79 
71. Jungermann K, Katz N. 1989. Functional specialization of different hepatocyte 
populations. Physiol Rev 69: 708-64 
72. Jho EH, Zhang T, Domon C, Joo CK, Freund JN, Costantini F. 2002. Wnt/beta-catenin/Tcf 
signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. 
Mol Cell Biol 22: 1172-83 
73. Sekine S, Lan BY, Bedolli M, Feng S, Hebrok M. 2006. Liver-specific loss of beta-catenin 
blocks glutamine synthesis pathway activity and cytochrome p450 expression in mice. 
Hepatology 43: 817-25 
74. Tan X, Behari J, Cieply B, Michalopoulos GK, Monga SP. 2006. Conditional deletion of 
beta-catenin reveals its role in liver growth and regeneration. Gastroenterology 131: 1561-
72 
 127 
75. Planas-Paz L, Orsini V, Boulter L, Calabrese D, Pikiolek M, Nigsch F, Xie Y, Roma G, 
Donovan A, Marti P, Beckmann N, Dill MT, Carbone W, Bergling S, Isken A, Mueller M, 
Kinzel B, Yang Y, Mao X, Nicholson TB, Zamponi R, Capodieci P, Valdez R, Rivera D, 
Loew A, Ukomadu C, Terracciano LM, Bouwmeester T, Cong F, Heim MH, Forbes SJ, 
Ruffner H, Tchorz JS. 2016. The RSPO-LGR4/5-ZNRF3/RNF43 module controls liver 
zonation and size. Nat Cell Biol 18: 467-79 
76. Gougelet A, Torre C, Veber P, Sartor C, Bachelot L, Denechaud PD, Godard C, Moldes 
M, Burnol AF, Dubuquoy C, Terris B, Guillonneau F, Ye T, Schwarz M, Braeuning A, 
Perret C, Colnot S. 2014. T-cell factor 4 and β-catenin chromatin occupancies pattern zonal 
liver metabolism in mice. Hepatology 59: 2344-57 
77. Benhamouche S, Decaens T, Godard C, Chambrey R, Rickman DS, Moinard C, Vasseur-
Cognet M, Kuo CJ, Kahn A, Perret C, Colnot S. 2006. Apc tumor suppressor gene is the 
"zonation-keeper" of mouse liver. Dev Cell 10: 759-70 
78. Stanulović VS, Kyrmizi I, Kruithof-de Julio M, Hoogenkamp M, Vermeulen JL, Ruijter 
JM, Talianidis I, Hakvoort TB, Lamers WH. 2007. Hepatic HNF4alpha deficiency induces 
periportal expression of glutamine synthetase and other pericentral enzymes. Hepatology 
45: 433-44 
79. Fitamant J, Kottakis F, Benhamouche S, Tian HS, Chuvin N, Parachoniak CA, Nagle JM, 
Perera RM, Lapouge M, Deshpande V, Zhu AX, Lai A, Min B, Hoshida Y, Avruch J, Sia 
D, Campreciós G, McClatchey AI, Llovet JM, Morrissey D, Raj L, Bardeesy N. 2015. YAP 
Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor 
Regression. Cell Rep  
80. Thorgeirsson SS. 1996. Hepatic stem cells in liver regeneration. FASEB J 10: 1249-56 
81. Michalopoulos GK, DeFrances MC. 1997. Liver regeneration. Science 276: 60-6 
82. Monga SP, Pediaditakis P, Mule K, Stolz DB, Michalopoulos GK. 2001. Changes in 
WNT/beta-catenin pathway during regulated growth in rat liver regeneration. Hepatology 
33: 1098-109 
83. Nelsen CJ, Rickheim DG, Timchenko NA, Stanley MW, Albrecht JH. 2001. Transient 
expression of cyclin D1 is sufficient to promote hepatocyte replication and liver growth in 
vivo. Cancer Res 61: 8564-8 
84. Yang J, Cusimano A, Monga JK, Preziosi ME, Pullara F, Calero G, Lang R, Yamaguchi 
TP, Nejak-Bowen KN, Monga SP. 2015. WNT5A inhibits hepatocyte proliferation and 
concludes β-catenin signaling in liver regeneration. Am J Pathol 185: 2194-205 
85. Hinson JA, Roberts DW, James LP. 2010. Mechanisms of acetaminophen-induced liver 
necrosis. Handb Exp Pharmacol: 369-405 
 128 
86. Zaher H, Buters JT, Ward JM, Bruno MK, Lucas AM, Stern ST, Cohen SD, Gonzalez FJ. 
1998. Protection against acetaminophen toxicity in CYP1A2 and CYP2E1 double-null 
mice. Toxicol Appl Pharmacol 152: 193-9 
87. Apte U, Singh S, Zeng G, Cieply B, Virji MA, Wu T, Monga SP. 2009. Beta-catenin 
activation promotes liver regeneration after acetaminophen-induced injury. Am J Pathol 
175: 1056-65 
88. Kaidi A, Williams AC, Paraskeva C. 2007. Interaction between beta-catenin and HIF-1 
promotes cellular adaptation to hypoxia. Nat Cell Biol 9: 210-7 
89. Lehwald N, Tao GZ, Jang KY, Sorkin M, Knoefel WT, Sylvester KG. 2011. Wnt-β-catenin 
signaling protects against hepatic ischemia and reperfusion injury in mice. 
Gastroenterology 141: 707-18, 18.e1-5 
90. Mani A, Radhakrishnan J, Wang H, Mani MA, Nelson-Williams C, Carew KS, Mane S, 
Najmabadi H, Wu D, Lifton RP. 2007. LRP6 mutation in a family with early coronary 
disease and metabolic risk factors. Science 315: 1278-82 
91. Go GW, Srivastava R, Hernandez-Ono A, Gang G, Smith SB, Booth CJ, Ginsberg HN, 
Mani A. 2014. The combined hyperlipidemia caused by impaired Wnt-LRP6 signaling is 
reversed by Wnt3a rescue. Cell Metab 19: 209-20 
92. Lehwald N, Tao GZ, Jang KY, Papandreou I, Liu B, Pysz MA, Willmann JK, Knoefel WT, 
Denko NC, Sylvester KG. 2012. β-Catenin regulates hepatic mitochondrial function and 
energy balance in mice. Gastroenterology 143: 754-64 
93. Essers MA, de Vries-Smits LM, Barker N, Polderman PE, Burgering BM, Korswagen HC. 
2005. Functional interaction between beta-catenin and FOXO in oxidative stress signaling. 
Science 308: 1181-4 
94. Liu H, Fergusson MM, Wu JJ, Rovira II, Liu J, Gavrilova O, Lu T, Bao J, Han D, Sack 
MN, Finkel T. 2011. Wnt signaling regulates hepatic metabolism. Sci Signal 4: ra6 
95. Russell DW. 2003. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev 
Biochem 72: 137-74 
96. Gebhardt R. 1992. Metabolic zonation of the liver: regulation and implications for liver 
function. Pharmacol Ther 53: 275-354 
97. Behari J, Yeh TH, Krauland L, Otruba W, Cieply B, Hauth B, Apte U, Wu T, Evans R, 
Monga SP. 2010. Liver-specific beta-catenin knockout mice exhibit defective bile acid and 
cholesterol homeostasis and increased susceptibility to diet-induced steatohepatitis. Am J 
Pathol 176: 744-53 
98. Stoick-Cooper CL, Moon RT, Weidinger G. 2007. Advances in signaling in vertebrate 
regeneration as a prelude to regenerative medicine. Genes Dev 21: 1292-315 
 129 
99. Cordero-Espinoza L, Huch M. 2018. The balancing act of the liver: tissue regeneration 
versus fibrosis. J Clin Invest 128: 85-96 
100. Vivien CJ, Hudson JE, Porrello ER. 2016. Evolution, comparative biology and ontogeny 
of vertebrate heart regeneration. NPJ Regen Med 1: 16012 
101. Ferretti P, Zhang F, O'Neill P. 2003. Changes in spinal cord regenerative ability through 
phylogenesis and development: lessons to be learnt. Dev Dyn 226: 245-56 
102. Wynn TA. 2008. Cellular and molecular mechanisms of fibrosis. J Pathol 214: 199-210 
103. Forbes SJ, Newsome PN. 2016. Liver regeneration - mechanisms and models to clinical 
application. Nat Rev Gastroenterol Hepatol 13: 473-85 
104. Michalopoulos GK, Khan Z. 2015. Liver Stem Cells: Experimental Findings and 
Implications for Human Liver Disease. Gastroenterology 149: 876-82 
105. Fausto N, Campbell JS. 2003. The role of hepatocytes and oval cells in liver regeneration 
and repopulation. Mech Dev 120: 117-30 
106. Tabibian JH, Masyuk AI, Masyuk TV, O'Hara SP, LaRusso NF. 2013. Physiology of 
cholangiocytes. Compr Physiol 3: 541-65 
107. Roskams TA, Theise ND, Balabaud C, Bhagat G, Bhathal PS, Bioulac-Sage P, Brunt EM, 
Crawford JM, Crosby HA, Desmet V, Finegold MJ, Geller SA, Gouw AS, Hytiroglou P, 
Knisely AS, Kojiro M, Lefkowitch JH, Nakanuma Y, Olynyk JK, Park YN, Portmann B, 
Saxena R, Scheuer PJ, Strain AJ, Thung SN, Wanless IR, West AB. 2004. Nomenclature 
of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human 
livers. Hepatology 39: 1739-45 
108. Sato K, Marzioni M, Meng F, Francis H, Glaser S, Alpini G. 2019. Ductular Reaction in 
Liver Diseases: Pathological Mechanisms and Translational Significances. Hepatology 69: 
420-30 
109. Kim WR, Lake JR, Smith JM, Schladt DP, Skeans MA, Harper AM, Wainright JL, Snyder 
JJ, Israni AK, Kasiske BL. 2018. OPTN/SRTR 2016 Annual Data Report: Liver. Am J 
Transplant 18 Suppl 1: 172-253 
110. Katoonizadeh A, Nevens F, Verslype C, Pirenne J, Roskams T. 2006. Liver regeneration 
in acute severe liver impairment: a clinicopathological correlation study. Liver Int 26: 
1225-33 
111. Weng HL, Cai X, Yuan X, Liebe R, Dooley S, Li H, Wang TL. 2015. Two sides of one 
coin: massive hepatic necrosis and progenitor cell-mediated regeneration in acute liver 
failure. Front Physiol 6: 178 
112. Stueck AE, Wanless IR. 2015. Hepatocyte buds derived from progenitor cells repopulate 
regions of parenchymal extinction in human cirrhosis. Hepatology 61: 1696-707 
 130 
113. Dechêne A, Sowa JP, Gieseler RK, Jochum C, Bechmann LP, El Fouly A, Schlattjan M, 
Saner F, Baba HA, Paul A, Dries V, Odenthal M, Gerken G, Friedman SL, Canbay A. 
2010. Acute liver failure is associated with elevated liver stiffness and hepatic stellate cell 
activation. Hepatology 52: 1008-16 
114. Williams MJ, Clouston AD, Forbes SJ. 2014. Links between hepatic fibrosis, ductular 
reaction, and progenitor cell expansion. Gastroenterology 146: 349-56 
115. Lowes KN, Brennan BA, Yeoh GC, Olynyk JK. 1999. Oval cell numbers in human chronic 
liver diseases are directly related to disease severity. Am J Pathol 154: 537-41 
116. Gouw AS, Clouston AD, Theise ND. 2011. Ductular reactions in human liver: diversity at 
the interface. Hepatology 54: 1853-63 
117. Machado MV, Michelotti GA, Pereira TA, Xie G, Premont R, Cortez-Pinto H, Diehl AM. 
2015. Accumulation of duct cells with activated YAP parallels fibrosis progression in non-
alcoholic fatty liver disease. J Hepatol 63: 962-70 
118. Guldiken N, Kobazi Ensari G, Lahiri P, Couchy G, Preisinger C, Liedtke C, Zimmermann 
HW, Ziol M, Boor P, Zucman-Rossi J, Trautwein C, Strnad P. 2016. Keratin 23 is a stress-
inducible marker of mouse and human ductular reaction in liver disease. J Hepatol 65: 552-
9 
119. Helal TESA, Ehsan NA, Radwan NA, Abdelsameea E. 2018. Relationship between hepatic 
progenitor cells and stellate cells in chronic hepatitis C genotype 4. APMIS 126: 14-20 
120. El-Araby HA, Ehsan NA, Konsowa HA, Abd-Elaati BM, Sira AM. 2015. Hepatic 
progenitor cells in children with chronic hepatitis C: correlation with histopathology, 
viremia, and treatment response. Eur J Gastroenterol Hepatol 27: 561-9 
121. Richardson MM, Jonsson JR, Powell EE, Brunt EM, Neuschwander-Tetri BA, Bhathal PS, 
Dixon JB, Weltman MD, Tilg H, Moschen AR, Purdie DM, Demetris AJ, Clouston AD. 
2007. Progressive fibrosis in nonalcoholic steatohepatitis: association with altered 
regeneration and a ductular reaction. Gastroenterology 133: 80-90 
122. Gadd VL, Skoien R, Powell EE, Fagan KJ, Winterford C, Horsfall L, Irvine K, Clouston 
AD. 2014. The portal inflammatory infiltrate and ductular reaction in human nonalcoholic 
fatty liver disease. Hepatology 59: 1393-405 
123. Zhao L, Westerhoff M, Pai RK, Choi WT, Gao ZH, Hart J. 2018. Centrilobular ductular 
reaction correlates with fibrosis stage and fibrosis progression in non-alcoholic 
steatohepatitis. Mod Pathol 31: 150-9 
124. Carpino G, Nobili V, Renzi A, De Stefanis C, Stronati L, Franchitto A, Alisi A, Onori P, 
De Vito R, Alpini G, Gaudio E. 2016. Macrophage Activation in Pediatric Nonalcoholic 
Fatty Liver Disease (NAFLD) Correlates with Hepatic Progenitor Cell Response via Wnt3a 
Pathway. PLoS One 11: e0157246 
 131 
125. Carpino G, Cardinale V, Folseraas T, Overi D, Floreani A, Franchitto A, Onori P, 
Cazzagon N, Berloco PB, Karlsen TH, Alvaro D, Gaudio E. 2018. Hepatic Stem/Progenitor 
Cell Activation Differs between Primary Sclerosing and Primary Biliary Cholangitis. Am 
J Pathol 188: 627-39 
126. Govaere O, Cockell S, Van Haele M, Wouters J, Van Delm W, Van den Eynde K, Bianchi 
A, van Eijsden R, Van Steenbergen W, Monbaliu D, Nevens F, Roskams T. 2018. High-
throughput sequencing identifies aetiology-dependent differences in ductular reaction in 
human chronic liver disease. J Pathol  
127. Svegliati-Baroni G, De Minicis S, Marzioni M. 2008. Hepatic fibrogenesis in response to 
chronic liver injury: novel insights on the role of cell-to-cell interaction and transition. 
Liver Int 28: 1052-64 
128. Aguilar-Bravo B, Rodrigo-Torres D, Ariño S, Coll M, Pose E, Blaya D, Graupera I, Perea 
L, Vallverdú J, Rubio-Tomás T, Dubuquoy L, Armengol C, Lo Nigro A, Stärkel P, 
Mathurin P, Bataller R, Caballería J, Lozano JJ, Ginès P, Sancho-Bru P. 2018. Ductular 
reaction cells display an inflammatory profile and recruit neutrophils in alcoholic hepatitis. 
Hepatology  
129. Elßner C, Goeppert B, Longerich T, Scherr AL, Stindt J, Nanduri LK, Rupp C, Kather JN, 
Schmitt N, Kautz N, Breuhahn K, Ismail L, Heide D, Hetzer J, García-Beccaria M, 
Hövelmeyer N, Waisman A, Urbanik T, Mueller S, Gdynia G, Banales JM, Roessler S, 
Schirmacher P, Jäger D, Schölch S, Keitel V, Heikenwalder M, Schulze-Bergkamen H, 
Köhler BC. 2018. Nuclear Translocation of RELB is Increased in Diseased Human Liver 
and Promotes Ductular Reaction and Biliary Fibrosis in Mice. Gastroenterology  
130. Yu LX, Ling Y, Wang HY. 2018. Role of nonresolving inflammation in hepatocellular 
carcinoma development and progression. NPJ Precis Oncol 2: 6 
131. Sia D, Villanueva A, Friedman SL, Llovet JM. 2017. Liver Cancer Cell of Origin, 
Molecular Class, and Effects on Patient Prognosis. Gastroenterology 152: 745-61 
132. Roskams T. 2006. Liver stem cells and their implication in hepatocellular and 
cholangiocarcinoma. Oncogene 25: 3818-22 
133. Ye F, Jing YY, Guo SW, Yu GF, Fan QM, Qu FF, Gao L, Yang Y, Wu D, Meng Y, Yu 
FH, Wei LX. 2014. Proliferative ductular reactions correlate with hepatic progenitor cell 
and predict recurrence in HCC patients after curative resection. Cell Biosci 4: 50 
134. Xu M, Xie F, Qian G, Jing Y, Zhang S, Gao L, Zheng T, Wu M, Yang J, Wei L. 2014. 
Peritumoral ductular reaction: a poor postoperative prognostic factor for hepatocellular 
carcinoma. BMC Cancer 14: 65 
135. Cai X, Zhai J, Kaplan DE, Zhang Y, Zhou L, Chen X, Qian G, Zhao Q, Li Y, Gao L, Cong 
W, Zhu M, Yan Z, Shi L, Wu D, Wei L, Shen F, Wu M. 2012. Background progenitor 
activation is associated with recurrence after hepatectomy of combined hepatocellular-
cholangiocarcinoma. Hepatology 56: 1804-16 
 132 
136. Gérard C, Tys J, Lemaigre FP. 2017. Gene regulatory networks in differentiation and direct 
reprogramming of hepatic cells. Semin Cell Dev Biol 66: 43-50 
137. Suzuki A, Zheng YW, Kaneko S, Onodera M, Fukao K, Nakauchi H, Taniguchi H. 2002. 
Clonal identification and characterization of self-renewing pluripotent stem cells in the 
developing liver. J Cell Biol 156: 173-84 
138. Tanimizu N, Nishikawa M, Saito H, Tsujimura T, Miyajima A. 2003. Isolation of 
hepatoblasts based on the expression of Dlk/Pref-1. J Cell Sci 116: 1775-86 
139. Nava S, Westgren M, Jaksch M, Tibell A, Broomé U, Ericzon BG, Sumitran-Holgersson 
S. 2005. Characterization of cells in the developing human liver. Differentiation 73: 249-
60 
140. Schmelzer E, Zhang L, Bruce A, Wauthier E, Ludlow J, Yao HL, Moss N, Melhem A, 
McClelland R, Turner W, Kulik M, Sherwood S, Tallheden T, Cheng N, Furth ME, Reid 
LM. 2007. Human hepatic stem cells from fetal and postnatal donors. J Exp Med 204: 
1973-87 
141. Dan YY, Riehle KJ, Lazaro C, Teoh N, Haque J, Campbell JS, Fausto N. 2006. Isolation 
of multipotent progenitor cells from human fetal liver capable of differentiating into liver 
and mesenchymal lineages. Proc Natl Acad Sci U S A 103: 9912-7 
142. Oertel M, Menthena A, Dabeva MD, Shafritz DA. 2006. Cell competition leads to a high 
level of normal liver reconstitution by transplanted fetal liver stem/progenitor cells. 
Gastroenterology 130: 507-20; quiz 90 
143. Turner R, Lozoya O, Wang Y, Cardinale V, Gaudio E, Alpini G, Mendel G, Wauthier E, 
Barbier C, Alvaro D, Reid LM. 2011. Human hepatic stem cell and maturational liver 
lineage biology. Hepatology 53: 1035-45 
144. Cardinale V, Wang Y, Carpino G, Cui CB, Gatto M, Rossi M, Berloco PB, Cantafora A, 
Wauthier E, Furth ME, Inverardi L, Dominguez-Bendala J, Ricordi C, Gerber D, Gaudio 
E, Alvaro D, Reid L. 2011. Multipotent stem/progenitor cells in human biliary tree give 
rise to hepatocytes, cholangiocytes, and pancreatic islets. Hepatology 54: 2159-72 
145. Isse K, Lesniak A, Grama K, Maier J, Specht S, Castillo-Rama M, Lunz J, Roysam B, 
Michalopoulos G, Demetris AJ. 2013. Preexisting epithelial diversity in normal human 
livers: a tissue-tethered cytometric analysis in portal/periportal epithelial cells. Hepatology 
57: 1632-43 
146. Kamiya A, Kakinuma S, Yamazaki Y, Nakauchi H. 2009. Enrichment and clonal culture 
of progenitor cells during mouse postnatal liver development in mice. Gastroenterology 
137: 1114-26, 26.e1-14 
147. Okabe M, Tsukahara Y, Tanaka M, Suzuki K, Saito S, Kamiya Y, Tsujimura T, Nakamura 
K, Miyajima A. 2009. Potential hepatic stem cells reside in EpCAM+ cells of normal and 
injured mouse liver. Development 136: 1951-60 
 133 
148. Dorrell C, Erker L, Schug J, Kopp JL, Canaday PS, Fox AJ, Smirnova O, Duncan AW, 
Finegold MJ, Sander M, Kaestner KH, Grompe M. 2011. Prospective isolation of a 
bipotential clonogenic liver progenitor cell in adult mice. Genes Dev 25: 1193-203 
149. Tanimizu N, Kobayashi S, Ichinohe N, Mitaka T. 2014. Downregulation of miR122 by 
grainyhead-like 2 restricts the hepatocytic differentiation potential of adult liver progenitor 
cells. Development 141: 4448-56 
150. Tarlow BD, Finegold MJ, Grompe M. 2014. Clonal tracing of Sox9+ liver progenitors in 
mouse oval cell injury. Hepatology 60: 278-89 
151. Li B, Dorrell C, Canaday PS, Pelz C, Haft A, Finegold M, Grompe M. 2017. Adult Mouse 
Liver Contains Two Distinct Populations of Cholangiocytes. Stem Cell Reports 9: 478-89 
152. Kuwahara R, Kofman AV, Landis CS, Swenson ES, Barendswaard E, Theise ND. 2008. 
The hepatic stem cell niche: identification by label-retaining cell assay. Hepatology 47: 
1994-2002 
153. Kordes C, Häussinger D. 2013. Hepatic stem cell niches. J Clin Invest 123: 1874-80 
154. Sicklick JK, Li YX, Melhem A, Schmelzer E, Zdanowicz M, Huang J, Caballero M, Fair 
JH, Ludlow JW, McClelland RE, Reid LM, Diehl AM. 2006. Hedgehog signaling 
maintains resident hepatic progenitors throughout life. Am J Physiol Gastrointest Liver 
Physiol 290: G859-70 
155. Español-Suñer R, Carpentier R, Van Hul N, Legry V, Achouri Y, Cordi S, Jacquemin P, 
Lemaigre F, Leclercq IA. 2012. Liver progenitor cells yield functional hepatocytes in 
response to chronic liver injury in mice. Gastroenterology 143: 1564-75.e7 
156. Clayton E, Forbes SJ. 2009. The isolation and in vitro expansion of hepatic Sca-1 
progenitor cells. Biochem Biophys Res Commun 381: 549-53 
157. Lorenzini S, Bird TG, Boulter L, Bellamy C, Samuel K, Aucott R, Clayton E, Andreone P, 
Bernardi M, Golding M, Alison MR, Iredale JP, Forbes SJ. 2010. Characterisation of a 
stereotypical cellular and extracellular adult liver progenitor cell niche in rodents and 
diseased human liver. Gut 59: 645-54 
158. Van Hul NK, Abarca-Quinones J, Sempoux C, Horsmans Y, Leclercq IA. 2009. Relation 
between liver progenitor cell expansion and extracellular matrix deposition in a CDE-
induced murine model of chronic liver injury. Hepatology 49: 1625-35 
159. Factor VM, Radaeva SA, Thorgeirsson SS. 1994. Origin and fate of oval cells in dipin-
induced hepatocarcinogenesis in the mouse. Am J Pathol 145: 409-22 
160. FARBER E. 1956. Similarities in the sequence of early histological changes induced in the 
liver of the rat by ethionine, 2-acetylamino-fluorene, and 3'-methyl-4-
dimethylaminoazobenzene. Cancer Res 16: 142-8 
 134 
161. Dempo K, Chisaka N, Yoshida Y, Kaneko A, Onoé T. 1975. Immunofluorescent study on 
alpha-fetoprotein-producing cells in the early stage of 3'-methyl-4-
dimethylaminoazobenzene carcinogenesis. Cancer Res 35: 1282-7 
162. Inaoka Y. 1967. Significance of the so-called oval cell proliferation during azo-dye 
hepatocarcinogenesis. Gan 58: 355-66 
163. Ogawa K, Minase T, Onhoe T. 1974. Demonstration of glucose 6-phosphatase activity in 
the oval cells of rat liver and the significance of the oval cells in azo dye carcinogenesis. 
Cancer Res 34: 3379-86 
164. RUBIN E. 1964. THE ORIGIN AND FATE OF PROLIFERATED BILE DUCTULAR 
CELLS. Exp Mol Pathol 3: 279-86 
165. GRISHAM JW, PORTA EA. 1964. ORIGIN AND FATE OF PROLIFERATED 
HEPATIC DUCTAL CELLS IN THE RAT: ELECTRON MICROSCOPIC AND 
AUTORADIOGRAPHIC STUDIES. Exp Mol Pathol 3: 242-61 
166. Tatematsu M, Ho RH, Kaku T, Ekem JK, Farber E. 1984. Studies on the proliferation and 
fate of oval cells in the liver of rats treated with 2-acetylaminofluorene and partial 
hepatectomy. Am J Pathol 114: 418-30 
167. SOLT D, FARBER E. 1976. New principle for the analysis of chemical carcinogenesis. 
Nature 263: 703 
168. Petersen BE, Zajac VF, Michalopoulos GK. 1997. Bile ductular damage induced by 
methylene dianiline inhibits oval cell activation. Am J Pathol 151: 905-9 
169. Evarts RP, Nagy P, Marsden E, Thorgeirsson SS. 1987. A precursor-product relationship 
exists between oval cells and hepatocytes in rat liver. Carcinogenesis 8: 1737-40 
170. Evarts RP, Nagy P, Nakatsukasa H, Marsden E, Thorgeirsson SS. 1989. In vivo 
differentiation of rat liver oval cells into hepatocytes. Cancer Res 49: 1541-7 
171. Alison M, Golding M, Lalani EN, Nagy P, Thorgeirsson S, Sarraf C. 1997. Wholesale 
hepatocytic differentiation in the rat from ductular oval cells, the progeny of biliary stem 
cells. J Hepatol 26: 343-52 
172. Copeland DH, Salmon WD. 1946. The Occurrence of Neoplasms in the Liver, Lungs, and 
Other Tissues of Rats as a Result of Prolonged Choline Deficiency. Am J Pathol 22: 1059-
79 
173. Newberne PM, Camargo JL, Clark AJ. 1982. Choline Deficiency, Partial Hepatectomy, 
and Liver Tumors in Rats and Mice. Toxicol Pathol 10: 95-106 
174. Alix JH. 1982. Molecular aspects of the in vivo and in vitro effects of ethionine, an analog 
of methionine. Microbiol Rev 46: 281-95 
 135 
175. Shinozuka H, Lombardi B, Sell S, Iammarino RM. 1978. Early histological and functional 
alterations of ethionine liver carcinogenesis in rats fed a choline-deficient diet. Cancer Res 
38: 1092-8 
176. Akhurst B, Croager EJ, Farley-Roche CA, Ong JK, Dumble ML, Knight B, Yeoh GC. 
2001. A modified choline-deficient, ethionine-supplemented diet protocol effectively 
induces oval cells in mouse liver. Hepatology 34: 519-22 
177. Pradhan-Sundd T, Vats R, Russell JM, Singh S, Michael AA, Molina L, Kakar S, Cornuet 
P, Poddar M, Watkins SC, Nejak-Bowen KN, Monga SP, Sundd P. 2018. Dysregulated 
bile transporters and impaired tight junctions during chronic liver injury in mice. 
Gastroenterology  
178. Knight B, Matthews VB, Akhurst B, Croager EJ, Klinken E, Abraham LJ, Olynyk JK, 
Yeoh G. 2005. Liver inflammation and cytokine production, but not acute phase protein 
synthesis, accompany the adult liver progenitor (oval) cell response to chronic liver injury. 
Immunol Cell Biol 83: 364-74 
179. Knight B, Akhurst B, Matthews VB, Ruddell RG, Ramm GA, Abraham LJ, Olynyk JK, 
Yeoh GC. 2007. Attenuated liver progenitor (oval) cell and fibrogenic responses to the 
choline deficient, ethionine supplemented diet in the BALB/c inbred strain of mice. J 
Hepatol 46: 134-41 
180. Strick-Marchand H, Masse GX, Weiss MC, Di Santo JP. 2008. Lymphocytes support oval 
cell-dependent liver regeneration. J Immunol 181: 2764-71 
181. Bird TG, Lu WY, Boulter L, Gordon-Keylock S, Ridgway RA, Williams MJ, Taube J, 
Thomas JA, Wojtacha D, Gambardella A, Sansom OJ, Iredale JP, Forbes SJ. 2013. Bone 
marrow injection stimulates hepatic ductular reactions in the absence of injury via 
macrophage-mediated TWEAK signaling. Proc Natl Acad Sci U S A 110: 6542-7 
182. Karaca G, Swiderska-Syn M, Xie G, Syn WK, Krüger L, Machado MV, Garman K, Choi 
SS, Michelotti GA, Burkly LC, Ochoa B, Diehl AM. 2014. TWEAK/Fn14 signaling is 
required for liver regeneration after partial hepatectomy in mice. PLoS One 9: e83987 
183. Carpentier R, Suñer RE, van Hul N, Kopp JL, Beaudry JB, Cordi S, Antoniou A, Raynaud 
P, Lepreux S, Jacquemin P, Leclercq IA, Sander M, Lemaigre FP. 2011. Embryonic ductal 
plate cells give rise to cholangiocytes, periportal hepatocytes, and adult liver progenitor 
cells. Gastroenterology 141: 1432-8, 8.e1-4 
184. Shin S, Upadhyay N, Greenbaum LE, Kaestner KH. 2015. Ablation of Foxl1-Cre-labeled 
hepatic progenitor cells and their descendants impairs recovery of mice from liver injury. 
Gastroenterology 148: 192-202.e3 
185. Rodrigo-Torres D, Affò S, Coll M, Morales-Ibanez O, Millán C, Blaya D, Alvarez-Guaita 
A, Rentero C, Lozano JJ, Maestro MA, Solar M, Arroyo V, Caballería J, van Grunsven 
LA, Enrich C, Ginès P, Bataller R, Sancho-Bru P. 2014. The biliary epithelium gives rise 
to liver progenitor cells. Hepatology 60: 1367-77 
 136 
186. Yanger K, Knigin D, Zong Y, Maggs L, Gu G, Akiyama H, Pikarsky E, Stanger BZ. 2014. 
Adult hepatocytes are generated by self-duplication rather than stem cell differentiation. 
Cell Stem Cell 15: 340-9 
187. Raven A, Lu WY, Man TY, Ferreira-Gonzalez S, O'Duibhir E, Dwyer BJ, Thomson JP, 
Meehan RR, Bogorad R, Koteliansky V, Kotelevtsev Y, Ffrench-Constant C, Boulter L, 
Forbes SJ. 2017. Cholangiocytes act as facultative liver stem cells during impaired 
hepatocyte regeneration. Nature  
188. Russell JO, Lu WY, Okabe H, Abrams M, Oertel M, Poddar M, Singh S, Forbes SJ, Monga 
SP. 2018. Hepatocyte-specific β-catenin deletion during severe liver injury provokes 
cholangiocytes to differentiate into hepatocytes. Hepatology  
189. Malato Y, Naqvi S, Schürmann N, Ng R, Wang B, Zape J, Kay MA, Grimm D, Willenbring 
H. 2011. Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. 
J Clin Invest 121: 4850-60 
190. Schaub JR, Malato Y, Gormond C, Willenbring H. 2014. Evidence against a Stem Cell 
Origin of New Hepatocytes in a Common Mouse Model of Chronic Liver Injury. Cell Rep 
8: 933-9 
191. Lu WY, Bird TG, Boulter L, Tsuchiya A, Cole AM, Hay T, Guest RV, Wojtacha D, Man 
TY, Mackinnon A, Ridgway RA, Kendall T, Williams MJ, Jamieson T, Raven A, Hay DC, 
Iredale JP, Clarke AR, Sansom OJ, Forbes SJ. 2015. Hepatic progenitor cells of biliary 
origin with liver repopulation capacity. Nat Cell Biol 17: 971-83 
192. Fickert P, Stöger U, Fuchsbichler A, Moustafa T, Marschall HU, Weiglein AH, 
Tsybrovskyy O, Jaeschke H, Zatloukal K, Denk H, Trauner M. 2007. A new xenobiotic-
induced mouse model of sclerosing cholangitis and biliary fibrosis. Am J Pathol 171: 525-
36 
193. Yanger K, Zong Y, Maggs LR, Shapira SN, Maddipati R, Aiello NM, Thung SN, Wells 
RG, Greenbaum LE, Stanger BZ. 2013. Robust cellular reprogramming occurs 
spontaneously during liver regeneration. Genes Dev 27: 719-24 
194. Huch M, Dorrell C, Boj SF, van Es JH, Li VS, van de Wetering M, Sato T, Hamer K, 
Sasaki N, Finegold MJ, Haft A, Vries RG, Grompe M, Clevers H. 2013. In vitro expansion 
of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. Nature 494: 247-50 
195. Deng X, Zhang X, Li W, Feng RX, Li L, Yi GR, Zhang XN, Yin C, Yu HY, Zhang JP, Lu 
B, Hui L, Xie WF. 2018. Chronic Liver Injury Induces Conversion of Biliary Epithelial 
Cells into Hepatocytes. Cell Stem Cell 23: 114-22.e3 
196. Aoki R, Chiba T, Miyagi S, Negishi M, Konuma T, Taniguchi H, Ogawa M, Yokosuka O, 
Iwama A. 2010. The polycomb group gene product Ezh2 regulates proliferation and 
differentiation of murine hepatic stem/progenitor cells. J Hepatol 52: 854-63 
 137 
197. Koike H, Ouchi R, Ueno Y, Nakata S, Obana Y, Sekine K, Zheng YW, Takebe T, Isono 
K, Koseki H, Taniguchi H. 2014. Polycomb group protein Ezh2 regulates hepatic 
progenitor cell proliferation and differentiation in murine embryonic liver. PLoS One 9: 
e104776 
198. Jalan-Sakrikar N, De Assuncao TM, Lu J, Almada LL, Lomberk G, Fernandez-Zapico ME, 
Urrutia R, Huebert RC. 2016. Hedgehog Signaling Overcomes an EZH2-Dependent 
Epigenetic Barrier to Promote Cholangiocyte Expansion. PLoS One 11: e0168266 
199. Hunter AL, Holscher MA, Neal RA. 1977. Thioacetamide-induced hepatic necrosis. I. 
Involvement of the mixed-function oxidase enzyme system. J Pharmacol Exp Ther 200: 
439-48 
200. Müller A, Machnik F, Zimmermann T, Schubert H. 1988. Thioacetamide-induced 
cirrhosis-like liver lesions in rats--usefulness and reliability of this animal model. Exp 
Pathol 34: 229-36 
201. Gracz AD, Fuller MK, Wang F, Li L, Stelzner M, Dunn JC, Martin MG, Magness ST. 
2013. Brief report: CD24 and CD44 mark human intestinal epithelial cell populations with 
characteristics of active and facultative stem cells. Stem Cells 31: 2024-30 
202. Michalopoulos GK, Bowen WC, Mulè K, Lopez-Talavera JC, Mars W. 2002. Hepatocytes 
undergo phenotypic transformation to biliary epithelium in organoid cultures. Hepatology 
36: 278-83 
203. Tag CG, Sauer-Lehnen S, Weiskirchen S, Borkham-Kamphorst E, Tolba RH, Tacke F, 
Weiskirchen R. 2015. Bile duct ligation in mice: induction of inflammatory liver injury 
and fibrosis by obstructive cholestasis. J Vis Exp  
204. Michalopoulos GK, Barua L, Bowen WC. 2005. Transdifferentiation of rat hepatocytes 
into biliary cells after bile duct ligation and toxic biliary injury. Hepatology 41: 535-44 
205. Yovchev MI, Locker J, Oertel M. 2016. Biliary fibrosis drives liver repopulation and 
phenotype transition of transplanted hepatocytes. J Hepatol 64: 1348-57 
206. Tanimizu N, Nishikawa Y, Ichinohe N, Akiyama H, Mitaka T. 2014. Sry HMG box protein 
9-positive (Sox9+) epithelial cell adhesion molecule-negative (EpCAM-) biphenotypic 
cells derived from hepatocytes are involved in mouse liver regeneration. J Biol Chem 289: 
7589-98 
207. Nagahama Y, Sone M, Chen X, Okada Y, Yamamoto M, Xin B, Matsuo Y, Komatsu M, 
Suzuki A, Enomoto K, Nishikawa Y. 2014. Contributions of hepatocytes and bile ductular 
cells in ductular reactions and remodeling of the biliary system after chronic liver injury. 
Am J Pathol 184: 3001-12 
208. Lin S, Nascimento EM, Gajera CR, Chen L, Neuhöfer P, Garbuzov A, Wang S, Artandi 
SE. 2018. Distributed hepatocytes expressing telomerase repopulate the liver in 
homeostasis and injury. Nature 556: 244-8 
 138 
209. Sekiya S, Suzuki A. 2014. Hepatocytes, rather than cholangiocytes, can be the major source 
of primitive ductules in the chronically injured mouse liver. Am J Pathol 184: 1468-78 
210. Boulter L, Govaere O, Bird TG, Radulescu S, Ramachandran P, Pellicoro A, Ridgway RA, 
Seo SS, Spee B, Van Rooijen N, Sansom OJ, Iredale JP, Lowell S, Roskams T, Forbes SJ. 
2012. Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell 
fate in chronic liver disease. Nat Med 18: 572-9 
211. Yimlamai D, Christodoulou C, Galli GG, Yanger K, Pepe-Mooney B, Gurung B, Shrestha 
K, Cahan P, Stanger BZ, Camargo FD. 2014. Hippo pathway activity influences liver cell 
fate. Cell 157: 1324-38 
212. Font-Burgada J, Shalapour S, Ramaswamy S, Hsueh B, Rossell D, Umemura A, Taniguchi 
K, Nakagawa H, Valasek MA, Ye L, Kopp JL, Sander M, Carter H, Deisseroth K, Verma 
IM, Karin M. 2015. Hybrid Periportal Hepatocytes Regenerate the Injured Liver without 
Giving Rise to Cancer. Cell 162: 766-79 
213. Okabe H, Yang J, Sylakowski K, Yovchev M, Miyagawa Y, Nagarajan S, Chikina M, 
Thompson M, Oertel M, Baba H, Monga SP, Nejak-Bowen KN. 2016. Wnt signaling 
regulates hepatobiliary repair following cholestatic liver injury in mice. Hepatology 64: 
1652-66 
214. Tarlow BD, Pelz C, Naugler WE, Wakefield L, Wilson EM, Finegold MJ, Grompe M. 
2014. Bipotential adult liver progenitors are derived from chronically injured mature 
hepatocytes. Cell Stem Cell 15: 605-18 
215. Schaub JR, Huppert KA, Kurial SNT, Hsu BY, Cast AE, Donnelly B, Karns RA, Chen F, 
Rezvani M, Luu HY, Mattis AN, Rougemont AL, Rosenthal P, Huppert SS, Willenbring 
H. 2018. De novo formation of the biliary system by TGFβ-mediated hepatocyte 
transdifferentiation. Nature 557: 247-51 
216. Russell JO, Ko S, Saggi HS, Singh S, Poddar M, Shin D, Monga SP. 2018. Bromodomain 
and Extraterminal (BET) Proteins Regulate Hepatocyte Proliferation in Hepatocyte-Driven 
Liver Regeneration. Am J Pathol 188: 1389-405 
217. Michalopoulos GK, Khan Z. 2015. Liver Stem Cells: Experimental Findings and 
Implications for Human Liver Disease. Gastroenterology 149: 876-82 
218. Duncan AW, Dorrell C, Grompe M. 2009. Stem cells and liver regeneration. 
Gastroenterology 137: 466-81 
219. Kochanek KD, Murphy SL, Xu J, Tejada-Vera B. 2016. Deaths: Final Data for 2014. Natl 
Vital Stat Rep 65: 1-122 
220. Mittal S, El-Serag HB. 2013. Epidemiology of hepatocellular carcinoma: consider the 
population. J Clin Gastroenterol 47 Suppl: S2-6 
 139 
221. Njei B, Rotman Y, Ditah I, Lim JK. 2015. Emerging trends in hepatocellular carcinoma 
incidence and mortality. Hepatology 61: 191-9 
222. Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. 2014. Liver fibrosis and repair: 
immune regulation of wound healing in a solid organ. Nat Rev Immunol 14: 181-94 
223. Luedde T, Kaplowitz N, Schwabe RF. 2014. Cell death and cell death responses in liver 
disease: mechanisms and clinical relevance. Gastroenterology 147: 765-83.e4 
224. Lockwood WW, Zejnullahu K, Bradner JE, Varmus H. 2012. Sensitivity of human lung 
adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc 
Natl Acad Sci U S A 109: 19408-13 
225. Zhang P, Dong Z, Cai J, Zhang C, Shen Z, Ke A, Gao D, Fan J, Shi G. 2015. BRD4 
promotes tumor growth and epithelial-mesenchymal transition in hepatocellular 
carcinoma. Int J Immunopathol Pharmacol 28: 36-44 
226. Li GQ, Guo WZ, Zhang Y, Seng JJ, Zhang HP, Ma XX, Zhang G, Li J, Yan B, Tang HW, 
Li SS, Wang LD, Zhang SJ. 2016. Suppression of BRD4 inhibits human hepatocellular 
carcinoma by repressing MYC and enhancing BIM expression. Oncotarget 7: 2462-74 
227. Ko S, Choi TY, Russell JO, So J, Monga SP, Shin D. 2016. Bromodomain and 
extraterminal (BET) proteins regulate biliary-driven liver regeneration. J Hepatol 64: 316-
25 
228. Ye H, Holterman AX, Yoo KW, Franks RR, Costa RH. 1999. Premature expression of the 
winged helix transcription factor HFH-11B in regenerating mouse liver accelerates 
hepatocyte entry into S phase. Mol Cell Biol 19: 8570-80 
229. Tan XP, Behari J, Cieply B, Michalopoulos GK, Monga SPS. 2006. Conditional deletion 
of beta-catenin reveals its role in liver growth and regeneration. Gastroenterology 131: 
1561-72 
230. Du Q, Zhang X, Cardinal J, Cao Z, Guo Z, Shao L, Geller DA. 2009. Wnt/beta-catenin 
signaling regulates cytokine-induced human inducible nitric oxide synthase expression by 
inhibiting nuclear factor-kappaB activation in cancer cells. Cancer Res 69: 3764-71 
231. Westerfield M. 2007. The Zebrafish Book. A Guide for the Laboratory Use of Zebrafish 
(Danio rerio), 5th Edition. University of Oregon Press, Eugene (Book)  
232. Choi TY, Ninov N, Stainier DY, Shin D. 2014. Extensive conversion of hepatic biliary 
epithelial cells to hepatocytes after near total loss of hepatocytes in zebrafish. 
Gastroenterology 146: 776-88 
233. Ninov N, Borius M, Stainier DYR. 2012. Different levels of Notch signaling regulate 
quiescence, renewal and differentiation in pancreatic endocrine progenitors. Development 
139: 1557-67 
 140 
234. Shimizu N, Kawakami K, Ishitani T. 2012. Visualization and exploration of Tcf/Lef 
function using a highly responsive Wnt/beta-catenin signaling-reporter transgenic 
zebrafish. Developmental Biology 370: 71-85 
235. McCloy RA, Rogers S, Caldon CE, Lorca T, Castro A, Burgess A. 2014. Partial inhibition 
of Cdk1 in G 2 phase overrides the SAC and decouples mitotic events. Cell Cycle 13: 1400-
12 
236. Choi TY, Khaliq M, Ko S, So J, Shin D. 2015. Hepatocyte-specific ablation in zebrafish to 
study biliary-driven liver regeneration. J Vis Exp: e52785 
237. de Groh ED, Swanhart LM, Cosentino CC, Jackson RL, Dai W, Kitchens CA, Day BW, 
Smithgall TE, Hukriede NA. 2010. Inhibition of histone deacetylase expands the renal 
progenitor cell population. J Am Soc Nephrol 21: 794-802 
238. Weglarz TC, Sandgren EP. 2000. Timing of hepatocyte entry into DNA synthesis after 
partial hepatectomy is cell autonomous. Proc Natl Acad Sci U S A 97: 12595-600 
239. Taub R. 2004. Liver regeneration: from myth to mechanism. Nat Rev Mol Cell Biol 5: 836-
47 
240. Hall PA, Levison DA, Woods AL, Yu CC, Kellock DB, Watkins JA, Barnes DM, Gillett 
CE, Camplejohn R, Dover R. 1990. Proliferating cell nuclear antigen (PCNA) 
immunolocalization in paraffin sections: an index of cell proliferation with evidence of 
deregulated expression in some neoplasms. J Pathol 162: 285-94 
241. Albrecht JH, Hu MY, Cerra FB. 1995. Distinct patterns of cyclin D1 regulation in models 
of liver regeneration and human liver. Biochem Biophys Res Commun 209: 648-55 
242. Núñez KG, Gonzalez-Rosario J, Thevenot PT, Cohen AJ. 2017. Cyclin D1 in the Liver: 
Role of Noncanonical Signaling in Liver Steatosis and Hormone Regulation. Ochsner J 
17: 56-65 
243. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A. 
1999. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad 
Sci U S A 96: 5522-7 
244. Tetsu O, McCormick F. 1999. Beta-catenin regulates expression of cyclin D1 in colon 
carcinoma cells. Nature 398: 422-6 
245. Nejak-Bowen KN, Zeng G, Tan X, Cieply B, Monga SP. 2009. Beta-catenin regulates 
vitamin C biosynthesis and cell survival in murine liver. J Biol Chem 284: 28115-27 
246. Ovejero C, Cavard C, Périanin A, Hakvoort T, Vermeulen J, Godard C, Fabre M, Chafey 
P, Suzuki K, Romagnolo B, Yamagoe S, Perret C. 2004. Identification of the leukocyte 
cell-derived chemotaxin 2 as a direct target gene of beta-catenin in the liver. Hepatology 
40: 167-76 
 141 
247. Albrecht JH, Poon RY, Ahonen CL, Rieland BM, Deng C, Crary GS. 1998. Involvement 
of p21 and p27 in the regulation of CDK activity and cell cycle progression in the 
regenerating liver. Oncogene 16: 2141-50 
248. Rickheim DG, Nelsen CJ, Fassett JT, Timchenko NA, Hansen LK, Albrecht JH. 2002. 
Differential regulation of cyclins D1 and D3 in hepatocyte proliferation. Hepatology 36: 
30-8 
249. Delgado I, Fresnedo O, Iglesias A, Rueda Y, Syn WK, Zubiaga AM, Ochoa B. 2011. A 
role for transcription factor E2F2 in hepatocyte proliferation and timely liver regeneration. 
Am J Physiol Gastrointest Liver Physiol 301: G20-31 
250. Hong SH, Eun JW, Choi SK, Shen Q, Choi WS, Han JW, Nam SW, You JS. 2016. 
Epigenetic reader BRD4 inhibition as a therapeutic strategy to suppress E2F2-cell cycle 
regulation circuit in liver cancer. Oncotarget 7: 32628-40 
251. Timmers C, Sharma N, Opavsky R, Maiti B, Wu L, Wu J, Orringer D, Trikha P, Saavedra 
HI, Leone G. 2007. E2f1, E2f2, and E2f3 control E2F target expression and cellular 
proliferation via a p53-dependent negative feedback loop. Mol Cell Biol 27: 65-78 
252. Cressman DE, Greenbaum LE, Haber BA, Taub R. 1994. Rapid activation of post-
hepatectomy factor/nuclear factor kappa B in hepatocytes, a primary response in the 
regenerating liver. J Biol Chem 269: 30429-35 
253. FitzGerald MJ, Webber EM, Donovan JR, Fausto N. 1995. Rapid DNA binding by nuclear 
factor kappa B in hepatocytes at the start of liver regeneration. Cell Growth Differ 6: 417-
27 
254. North TE, Babu IR, Vedder LM, Lord AM, Wishnok JS, Tannenbaum SR, Zon LI, 
Goessling W. 2010. PGE2-regulated wnt signaling and N-acetylcysteine are synergistically 
hepatoprotective in zebrafish acetaminophen injury. Proc Natl Acad Sci U S A 107: 17315-
20 
255. Cox AG, Saunders DC, Kelsey PB, Jr., Conway AA, Tesmenitsky Y, Marchini JF, Brown 
KK, Stamler JS, Colagiovanni DB, Rosenthal GJ, Croce KJ, North TE, Goessling W. 2014. 
S-nitrosothiol signaling regulates liver development and improves outcome following toxic 
liver injury. Cell Rep 6: 56-69 
256. Jaeschke H, Xie Y, McGill MR. 2014. Acetaminophen-induced Liver Injury: from Animal 
Models to Humans. J Clin Transl Hepatol 2: 153-61 
257. He JH, Guo SY, Zhu F, Zhu JJ, Chen YX, Huang CJ, Gao JM, Dong QX, Xuan YX, Li 
CQ. 2013. A zebrafish phenotypic assay for assessing drug-induced hepatotoxicity. J 
Pharmacol Toxicol Methods 67: 25-32 
258. Nourjah P, Ahmad SR, Karwoski C, Willy M. 2006. Estimates of acetaminophen 
(Paracetomal)-associated overdoses in the United States. Pharmacoepidemiol Drug Saf 15: 
398-405 
 142 
259. Lorent K, Moore JC, Siekmann AF, Lawson N, Pack M. 2010. Reiterative use of the notch 
signal during zebrafish intrahepatic biliary development. Dev Dyn 239: 855-64 
260. Sugiyama M, Sakaue-Sawano A, Iimura T, Fukami K, Kitaguchi T, Kawakami K, 
Okamoto H, Higashijima SI, Miyawaki A. 2009. Illuminating cell-cycle progression in the 
developing zebrafish embryo. Proc Natl Acad Sci U S A 106: 20812-7 
261. Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW, Chandwani R, 
Marazzi I, Wilson P, Coste H, White J, Kirilovsky J, Rice CM, Lora JM, Prinjha RK, Lee 
K, Tarakhovsky A. 2010. Suppression of inflammation by a synthetic histone mimic. 
Nature 468: 1119-23 
262. Xu Y, Vakoc CR. 2014. Brd4 is on the move during inflammation. Trends Cell Biol 24: 
615-6 
263. Chu J, Sadler KC. 2009. New school in liver development: lessons from zebrafish. 
Hepatology 50: 1656-63 
264. Tao J, Calvisi DF, Ranganathan S, Cigliano A, Zhou L, Singh S, Jiang L, Fan B, 
Terracciano L, Armeanu-Ebinger S, Ribback S, Dombrowski F, Evert M, Chen X, Monga 
SP. 2014. Activation of β-catenin and Yap1 in human hepatoblastoma and induction of 
hepatocarcinogenesis in mice. Gastroenterology 147: 690-701 
265. Tao J, Xu E, Zhao Y, Singh S, Li X, Couchy G, Chen X, Zucman-Rossi J, Chikina M, 
Monga SP. 2016. Modeling a human hepatocellular carcinoma subset in mice through 
coexpression of met and point-mutant β-catenin. Hepatology 64: 1587-605 
266. Tao J, Zhang R, Singh S, Poddar M, Xu E, Oertel M, Chen X, Ganesh S, Abrams M, Monga 
SP. 2016. Targeting β-catenin in hepatocellular cancers induced by coexpression of mutant 
β-catenin and K-Ras in mice. Hepatology  
267. Delgado E, Okabe H, Preziosi M, Russell JO, Alvarado TF, Oertel M, Nejak-Bowen KN, 
Zhang Y, Monga SP. 2015. Complete response of Ctnnb1-mutated tumours to β-catenin 
suppression by locked nucleic acid antisense in a mouse hepatocarcinogenesis model. J 
Hepatol 62: 380-7 
268. Tögel L, Nightingale R, Chueh AC, Jayachandran A, Tran H, Phesse T, Wu R, Sieber OM, 
Arango D, Dhillon AS, Dawson MA, Diez-Dacal B, Gahman TC, Filippakopoulos P, Shiau 
AK, Mariadason JM. 2016. Dual Targeting of Bromodomain and Extraterminal Domain 
Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of 
Colorectal Cancer Cells. Mol Cancer Ther 15: 1217-26 
269. Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, Rahl PB, Lee TI, 
Young RA. 2013. Master transcription factors and mediator establish super-enhancers at 
key cell identity genes. Cell 153: 307-19 
 
 143 
270. Parker SC, Stitzel ML, Taylor DL, Orozco JM, Erdos MR, Akiyama JA, van Bueren KL, 
Chines PS, Narisu N, Black BL, Visel A, Pennacchio LA, Collins FS, Program NCS, 
Authors NIoHISCCSP, Authors NCSP. 2013. Chromatin stretch enhancer states drive cell-
specific gene regulation and harbor human disease risk variants. Proc Natl Acad Sci U S A 
110: 17921-6 
271. Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-André V, Sigova AA, Hoke HA, Young RA. 
2013. Super-enhancers in the control of cell identity and disease. Cell 155: 934-47 
272. Hnisz D, Schuijers J, Lin CY, Weintraub AS, Abraham BJ, Lee TI, Bradner JE, Young 
RA. 2015. Convergence of developmental and oncogenic signaling pathways at 
transcriptional super-enhancers. Mol Cell 58: 362-70 
273. Kennedy AL, Vallurupalli M, Chen L, Crompton B, Cowley G, Vazquez F, Weir BA, 
Tsherniak A, Parasuraman S, Kim S, Alexe G, Stegmaier K. 2015. Functional, chemical 
genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway 
inhibition in Ewing sarcoma. Oncotarget 6: 30178-93 
274. Kim WR, Lake JR, Smith JM, Skeans MA, Schladt DP, Edwards EB, Harper AM, 
Wainright JL, Snyder JJ, Israni AK, Kasiske BL. 2017. OPTN/SRTR 2015 Annual Data 
Report: Liver. Am J Transplant 17 Suppl 1: 174-251 
275. Carpino G, Renzi A, Onori P, Gaudio E. 2013. Role of hepatic progenitor cells in 
nonalcoholic fatty liver disease development: cellular cross-talks and molecular networks. 
Int J Mol Sci 14: 20112-30 
276. Zhang L, Theise N, Chua M, Reid LM. 2008. The stem cell niche of human livers: 
symmetry between development and regeneration. Hepatology 48: 1598-607 
277. Libbrecht L, Roskams T. 2002. Hepatic progenitor cells in human liver diseases. Semin 
Cell Dev Biol 13: 389-96 
278. Yanger K, Knigin D, Zong Y, Maggs L, Gu G, Akiyama H, Pikarsky E, Stanger BZ. 2014. 
Adult Hepatocytes Are Generated by Self-Duplication Rather than Stem Cell 
Differentiation. Cell Stem Cell  
279. Monga SP. 2015. β-Catenin Signaling and Roles in Liver Homeostasis, Injury, and 
Tumorigenesis. Gastroenterology 148: 1294-310 
280. Nair JK, Willoughby JL, Chan A, Charisse K, Alam MR, Wang Q, Hoekstra M, 
Kandasamy P, Kel'in AV, Milstein S, Taneja N, O'Shea J, Shaikh S, Zhang L, van der Sluis 
RJ, Jung ME, Akinc A, Hutabarat R, Kuchimanchi S, Fitzgerald K, Zimmermann T, van 
Berkel TJ, Maier MA, Rajeev KG, Manoharan M. 2014. Multivalent N-
acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-
mediated gene silencing. J Am Chem Soc 136: 16958-61 
281. Soriano P. 1999. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat 
Genet 21: 70-1 
 144 
282. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. 2008. Analysis of AAV serotypes 1-9 
mediated gene expression and tropism in mice after systemic injection. Mol Ther 16: 1073-
80 
283. Cadoret A, Ovejero C, Terris B, Souil E, Lévy L, Lamers WH, Kitajewski J, Kahn A, Perret 
C. 2002. New targets of beta-catenin signaling in the liver are involved in the glutamine 
metabolism. Oncogene 21: 8293-301 
284. Wang EY, Yeh SH, Tsai TF, Huang HP, Jeng YM, Lin WH, Chen WC, Yeh KH, Chen PJ, 
Chen DS. 2011. Depletion of β-catenin from mature hepatocytes of mice promotes 
expansion of hepatic progenitor cells and tumor development. Proc Natl Acad Sci U S A 
108: 18384-9 
285. Fabris L, Spirli C, Cadamuro M, Fiorotto R, Strazzabosco M. 2017. Emerging concepts in 
biliary repair and fibrosis. Am J Physiol Gastrointest Liver Physiol 313: G102-G16 
286. Xu J, Murphy SL, Kochanek KD, Bastian BA. 2016. Deaths: Final Data for 2013. Natl 
Vital Stat Rep 64: 1-119 
287. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. 2013. The 
burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 
58: 593-608 
288. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M. 2011. 
Changes in the prevalence of the most common causes of chronic liver diseases in the 
United States from 1988 to 2008. Clin Gastroenterol Hepatol 9: 524-30.e1; quiz e60 
289. Schuppan D, Schattenberg JM. 2013. Non-alcoholic steatohepatitis: pathogenesis and 
novel therapeutic approaches. J Gastroenterol Hepatol 28 Suppl 1: 68-76 
290. Bataller R, Brenner DA. 2005. Liver fibrosis. J Clin Invest 115: 209-18 
291. Kim WR, Lake JR, Smith JM, Skeans MA, Schladt DP, Edwards EB, Harper AM, 
Wainright JL, Snyder JJ, Israni AK, Kasiske BL. 2015. OPTN/SRTR 2013 Annual Data 
Report: liver. Am J Transplant 15 Suppl 2: 1-28 
292. Demetris AJ, Seaberg EC, Wennerberg A, Ionellie J, Michalopoulos G. 1996. Ductular 
reaction after submassive necrosis in humans. Special emphasis on analysis of ductular 
hepatocytes. Am J Pathol 149: 439-48 
293. Nejak-Bowen K, Monga SP. 2008. Wnt/beta-catenin signaling in hepatic organogenesis. 
Organogenesis 4: 92-9 
294. Haegel H, Larue L, Ohsugi M, Fedorov L, Herrenknecht K, Kemler R. 1995. Lack of beta-
catenin affects mouse development at gastrulation. Development 121: 3529-37 
 145 
295. Cheng JH, She H, Han YP, Wang J, Xiong S, Asahina K, Tsukamoto H. 2008. Wnt 
antagonism inhibits hepatic stellate cell activation and liver fibrosis. Am J Physiol 
Gastrointest Liver Physiol 294: G39-49 
296. Ge WS, Wang YJ, Wu JX, Fan JG, Chen YW, Zhu L. 2014. β-catenin is overexpressed in 
hepatic fibrosis and blockage of Wnt/β-catenin signaling inhibits hepatic stellate cell 
activation. Mol Med Rep 9: 2145-51 
297. Lin Y, Fang ZP, Liu HJ, Wang LJ, Cheng Z, Tang N, Li T, Liu T, Han HX, Cao G, Liang 
L, Ding YQ, Zhou WJ. 2017. HGF/R-spondin1 rescues liver dysfunction through the 
induction of Lgr5. Nat Commun 8: 1175 
298. Xu J, Tan Y, Shao X, Zhang C, He Y, Wang J, Xi Y. 2018. Evaluation of NCAM and c-
Kit as hepatic progenitor cell markers for intrahepatic cholangiocarcinomas. Pathol Res 
Pract 214: 2011-7 
 
